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Abstract
Quantifying underlying DNA methylation signatures of complex traits presents an op-
portunity to identify biomarkers and modes of disease intervention. Years of epigenome-
wide association studies (EWAS) have shown signatures vary greatly by trait and the
interpretation of signals remains difficult. This thesis explores potential explanations for
this and examines the role of EWAS in understanding complex traits.
To ascertain necessary data, I led a collection of EWAS results and developed a web re-
source for storing and querying the 975,574 associations across 1244 EWAS. Evidence
was found that results for EWAS that accounted for common biases, such as batch ef-
fects and cell composition, could partially be explained by variance and heritability of
DNA methylation. Further, identified sites were enriched in promoter regions, enhancer
regions and transcription factor binding sites.
Across the EWAS surveyed, DNA methylation was commonly measured in blood at
roughly 450,000 sites genome-wide. I examined the predictive capacity of DNA methy-
lation in this context and found that it captured little variance of 400 independent com-
plex traits.
Next, commonalities between the overlap in biology highlighted by EWAS and GWAS
of corresponding traits was explored and I found that the genes and genesets identified
were substantially different. Trait aetiology may still be explored through EWAS, but
the largely differential biology highlighted suggests the majority of EWAS results here
are due to confounding and reverse causation.
Mendelian randomization (MR) analyses further suggested residual confounding as be-
ing responsible for EWAS results as marked differences were found between an EWAS
meta-analysis of lung cancer and the corresponding MR analyses.
Through cataloguing published results and integrating methods and results from other
fields, this thesis identifies limitations to the current EWAS study design that reveal the
complexity of the role of DNA methylation on mediating the path from genotype or
environment to phenotype.
Acknowledgements
I would like to thank all of the lovely people who have helped me throughout my PhD.
There are so many people to thank and if I detailed my gratitude towards each of them
(my friends, family, supervisors, and colleagues) for all their support then I would have
no time to write my thesis. . . All those who have helped me know who they are and
hopefully know I appreciate them and love them dearly. There are just a couple of
extremely special mentions I would like to make.
Firstly, I am forever indebted to my parents for everything they have done to support me
in every aspect of my life. From looking after me during difficult times when growing
up, to taking my mind off of work by having a chat and pouring me another glass of
wine, they are always there when I need them. Secondly, I thank my beautiful flatmates,
Kaitlin Wade and Tom Mantle. During a pandemic they have kept me sane (as sane as I
could be), made me laugh every single day and have brought me countless (yeah I said it
Tom) cups of tea. Writing this thesis would have been LITERALLY impossible without
them.
List of Publications
Below is a list of publications I have been involved with throughout my PhD, some of
which is presented in this thesis. I conducted the vast majority of the work, but in certain
scenarios others also contributed and I have detailed this in contributions statements at
the start of each chapter. The first and senior authors for each piece of work have agreed
on my contributions detailed in these statements.
Relevant to this thesis
Battram,T., Richmond,R.C., Baglietto,L., Haycock,P.C., Perduca,V., Bojesen,S.E.,
Gaunt,T.R., Hemani,G., Guida,F., Carreras-Torres,R., et al. (2019) Appraising the
causal relevance of DNA methylation for risk of lung cancer. Int. J. Epidemiol.
Battram,T., Gaunt,T.R., Speed,D., Timpson,N.J. and Hemani,G. (2020) Exploring the
variance in complex traits captured by DNA methylation assays. bioRxiv
Battram,T., Yousefi,P., Crawford,C., Prince,C., Babaei,M., Khodabakhsh,S., White-
hurst,O., Mahoney,L., Hemani,G., Gaunt,T.R., et al. The EWAS Catalog: a database
of epigenome-wide association studies. Submitted to Bioinformatics November
2020.
Not relevant to this thesis
Battram,T., Hoskins,L., Hughes,D.A., Kettunen,J., Ring,S.M., Smith,G.D. and Timp-
son,N.J. (2019) Coronary artery disease, genetic risk and the metabolome in young in-
dividuals. Wellcome Open Res.
Howe,L.J., Battram,T., Morris,T.T., Hartwig,F.P., Hemani,G., Davies,N.M. and
Smith,G.D. (2020) Assortative mating and within-spouse pair comparisons. bioRxiv.
Trejo Banos,D., McCartney,D.L., Patxot,M., Anchieri,L., Battram,T., Christiansen,C.,
Costeira,R., Walker,R.M., Morris,S.W., Campbell,A., et al. (2020) Bayesian reassess-
ment of the epigenetic architecture of complex traits. Nat. Commun.
Jamieson,E., Korologou-Linden,R., Wootton,R.E., Guyatt,A.L., Battram,T., Bur-
rows,K., Gaunt,T.R., Tobin,M.D., Munafò,M., Davey Smith,G., et al. (2020) Smoking,
DNA Methylation, and Lung Function: a Mendelian Randomization Analysis to
Investigate Causal Pathways. Am. J. Hum. Genet.
Declaration
I declare that the work in this dissertation was carried out in accordance with the re-
quirements of the University’s Regulations and Code of Practice for Research Degree
Programmes and that it has not been submitted for any other academic award. Except
where indicated by specific reference in the text, the work is the candidate’s own work.
Work done in collaboration with, or with the assistance of, others, is indicated as such.




Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . i
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii
List of Publications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
Declaration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
Chapter 1: Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 Moving on from the central dogma of molecular biology . . . . . . . . . . . . . 1
1.2 DNA methylation as part of the regulatory machinery . . . . . . . . . . . . . . . 3
1.2.1 Defining epigenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2.2 Histone modifications . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2.3 DNA methylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.3 Population-based studies of DNA methylation associations . . . . . . . . . . . . 5
1.3.1 Studying complex trait associations . . . . . . . . . . . . . . . . . . . . 6
1.3.2 The potential value of DNA methylation measures to epidemiologists . . 6
1.3.3 Epigenome-wide association studies . . . . . . . . . . . . . . . . . . . . 7
1.3.4 Problems for EWAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.4 Using methods from statistical genetics to help inform future EWAS . . . . . . . 12
1.4.1 Catalogues of genome-wide associations . . . . . . . . . . . . . . . . . 12
1.4.2 Total variance captured by all sites measured genome-wide . . . . . . . . 12
1.4.3 Inferring biology from signals . . . . . . . . . . . . . . . . . . . . . . . 13
1.4.4 Establishing causality . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.5 Overview of thesis aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Chapter 2: Data sources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.1 Accessible Resource for Integrated Epigenomic Studies (ARIES) . . . . . . . . . 21
2.1.1 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.1.2 ALSPAC description . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.1.3 ALSPAC genetic data . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.1.4 ARIES DNA methylation data . . . . . . . . . . . . . . . . . . . . . . . 22
2.2 Gene expression omnibus (GEO) . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.3 UK Biobank . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.4 IEU OpenGWAS Project . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.5 Summary data for an EWAS of lung cancer . . . . . . . . . . . . . . . . . . . . 24
2.5.1 European Prospective Investigation into Cancer and Nutrition-Italy
(EPIC-Italy) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.5.2 Melbourne Collaborative Cohort Study (MCCS) . . . . . . . . . . . . . 24
2.5.3 Norwegian Women and Cancer (NOWAC) . . . . . . . . . . . . . . . . 25
2.5.4 Northern Sweden Health and Disease Study (NSHDS) . . . . . . . . . . 25
2.6 Transdisciplinary Research in Cancer of the Lung and The International Lung
Cancer Consortium (TRICL-ILCCO) . . . . . . . . . . . . . . . . . . . . . . . . 26
2.7 Copenhagen City Heart Study (CCHS) . . . . . . . . . . . . . . . . . . . . . . . 26
2.7.1 Phenotypic data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.7.2 DNA methylation data . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.7.3 Genotype data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Chapter 3: The EWAS Catalog: a database of epigenome-wide association studies . . 29
3.1 Chapter summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.1.1 Contributions statement . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.3.1 Implementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.3.2 Overview of publication data extraction . . . . . . . . . . . . . . . . . . 31
3.3.3 New EWAS performed . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.4.1 Database interface and use . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Chapter 4: Properties of epigenome-wide association studies . . . . . . . . . . . . . . 37
4.1 Chapter summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
4.1.1 Contributions statement . . . . . . . . . . . . . . . . . . . . . . . . . . 38
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
4.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.3.1 Epigenome-wide association studies data . . . . . . . . . . . . . . . . . 40
Description of catalog data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.3.2 Identifying faulty probes . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.3.3 Replication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.3.4 Selecting data to assess DNA methylation characteristics . . . . . . . . . 41
4.3.5 DNA methylation characteristics . . . . . . . . . . . . . . . . . . . . . . 41
4.3.6 Enrichment tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Description of the catalog . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.4.1 Robustness of results . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4.4.2 CpG characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.4.3 Enrichment of DMPs for genomic annotations . . . . . . . . . . . . . . 53
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
4.5.1 Identifying mediators . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
4.5.2 Biased results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
4.5.3 Understanding CpG characteristics . . . . . . . . . . . . . . . . . . . . . 56
4.5.4 Choosing sites to measure . . . . . . . . . . . . . . . . . . . . . . . . . 57
4.5.5 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
4.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Chapter 5: Exploring the variance in complex traits captured by DNA methylation
assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.1 Chapter summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.1.1 Contributions statement . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.3 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
5.3.1 Study samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
5.3.2 DNA methylation data . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
5.3.3 REML analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
5.3.4 Generating genetic principal components . . . . . . . . . . . . . . . . . 65
5.3.5 Epigenome-wide association studies . . . . . . . . . . . . . . . . . . . . 66
5.3.6 Association between h2EWAS and epigenome-wide association studies re-
sults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5.4.1 Estimating the proportion of phenotypic variance associated with DNA
methylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
5.4.2 Sensitivity analyses when estimating the proportion of phenotypic vari-
ance associated with DNA methylation . . . . . . . . . . . . . . . . . . 68
5.4.3 EWAS analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
5.5.1 Estimation of h2EWAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
5.5.2 Future EWAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.5.3 Contributions of individual CpG sites . . . . . . . . . . . . . . . . . . . 76
5.5.4 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
Chapter 6: A comparison of the genes and genesets identified by EWAS and GWAS of
eight complex traits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
6.1 Chapter summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
6.1.1 Contributions statement . . . . . . . . . . . . . . . . . . . . . . . . . . 80
6.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.3.1 Study data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.3.2 Genomic position overlap . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.3.3 Assessing power to detect shared annotations between GWAS and EWAS 83
6.3.4 Gene and geneset overlap between GWAS and EWAS . . . . . . . . . . 87
6.3.5 Understanding architecture from geneset overlap . . . . . . . . . . . . . 88
6.3.6 Overlap of non-corresponding EWAS and GWAS . . . . . . . . . . . . . 92
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
6.4.1 Overlap expected . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
6.4.2 Little overlap with any GWAS . . . . . . . . . . . . . . . . . . . . . . . 94
6.4.3 Information gained from EWAS . . . . . . . . . . . . . . . . . . . . . . 94
6.4.4 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
6.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
6.6 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
6.6.1 Samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
6.6.2 Overlapping genomic regions . . . . . . . . . . . . . . . . . . . . . . . 96
6.6.3 Mapping sites to genes and genesets . . . . . . . . . . . . . . . . . . . . 97
6.6.4 Methods for assessing overlap . . . . . . . . . . . . . . . . . . . . . . . 97
6.6.5 Testing power to detect overlap . . . . . . . . . . . . . . . . . . . . . . 98
6.6.6 Empirical analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
6.6.7 Understanding architecture from geneset overlap . . . . . . . . . . . . . 99
6.6.8 Assessing the correlation between geneset enrichment results . . . . . . . 100
Chapter 7: Appraising the causal relevance of DNA methylation for risk of lung cancer101
7.1 Chapter summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
7.1.1 Contributions statement . . . . . . . . . . . . . . . . . . . . . . . . . . 102
7.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
7.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
7.3.1 EWAS study details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
7.3.2 EWAS Meta-analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
7.3.3 Mendelian randomization . . . . . . . . . . . . . . . . . . . . . . . . . 103
7.3.4 Supplementary analyses . . . . . . . . . . . . . . . . . . . . . . . . . . 106
7.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
7.4.1 EWAS meta-analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
7.4.2 Mendelian randomization . . . . . . . . . . . . . . . . . . . . . . . . . 112
7.4.3 Tumour and adjacent normal lung tissue methylation patterns . . . . . . 125
7.4.4 Gene expression associated with mQTLs in blood and lung tissue . . . . 128
7.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Chapter 8: Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
8.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
8.2 Extensions to this work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
8.2.1 Beyond the HM450 array in blood . . . . . . . . . . . . . . . . . . . . . 135
8.2.2 New methods and data . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
8.2.3 Beyond DNA methylation . . . . . . . . . . . . . . . . . . . . . . . . . 137
8.3 Final conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Appendix A: Further assessment of the overlap between genes and genesets identified
by EWAS and GWAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
List of Tables
2.1 Overview of data used in this thesis . . . . . . . . . . . . . . . . . . . . . . . . 27
4.1 Description of data present in the EWAS Catalog . . . . . . . . . . . . . . . . . 43
4.2 GEO re-analysis replication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.3 Replication rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.4 Replication rate in EWAS of smoking . . . . . . . . . . . . . . . . . . . . . . . 51
4.5 Replication rate in EWAS of body mass index . . . . . . . . . . . . . . . . . . . 52
5.1 Summary of how well models fit to test the association between h2EWAS and the
number of differentially methylated positions identified across 400 traits at P <
1x10−5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
6.1 Study data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.2 Overlap of genes identified by EWAS and GWAS . . . . . . . . . . . . . . . . . 87
6.3 Correlation of geneset enrichment scores between EWAS and GWAS . . . . . . . 87
7.1 Instrument strength in ARIES . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
7.2 Meta-analyses of EWAS of lung cancer using four separate cohorts: 16 CpG
sites associated with lung cancer at false discovery rate < 0.05. . . . . . . . . . . 110
7.3 Heterogeneity between studies and smoker groups in the meta-analysis of EWAS
in four cohorts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
7.4 The SNP-exposure association estimates from ARIES and NSHDS . . . . . . . . 113
7.5 Full results for MR of DNA methylation of 14 CpG sites on lung cancer . . . . . 114
7.6 The association between mQTLs and their CpG sites across the five timepoints
in ARIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
7.7 Estimates of heterogeneity of MR estimates across multiple SNPs . . . . . . . . 120
7.8 Association of AHRR methylation and methylation allele score with confounding
factors in the CCHS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
7.9 One-sample MR analysis of the effect of AHRR methylation (%) on lung cancer
risk in the CCHS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
7.10 Two sample MR analysis for AHRR . . . . . . . . . . . . . . . . . . . . . . . . 125
7.11 Comparison of MR results with tumour-healthy tissue differential methylation . . 127
7.12 mQTL-gene expression analysis in lung and whole blood using data from GTEx . 128
List of Figures
1.1 The central dogma of molecular biology . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Simplified diagrams of the associations between DNA methylation and gene reg-
ulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3 Mendelian randomization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.4 Thesis flowchart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
3.1 EWAS Catalog project flowchart . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.2 Using The EWAS Catalog . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.1 Number of unique traits associated with DNA methylation at each CpG . . . . . 45
4.2 Distribution of r2 values across all CpG sites in The EWAS Catalog . . . . . . . 46
4.3 Distribution of the sum of r2 values across each study in The EWAS Catalog . . . 47
4.4 The percentage of DMPs that may have been identified by faulty probes and the
percentage of EWAS that reported identifying at least one of these probes . . . . 48
4.5 Enrichment of DMPs for 25 chromatin states . . . . . . . . . . . . . . . . . . . 54
4.6 Enrichment of DMPs for 167 transcription factor binding sites . . . . . . . . . . 55
5.1 Comparison of the grouping and blanket models in the context of the relationship
between DNA methylation and gene expression . . . . . . . . . . . . . . . . . . 62
5.2 A summary of the data cleaning steps . . . . . . . . . . . . . . . . . . . . . . . 64
5.3 Study design with a summary of the results . . . . . . . . . . . . . . . . . . . . 67
5.4 A comparison of h2EWAS estimates given by applying REML using the blanket
and grouping models across 400 traits . . . . . . . . . . . . . . . . . . . . . . . 68
5.5 Boxplots summarising of sensitivity analyses . . . . . . . . . . . . . . . . . . . 70
5.6 The distribution of the number of DNA methylation sites identified at P<1x10-5
across EWAS of 400 traits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
5.7 Association between h2EWAS and number of DMPs identified in EWAS . . . . . . 72
5.8 The ability of h2EWAS values to predict whether the number of differentially
methylated positions identified in an EWAS is higher than expected by chance . . 74
6.1 Overlap between genomic positions identified by corresponding EWAS and GWAS 82
6.2 Can genetic variant associations predict the presence of DNA methylation asso-
ciations in the same region? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
6.3 Flowchart demonstrating how the first set of simulations were set up . . . . . . . 85
6.4 Power to detect overlap between genes and genesets identified by corresponding
EWAS and GWAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
6.5 Flowchart demonstrating how the second set of simulations were set up for each
trait . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
6.6 Simulations to understand the likely number of genes still to identify in EWAS
and GWAS of c-reactive protein and smoking (former vs. never smokers) under
different trait architectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
7.1 Study design with results summary . . . . . . . . . . . . . . . . . . . . . . . . . 108
7.2 Observational associations of DNA methylation and lung cancer: A fixed ef-
fects meta-analysis of lung cancer EWAS weighted on the inverse variance was
performed to establish the observational association between differential DNA
methylation and lung cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
7.3 Mendelian randomization (MR) vs. observational analysis . . . . . . . . . . . . 115
7.4 Comparison of two-sample Mendelian randomization results when using the dis-
covery (ARIES, n = 1018) and replication (NSHDS, n = 468) . . . . . . . . . . . 117
7.5 DNA methylation – lung cancer Mendelian randomization effect estimates in
ever and never smokers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
7.6 Mendelian randomization of DNA methylation on three lung cancer subgroups . 119
7.7 Associations of mQTLs and smoking behaviours . . . . . . . . . . . . . . . . . 121
7.8 Two-sample Mendelian randomization analysis of DNA methylation at AHRR
on lung cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
7.9 Differential DNA methylation in lung cancer tissue . . . . . . . . . . . . . . . . 126
A.1 Full results from simulations assessing power to detect overlap between genes
and genesets identified by corresponding EWAS and GWAS . . . . . . . . . . . 144
A.2 Simulations to understand the likely number of genes still to identify in EWAS
and GWAS of six traits under different trait architectures . . . . . . . . . . . . . 145
A.3 Power to detect overlap between genes and genesets identified by corresponding
EWAS and GWAS when mapping signal to all genes and protein coding genes . . 150
Abbreviations
ALSPAC - Avon Longitudinal Study of Parents and Children
ARIES - Accessible Resource for Integrated Epigenomics Studies
AUC - area under the curve
BMI - body mass index
CCHS - Copenhagen City Heart Study
CI - confidence interval
DMP - differentially methylated position
DMR - differentially methylated region
EFO - experimental factor ontology
ENCODE - Encyclopedia of DNA Elements
EPIC - European Prospective Investigation into Cancer and Nutrition
EWAS - epigenome-wide association study
FDR - false discovery rate
GEO - Gene Expression Omnibus
GO - Gene Ontology
GoDMC - Genetics of DNA Methylation Consortium
GTEx - Gene-Tissue Expression (consortium)
GWAS - genome-wide association study
h2 - narrow-sense heritability
H2 - broad-sense heritability
h2EWAS - the proportion of trait variation captured by DNA methylation commonly
measured in epigenome-wide association studies
h2SNP - SNP-heritability
HM450 array - Illumina Infinium HumanMethylation450 BeadChip
HMEPIC array - Illumina Infinium HumanMethylationEPIC BeadChip
HR - hazard ratio
IQR - interquartile range
KEGG - Kyoto Encyclopedia of Genes and Genomes
LD - linkage disequilibrium
LOLA - Locus Overlap Analysis
MCCS - Melbourne Collaborative Cohort Study
MR - Mendelian randomization
MRM - methylation relationship matrix
mQTL - methylation quantitative trait loci
NOWAC - Norwegian Women and Cancer
NSHDS - Northern Sweden Health and Disease Study
OR - odds ratio
PACE - Pregnancy and Childhood Epigenetics (consortium)
QC - quality control
REML - restricted maximum likelihood
ROC - receiver operating characteristic
SNP - single nucleotide polymorphism
SV - surrogate variable
SVA - surrogate variable analysis
TAG - Tobacco and Genetics (consortium)
TCGA - The Cancer Genome Atlas
TRICL-ILCCO - Transdisciplinary Research in Cancer of the Lung and The Interna-
tional Lung Cancer Consortium
Chapter 1
Introduction
The regulatory processes that occur within human cells can differentiate healthy and unhealthy
individuals. DNA methylation, a small chemical modification to the DNA, is a part of the molec-
ular machinery governing these regulatory processes. Therefore, understanding how variation in
DNA methylation across a population may manifest in observable phenotypic differences, may
yield great medical and sociological insights. Technological advances over recent years have
enabled measurement of DNA methylation at thousands of sites across the genome in hundreds
and thousands of samples. Coupled with these advances have come epigenome-wide association
studies (EWAS), which aim to identify and quantify relationships between DNA methylation
and other human phenotypes. Hundreds of EWAS have now been performed and successful
identification of these relationships vary widely by the trait being studied (1–5). Further, the in-
terpretation of any identified signal is not straightforward (6). This thesis explores explanations
for apparent differences between EWAS results and applies methods to aid interpretation and
future study design for EWAS.
In this chapter I present the historical interpretation of ‘information flow’ in human cells (the
central dogma), describe DNA methylation in the context of regulatory processes that augment
that information flow, discuss its potential for use in population level studies and describe the
current state of EWAS research. Then I explain how we might be able to draw on the methods
developed by geneticists to understand 1. what information has been gained from EWAS, 2.
what information is left to gain from EWAS and 3. the causal nature of DNA methylation-trait
associations identified in EWAS.
1.1 Moving on from the central dogma of molecular biology
To gauge how molecular mechanisms result in more observable phenotypes, it is important to
understand how molecular machinery interacts. The central dogma of molecular biology was
originally proposed by Francis Crick (7,8) and described how information flowed from nucleic
acids to proteins within cells (Figure 1.1). Crick postulated that information could flow from
nucleic acids to proteins, but not from proteins to nucleic acids. By information, Crick was
specifically referencing changes in polymer sequence. Although this is generally the process of
information flow, it does not describe other complex interactions that impact function without
changing polymer sequence. Post-translational and post-transcriptional modifications can influ-
ence the lifespan and function of proteins and RNA respectively (9–12). Proteins of the same
polypeptide sequence can take on slightly different conformations when interacting with other
cellular factors (13) and certain proteins (known as prions) can even alter the conformation of
other polypeptides with the same sequence (14). Further, modifications to the DNA and to DNA-
bound proteins may have a profound influence on the concentration of certain gene transcripts as
well as the post-transcriptional splicing of transcripts (15,16). As mentioned, DNA methylation






Figure 1.1: The central dogma of molecular biology. The dogma stipulates that sequence
changes (that is the addition, removal or mutation of elements) can only occur in the direction of
the arrows. 1. DNA replication 2. Transcription 3. Translation 4. Reverse transcription 5. RNA
replication 6. Direct DNA-protein translation.
The importance of these molecular alterations to phenotypic change is exemplified in the devel-
opmental stages of human life. Humans start as a single cell and after roughly nine months are
transformed into a multicellular organism with trillions of cells, including hundreds of distinct
cell types. As these cells arise from a single progenitor, they must contain identical genetic se-
quences (bar somatic mutations which occur at a low rate – recently estimated to be roughly one
mutation per cell division (17)). The process by which the body is able to create such diversely
functioning cells and tissues, must come from regulation of how the genetic sequence is read and
from the regulation of its products.
In addition to the intra-individual variation that makes the multicellular nature of humans pos-
sible, there is also inter-individual variation in molecular traits (18,19). DNA methylation is
now being used widely by epidemiologists to try and understand how molecular changes across
individuals, that do not involve direct sequence alterations, might result in variation amongst ob-
servable phenotypes in the population. The full rationale and details of these studies will be de-
scribed later, but first I will introduce what is known about the role DNA methylation has within
cells as this is necessary to understand how it may influence observable phenotypes.
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1.2 DNA methylation as part of the regulatory machinery
DNA methylation is correlated with gene expression levels and has been hypothesised to con-
tribute to gene regulation (20–23). This is the main mechanism by which it is thought DNA
methylation influences variability in phenotypes. However, DNA methylation is just one of
many epigenetic marks that are involved in gene regulation. In this section I describe epigenetics
and evidence gathered about the function of different epigenetic marks.
1.2.1 Defining epigenetics
The definition of epigenetics is much debated (24). In the 1940s the ‘epigenetic landscape’
was introduced by Waddington to describe how genes influence cell fates (25). Since then the
term “epigenetics” has been used in many forms, so to avoid confusion, throughout the rest of
the thesis, I will define epigenetics as: “the study of mitotically (and potentially meiotically)
heritable alterations in gene expression that are not caused by changes in DNA sequence” (16).
In an extension to this, epigenetic marks therefore refer to chemical changes to the genome and
genome-bound proteins that are mitotically heritable (i.e. changes that remain after cell division)
and may influence gene expression without changing the DNA sequence.
1.2.2 Histone modifications
DNA within the nuclei of human cells is contained in chromatin. This chromatin consists of DNA
strands wrapped around histone proteins in structures called nucleosomes, forming the “beads
on a string” structures that can be viewed under a microscope (26–28). This is necessary to
allow DNA to be compressed enough to fit into nuclei (26–28). Further, chromatin states can be
manipulated to alter the access other proteins have to the DNA. If a region of the genome is in a
state of heterochromatin then it is highly condensed, which prevents RNA polymerases accessing
the DNA and transcribing its code (27,28). Euchromatic DNA is less condensed, facilitating
easier transcription. Using the beads on a string analogy, one can think of heterochromatin as
being when the string is wrapped tightly around the beads, causing the beads to be in close
proximity of each other, leaving little or no free string, whereas euchromatin, the beads will be
separate and there will be stretches of free string that can be accessed. Without histones this
packaging of DNA into chromatin would not be possible (26,28).
The “beads” are histone octomers - four unique histone proteins each present twice in the nucleo-
some. Post-translational modifications can occur to any of the histone monomers and these have
been associated with both positive and negative changes in gene expression (29–31). Histone
modifications are numerous and complex in nature. To briefly describe the complexity, there are
at least nine types of histone modifications that can occur (32), each of the histone monomers
can be modified across many different sites (30–32), and for any one site multiple of the same
modification can occur (30,31). It is the combination of modifications across all histones that
plays a role in gene expression regulation (30,31). Furthermore, histone modifications are sub-
ject to rapid change upon environmental stimulus to help induce or repress gene expression (29).
Therefore, considerable variation in histone states between individuals at the same sites and in
the same tissue might exist, and this could explain some variation in health outcomes. However,
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the complexity of histone modifications, and the practical difficulties in collecting or assaying
samples to assess these epigenetic marks, remains a barrier to their wide-spread measurement for
use in population-based analyses (6). They may become far more prominent in the future as our
understanding and ability to measure the modifications in a meaningful way increases.
1.2.3 DNA methylation
DNA methylation is the addition of a methyl group to DNA. This primarily occurs at the 5’ cy-
tosine where a cytosine precedes a guanine in DNA sequence (CpG site), however the DNA may
be methylated at other sites (23). Little is known about the role of non-CpG site DNA methyla-
tion in humans and current EWAS tend to only measure CpG methylation. Two papers initially
suggested that the function of this epigenetic mark was to repress gene expression (33,34). Since
then, association with various important intracellular processes such as X-inactivation, genomic
imprinting and suppression of transposon action have been elucidated (34–36). This genomic
modification is also conserved amongst a wide variety of species, including various bacteria,
plants, fungi, and mammals (23,37–39). Interestingly, one of the hypothesised functions of DNA
methylation – protection against ‘parasitic genomic sequences’ – is common to both human cells
and bacterial cells (23,37). However, the relationship with gene expression may not be the same
in prokaryotic organisms (37). Despite the abundance of research conducted in the area in the
last 50 years, the role DNA methylation plays in regulating gene expression within human cells
is not fully understood and research is still ongoing.
One thing research has revealed is that the location of DNA methylation is important to its re-
lationship with gene expression. CpG sites are not randomly distributed throughout the genome
but are often found in clusters (23) and it is thought that methylation and de-methylation of CpG
sites in groups, is what drives their association with regulatory function (23). Clusters known
as ‘CpG islands’ are found at the majority of protein coding genes and constitute small areas
of the genome that are enriched for CpG sites (23,40). The location of these islands as well as
other CpG sites relative to genes and other regulatory elements is also of importance. Several
studies have shown that higher levels of DNA methylation at transcription start sites tends to
be associated with lower levels of gene expression (23,41,42), but gene body DNA methylation
is positively correlated with expression (Figure 1.2) (43,44). This suggests that regulation of
DNA methylation in clusters at specific sites relative to genes is important in determining ob-
served relationships with gene expression. Supporting this, there are clear biological processes
that regulate DNA methylation at nearby sites together, for example, CpGs at transcription factor
binding sites can be de-methylated as a group when the transcription factor binds (45). Further,
nearby sites are often correlated (46,47). However, there is no evidence to suggest that neigh-
bouring sites do indeed act in tandem or whether it is likely one site from the group is driving
regulatory function. This is something I explore in Chapter 5.
These strong associations between DNA methylation and gene expression do not necessarily
mean that the addition or removal of methyl groups will actively impact gene expression. Elu-
cidating the causal nature of the association between DNA methylation changes, at single sites
or across regions, and gene expression has been fraught with difficulties and has often provided
conflicting results. One study showed an enzyme that catalyzes the addition of methyl groups
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to the DNA, DNA methyltransferase 3A, is required in haematopoeitic stem cells for them to
differentiate, suggesting gene expression changes required for differentiation were not possible
without addition of methyl groups to the DNA (48). However, studies have provided evidence
that DNA methylation is unlikely to initiate the ‘silencing’ of gene expression and may occur at
transcription start sites of genes after they’ve already been repressed (49,50). To further com-
plicate things, if DNA methylation does influence gene expression, the mechanism of action is
unclear and may depend on the gene being examined. One study showed the presence of DNA
methylation at the binding sites of the transcription factor, MYC, was inversely associated with
its binding (51), but another study suggested the presence of DNA methylation didn’t have the
same impact on the binding of the transcription factor, SP1 (52). Although the body of work
presented in this thesis does not aim to explore if and how DNA methylation influences gene
expression, it is important to note the relationship between the two isn’t clear when thinking of




Figure 1.2: Simplified diagrams of the associations between DNA methylation and gene
regulation. In a, CpG sites are methylated at the promoter region, but not in the gene body,
which is associated with lack of gene expression. In b, the opposite is occurring.
1.3 Population-based studies of DNA methylation associations
The importance of DNA methylation in disease has already been established in rare developmen-
tal disorders caused by aberrant imprinting patterns (54,55). In the past 15 years, technological
advances have enabled researchers to measure DNA methylation across thousands of sites in the
genome at low cost (56,57). This provides the opportunity to study the relationship between
DNA methylation and common traits with more complicated aetiologies, where large samples
may be needed to ascertain reliable associations. Despite years of these studies, the relationship
between DNA methylation and complex traits is unclear. In this section I discuss the study of
complex traits, the appeal of studying DNA methylation for public health, introduce the most
common study design to assess DNA methylation-trait associations, EWAS, and overview some
successes and complications of the work.
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1.3.1 Studying complex trait associations
Using DNA methylation in population-based studies comprises studying its association with
complex traits, which are phenotypes that are caused by a myriad of factors. The phenotypic
value of any complex trait can be partitioned into its corresponding genetic (G) and environmen-
tal effects (E) like so
z = G+ E (1.1)
Both the genotypic and environmental values can further be partitioned into various effects (58).
As E can be defined as any variation in z that is not explained by G, this also includes stochastic
processes, which may account for a large proportion of E. It’s important to remember that DNA
methylation itself is a complex trait and thus methylation of DNA at a given CpG site, is the result
of a variety of genetic and environmental factors (23). However, unless explicitly stated, when
discussing complex traits, I will be referring to human health and socio-economic outcomes
rather than molecular phenotypes such as DNA methylation and gene expression.
Phenotypic values for any complex trait will vary across the population as each individual has
a unique genomic sequence (except monozygotic twins) and is exposed to a variety of different
environments, both external and internal.
Studying the associations between complex traits and other measures across the population can
help deduce the aetiology of that trait, but phenotypic values may also covary with measures that
have no implication for that traits aetiology. Identifying these covariations can still be useful for
phenotype prediction.
It should be noted that different fields of study may have different views on the importance of
certain factors for complex traits. As discussed, there is evidence that DNA methylation may be
inconsequential to gene expression changes (49,50), making it an unattractive measure to study
when interested in the aetiology of cellular phenotypes in molecular biology. For epidemiologi-
cal studies, understanding how DNA methylation covaries with complex traits could help provide
useful predictors and despite the difficulty in untangling the contributions of E to z, could yet
yield insights into the underlying biology of complex traits. This will be explained in more detail
in the coming sections.
1.3.2 The potential value of DNA methylation measures to epidemiologists
Epigenetic modifications are of potential interest to those studying any phenotype. Arguably,
epigenetics could be required at some level for all phenotypic changes and, if causal, could be
the difference between individuals who develop disease and those who do not (57). Further, epi-
genetic marks are modifiable, which means theoretically it would be possible to prevent or treat
disease by altering such epigenetic patterns of individuals (59). However, there are large practi-
cal issues with targeting DNA methylation with pharmaceutical agents, which are discussed in
more detail in Section 1.3.4. Even if targeting epigenetic marks is not easy, as long as it is pos-
sible to observe them, they could be used as diagnostic biomarkers and predictors (6,57,60,61).
Thus, the ability to measure, and the research in to understanding epigenetic mechanisms, could
have broad consequences for public health.
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A major difference between DNA methylation and other epigenetic marks, is that DNA methy-
lation is more stable. Enzymes do exist that can actively de-methylate the DNA, for example
the ten-eleven translocation (TET) enzymes, but cell division or excision of the nucleotide is
required for full de-methylation of a DNA molecule (62,63). Biologically, this suggests DNA
methylation might be involved in long-term repression of gene expression, which is thought to
be the case for X-inactivation (64), and practically it makes studying the epigenetic mark easier
because stability ensures the marks are more resistant to changes after collection of samples.
Also, even though it is not clear that DNA methylation precedes gene expression regulation, the
regulatory processes that govern whether genes are transcribed are linked. The totality of epige-
netic marks and the chromatin structure of a genomic region may be thought of as the “epigenetic
state” of that region. It is this state and not one mark that is likely responsible for the regulation of
gene expression (65,66). However, as the marks correlate with one another as well as chromatin
state, one may be able to proxy this state by measuring a limited number of the marks. There
are known examples of how DNA methylation tends to associate with other epigenetic marks,
including positive correlation with the histone modification H3K9me3 (23) and histone deacety-
lation (23,67). This means measuring DNA methylation may capture the epigenetic state, even
if addition or removal of methyl groups to the DNA would have little impact on gene expression.
Recently, it has been shown that epigenetic marks can be used to predict each other with high
accuracy (68), adding weight to the argument DNA methylation measurements capture far more
than just DNA methylation itself.
1.3.3 Epigenome-wide association studies
When considering designing a study to assess whether one trait associates with another, usually
there are a priori hypotheses or evidence that suggest studying the association would be of rele-
vance to scientific understanding and public health. For studying the association between DNA
methylation and complex traits, there is an abundance of evidence suggesting this could yield
results of relevance. As mentioned previously, no phenotypic change is possible without some
molecular change, DNA methylation is a relatively easy molecular measurement to make and it
is known to highly correlate with an important component of cellular regulation – gene expres-
sion. Further, DNA methylation has the potential to improve upon the prediction of complex
traits beyond what can be done with current epidemiological and clinical measures (57) as well
as with genetic variants (69,70).
EWAS are the most common study design for assessing the association between DNA methy-
lation and a complex trait. They typically involve measuring hundreds of thousands of DNA
methylation sites across the genome in a case-control or cohort setting and using linear models
to assess the association between DNA methylation and the trait of interest.
Ideally, in every sample used in an EWAS, DNA methylation would be measured across all
sites in the genome. Unfortunately, this is not currently possible and sequencing technologies
that offer something similar are often very expensive. There are three alternatives available to
measuring DNA methylation for studies assessing the relationship between the epigenetic mark
and complex traits of interest. Firstly, one could sequence a small portion of the genome if
this section is of particular interest. This candidate gene model was employed by the genetics
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community before the era of genome-wide association studies. It led to a large number of false
positives due to poor statistical practice and publication bias (71–73). Therefore, this candidate
gene approach is unlikely to be profitable unless the genes targeted already have very good
evidence for epigenetic variation with the trait of interest. As complex traits are polygenic (58)
and we have incomplete knowledge of their underlying biology, a hypothesis-free approach, that
samples from as much of the genome as possible, is preferable. Secondly, measuring DNA
methylation on repeat sequences of the genome, such as long interspersed nuclear elements
(LINEs) and short interspersed nuclear elements (SINEs), can provide estimates for global DNA
methylation changes (74). These measurements indicate if a trait is related to large perturbations
of DNA methylation across the genome, but give little mechanistic insight into what effects these
changes may be having, as methylation at functional genes is not measured. Thirdly, one could
employ an array approach that covers DNA methylation genome-wide at selected sites. This last
approach is the most common for population-based studies as it enables measurement of DNA
methylation at hundreds of thousands of sites at a relatively cheap price per sample (75).
Without capabilities to measure methylation at every site in the genome, one must decide which
sites are worth measuring. Current commonly used array technologies include the Illumina
Infinium HumanMethylation450 BeadChip (HM450 array) and the Illumina Infinium Human-
MethylationEPIC BeadChip (HMEPIC array), which measure DNA methylation at over 450,000
sites and over 800,000 sites respectively. They cover roughly 1.5-4% of CpG sites in the genome
(76). In order to capture what was thought to be the most relevant DNA methylation sites in
relation to complex traits, the probes were chosen to map to 99% of RefSeq genes and predom-
inantly map to the promoter regions of these genes (77). One reason for this was to potentially
help improve interpretation of EWAS findings (77). Identifying methylation changes at a specific
gene suggests investigating the relationship of that gene and the complex trait further may yield
interesting results, whereas interpreting complex trait associations with DNA methylation at a
site in a relatively uncharacterized region of the genome would be more difficult for obvious rea-
sons. The strongest association between DNA methylation and gene expression comes at CpG
sites clustered around transcription start sites (23), thus enrichment of probes targeting promoter
regions may also help with interpretation of EWAS.
To measure DNA methylation, these array technologies, as well as sequencing techniques, often
begin with bisulphite conversion of the DNA (56). This converts any un-methylated cytosine
base to uracil and leaves methylated cytosines unchanged (27). The DNA samples can then
be distributed amongst the array and the probes on the array will bind cytosines present at the
regions for which their sequence corresponds (27). If a probe binds its target cytosine, then it
will fluoresce, and this fluorescence can be quantified to give ‘beta values.’ Beta values range
between zero and one, with zero corresponding to no methylation across all DNA molecules (in
a sample) at the target cytosine and one corresponding to methylation across all DNA samples
at the target cytosine. DNA methylation is by nature a binary feature, but mixtures of DNA
molecules (i.e. multiple cells) mean that a continuous variable is generated unless single cell
procedures are adopted.
This study design has been widely adopted over the past ten years and the relationship between a
plethora of traits, from smoking to anthropometric measures to childhood adversities, and DNA
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methylation has now been studied (1–4). There are also large consortia that are pooling samples
to gain power for these studies, for example the Pregnancy and Childhood Epigenetics (PACE)
consortium (78). A few traits have been identified as being associated with large variations in
DNA methylation, one of which is smoking, where strong associations across thousands of sites
have been identified and many replicated in EWAS of smoking (1). It has been revealed that
the association at some sites is driven by smoking causing changes in DNA methylation and
over time these DNA methylation changes may be (mostly) reversible by giving up smoking
(79). Also, DNA methylation can be used to predict smoking status, and one study has provided
evidence that DNA methylation of a single locus can predict smoking status with high accuracy
(80). Another measure shown to relate to large variation in DNA methylation across the genome
is age. Similarly to smoking, DNA methylation makes a highly accurate predictor for age and is
thought to be able to establish whether rate of ‘biological’ aging is different from chronological
aging (81–83). These studies have shown that large perturbations in the DNA methylome can be
related to complex traits and highlight the potential for EWAS to identify accurate predictors for
these traits.
1.3.4 Problems for EWAS
Interpreting the associations discovered in EWAS, with regards to understanding trait biology and
development of interventions that target DNA methylation, require two key components. Firstly,
the causal nature of associations between DNA methylation and the complex trait of interest,
i.e. do the associations reflect epigenetic pertubations that are impacting complex trait variation,
is the reverse true, or are the effect estimates biased? Secondly, the cellular consequence of DNA
methylation variation at the identified genomic regions. As postulated previously, DNA methy-
lation may be marking an epigenetic state and alterations to the whole state could be required to
impact phenotypic variation.
Elucidating the truth from these components is extremely difficult. Therefore, despite the
promise of understanding the underlying biological processes related to traits, studying the
relationship between DNA methylation and complex traits provides many practical difficulties
that often make the results of EWAS hard to interpret (6).
Confounding
As discussed with the example of smoking EWAS, DNA methylation changes may come as a
response to complex traits. This inherently leads to two issues within EWAS that are pervasive
across observational epidemiology, confounding and reverse causation. Having EWAS identify
molecular changes that are caused by variation in the trait of interest (reverse causation) is not
necessarily a limitation. In fact, this allows for downstream consequences of a trait to be ex-
plored hypotheses regarding molecular mediation to be tested. Confounding amongst EWAS is
a far bigger issue. This is where the traits of interest share a common cause, which can gener-
ate effects and bias effect estimates, hindering correct interpretation of the association between
traits. For example, smoking is common cause of both DNA methylation and lung cancer risk,
thus without adequate adjustment for smoking behaviour in an EWAS of lung cancer, one might
incorrectly infer that changes in DNA methylation that are the result of smoking, cause an al-
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teration in lung cancer risk. Complex traits (including molecular traits) are strongly correlated
with each other, often in clusters, which can lead to large amounts of measured and unmeasured
confounding being present in EWAS (84,85). Of course, in order to produce therapies to prevent
or treat disease by altering DNA methylation or other parts of the epigenome, causality must be
established. Therefore, problems of confounding must be overcome in EWAS to use these re-
sults to start developing methods of targeting DNA methylation changes, this is discussed more
in Section 1.4.4.
Cell type heterogeneity
As discussed, epigenetic factors guide differentiation of a single pluripotent cell to hundreds of
cell types in human development. As these cell types can have large differences in morphology
and function, it is clear that epigenetic marks, including DNA methylation, will vary between
cell types (86,87). This poses two distinct problems for EWAS. Firstly, when collecting samples
to measure DNA methylation, unless cells are purified, then a pool of cell types will be present
in the samples, each with their own distinct DNA methylation patterns. This can lead to issues
of confounding by cell type. For example, in a case control study, cases may be more likely
to have increased numbers of CD4+ Th2 immune cells and these cells may on average have
a higher level of DNA methylation at site X. In this scenario if one were to take blood cells,
measure DNA methylation, and assess the association between DNA methylation and the trait
of interest, one might find an association between DNA methylation at site X and the trait, but
this may just be function of the increased number of CD4+ Th2 cells present in cases and site X
may have no causal relationship with the trait itself. In reality, there are often thousands of CpG
sites that have differential methylation between cell types, which could result in a host of biased
effect estimates. There have been efforts to try and account for cell type heterogeneity in EWAS
(86,88,89), but to completely prevent its confounding effects, cells should be collected from a
homogenous tissue or purified. In addition to generating false positives, this confounding could
mask true effects found within specific cell types. The second problem arising from cell-type
specific patterns of DNA methylation is the uncertainty that the cell type being studied is one in
which DNA methylation covaries with the trait of interest. Non-invasive cells to collect, such as
blood, skin, and saliva, are common amongst epidemiological studies, but it is unclear whether
EWAS in these studies are relevant to a large proportion of complex traits. This is studied,
with regards to blood, in Chapter 5. Studies have actually shown high levels of correlation
between DNA methylation across cell types at many CpGs (90), but it is unknown whether
the correlated sites are important to trait variation. Further, this correlation may complicate
interpretation of EWAS findings with regards to translational potential. Associations may be
found in blood because those CpGs correlate with causal CpGs in another tissue, such as the
brain, in this situation an intervention on DNA methylation levels in blood will fail to illicit the
expected response and it may transpire that targeting the causal CpGs in the correct tissue is
unfeasible.
Measuring DNA methylation
DNA methylation arrays face certain technical issues. Some probes map to single nucleotide
polymorphisms (SNPs), which can lead to inadvertent detection of genetic variation, others map
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to multiple sites across the genome (i.e. are non-specific) and others may cross-hybridise. Batch
effects can also substantially bias results in EWAS (91). Considerable effort has been made
to characterise the arrays to identifiy potentially faulty probes (92,93) and methods developed
(some originally for use in RNA-based studies) to help correct for batch effects (94–96). In
Chapter 4 I explore the extent to which batch effects tend to be removed in current EWAS
and whether EWAS results are enriched for potentially faulty probes not removed by study au-
thors.
Complexity of regulatory mechanisms
EWAS identify single sites in the genome for which DNA methylation variation is associated
with a trait of interest. As discussed, DNA methylation at a single site will likely be correlated
with DNA methylation at neighbouring sites and other nearby epigenetic marks. This makes
inferring mechanism of action very difficult. Differentially methylated region (DMR) analysis
is often employed, which aims to determine if multiple neighbouring sites share an association
with the trait of interest with the same direction of effect (47,87). These give evidence as to
whether the sites covary similarly with the trait of interest, but do not provide evidence that
the sites are acting independently or not. There are ways to circumvent the issues of biological
complexity, but without additional gene expression data these often involve assuming the genes
immediately adjacent to DNA methylation changes are of importance to the trait. However, no
systematic evaluation of whether this assumption holds true for the majority of cases has been
conducted.
Treatments
Currently there are therapies used in the clinic that target enzymes responsible for epigenetic
alterations, for example DNA methyltransferase inhibitors and histone deacetylase inhibitors
(97,98). They are primarily used to treat cancers, but as with many cancer treatments, are highly
toxic. These therapies impact the epigenome globally and do not target any specific regions
of the genome. This makes them highly undesirable for most diseases and as of yet there are
no epigenetic therapies targeting specific regions of the genome. Methods, such as adapting
CRISPR-cas9 enzymes, are being used in laboratories to alter DNA methylation at specific sites
(99), and some have even achieved in vivo targeted epigenetic modulation in mice (100). How-
ever, it is unclear whether these techniques can be scaled up for clinical use in humans and how
long it may take to overcome the various complications.
In summary, there is great potential for EWAS to identify sites in the genome that could be
targeted for treatment, but there are several challenges still to overcome. A great importance
should be placed on using the data available to inform future designs of EWAS to maximise the
potential of these studies.
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1.4 Using methods from statistical genetics to help inform future
EWAS
In order to remedy some of the problems EWAS face and to help understand whether the “ex-
periment” of measuring DNA methylation across many epidemiological cohorts and studies has
been successful, we can borrow ideas and methods developed in statistical genetics and genetic
epidemiology.
Statistical genetics is concerned with ascertaining the connection between traits and genetic vari-
ation. Germline genetic variants, the units of measurement for genome-wide association studies
(GWAS), are fixed from conception and the association between these variants and complex
traits tends to be unconfounded (101,102). Therefore, the properties of these variants and DNA
methylation are different and one would expect the genetic and epigenetic architectures of com-
plex traits to differ. However, genetic epidemiologists have had to overcome problems to help
interpret GWAS, which are also pertinent to EWAS. These include understanding how much trait
variation is captured by all the variants used in the study and how to infer function from genetic
variation. Further, cataloging genetic associations has proven an invaluable resource for the re-
search community (103) and these variants can be used as tools to augment the understanding
of DNA methylation-trait associations. In this section I briefly describe some examples of these
efforts and explain how they might be adapted to help inform future EWAS.
1.4.1 Catalogues of genome-wide associations
Cataloging genome-wide associations has a broad range of applications for researchers, from
replication of GWAS, to identifying overlapping GWAS signals between traits, to pooling the
data to try and understand the genetic architecture of complex traits as a whole. There are
multiple databases now available to the genetic epidemiologist community that have catalogued
these associations. These include manually curated databases of publicly available GWAS data,
The GWAS Catalog, (103) and the IEU OpenGWAS Project (104,105). A corollary database for
EWAS is likely to also provide value for epigenetic epidemiologists. At the very least it would
provide an easy tool to assess whether results replicate. Catalogues such as EWASdb (106) and
the EWAS Atlas (107) are currently available but fall short of some key researcher requirements
including ease of use and access to full summary statistics. The development of a new database,
The EWAS Catalog, is the focus of Chapter 3.
1.4.2 Total variance captured by all sites measured genome-wide
In addition to cataloguing the information gained, efforts also need to be made in understanding
the epigenetic architecture of complex traits to enable interpretation of these data.
As discussed, the phenotypic value of any trait can be partitioned into genetic effects and en-
vironmental effects. Thus, the variation of phenotypic values are the function of the genetic
variance (σ2G) and environmental variance (σ
2
E),
σ2z = σ2G + σ2E (1.2)
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The environmental effects could be split into a large number of different factors, most of which
would negligibly influence the phenotypic variance. Knowing the extent to which each factor
contributes to phenotypic variation is important for two reasons. Firstly, if a factor substantially
influenced phenotypic variation then by modifying that factor one could modify the phenotypic
values across a population. Secondly, one can identify which factors may best predict pheno-
typic values within a population. Currently, it is unknown how much variation in complex traits
is attributable to DNA methylation changes. As discussed, assessing whether DNA methylation
affects complex traits is difficult, but understanding whether they covary can still help quantify
its total predictive capacity. Further, understanding how DNA methylation, as measured in con-
temporary EWAS, covaries with complex traits can help give insight on the validity of current
study designs.
Many EWAS have been conducted and few have identified strong associations that capture sub-
stantial complex trait variation. Tissue types used and sites measured may partially explain this.
It is a possibility that DNA methylation might not covary with many complex traits, or it could
be that the associations between DNA methylation at individual sites are numerous, but the as-
sociations at each site are too small to detect with current sample sizes.
By combining information across all sites measured, one could quantify the total variation cap-
tured by DNA methylation for a complex trait of interest and so could properly assess the utility
of association studies using the tissue types and sites measured.
Methods have already been developed to assess the total contribution of genetic variants mea-
sured in GWAS to complex trait variation (108,109) and in Chapter 5, I repurpose these methods
developed to estimate the proportion of phenotypic variance correlated with DNA methylation
across a range of phenotypes.
1.4.3 Inferring biology from signals
As discussed, the complexity of cellular processes makes it difficult to infer what consequences a
change in methylation at a specific site may have. Similarly, for the majority of SNPs identified in
GWAS, the functional change that relates to an association between genetic variation at that site
and the trait of interest is unclear. Complex traits themselves are the result of a large number of
complicated biological pathways that are determined by potentially thousands of gene products.
It is often assumed that the signal from GWAS highlight genomic regions of importance to the
trait and thus as a step to investigate the nature of the signal, sites identified are mapped to nearby
genes. These genes can then be mapped to pathways and gene set enrichment analysis performed
to assess whether the genes identified are present in any particular pathways more than expected
by chance. This method has been adopted by epigenetic epidemiologists for use to examine
EWAS signal (110). Given the DNA methylation probes on contemporary arrays were chosen
specifically based on their proximity to protein coding genes, this gene mapping technique may
actually be more valid for CpG sites.
Establishing causality from DNA methylation signal is difficult (See Sections 1.3 and 1.4.4).
Thus, when applying gene set enrichment analyses to identify prominent pathways in EWAS
signals, the pathways identified may be downstream consequences of one or many confounders
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rather than of aetiological relevance to the trait of interest. Further, the EWAS signals, and there-
fore pathways they might influence, may be a consequence of trait variation. This is important to
remember when interpreting the results of such an analysis, but it does not render the results use-
less. There is a huge body of work that characterises gene action and relationships of this gene
action with various traits. By mapping EWAS signals to genes and pathways, a path between
the trait (or a confounder) and changes in DNA methylation might become clearer. One example
of this comes with EWAS of smoking, that have consistently identified DNA methylation at the
AHRR gene (1,111–114). This gene is known to play a role in handling toxic substances found in
tobacco smoke (115,116). Thus, large changes in DNA methylation related to this gene points to-
wards epigenetic changes at that locus influencing the cellular response to smoking. This shows,
that despite difficulties in interpreting EWAS findings and subsequent pathway analysis, EWAS
can actually add to the pool of information about underlying trait biology when used in conjunc-
ture with other evidence. Although, it is important to note this is one of many sites identified in
smoking EWAS and there are plenty of sites for which changes in DNA methylation are yet to
be explained.
Understanding both the causes and consequences of complex traits are pertinent to intervening on
health outcomes. As EWAS has the potential to identify both, it could identify important facets
of trait biology missed by GWAS studies; however, it is unclear as to whether the analogous
gene set enrichment design adopted by EWAS is currently adding to the information discovered
by GWAS. In Chapter 6 I compare overlap of GWAS and EWAS signals in this context and
discuss the use of both study designs in elucidating underlying trait biology.
1.4.4 Establishing causality
As discussed, EWAS are a form of observational epidemiological study. These studies are lim-
ited by the data at their disposal and the highly correlated nature of complex traits (101). When
studying relationships between complex traits, one would ideally be able to setup an experiment
to remove the influence of all factors other than the ones of interest. Randomised controlled trials
(RCTs) attempt to emulate this scenario and some EWAS have been conducted under the RCT
framework (117–119). However, they are expensive and not plausible to study some traits, so
relying on them to provide aetiological inference across the spectrum of complex traits studied
in EWAS is not realistic. Other study designs may be used to try and limit the impact of reverse
causation and confounding. For example, when studying the effect of an exposure on an out-
come, if the study participants are exposed before the outcome of interest then reverse causation
may be unlikely. Despite many efforts to avoid or adjust for confounding factors, observational
epidemiological findings often do not replicate in a trial setting (84).
Mendelian randomization
One method that aims to mitigate confounding and reverse causation is Mendelian randomiza-
tion (MR) (101,102,120), which uses genetic variants as proxies for the exposure of interest in
an instrumental variable framework (illustrated in Figure 1.3). Using genetic variants as instru-
ments has the advantage that the direction of effect will always be from instrument to exposure
and not vice versa, making interpretation of the studies simpler. Furthermore, unlike environ-
14
mental phenotypes, that tend to be highly correlated and clustered into groups, genetic variants
associated with a trait tend to be unconfounded (101,102). In the absence of assortative mating,
genetic variants should be distributed randomly across the population, so in effect those grouped
by genotype should exhibit differences in exposure, but confounding factors should not differ
between genotype groups (102). Assortative mating has been reliably shown to occur with some
traits such as social behaviours and anthropometric measures (121–123). Assortment tends to
occur on visible social factors and so intentional assortment based on DNA methylation profiles
is very unlikely. However, DNA methylation may associate with factors that are assorted on, for
example alcohol consumption (124,125), which may lead to unintentional assortment on DNA
methylation profiles. The impact this may have on MR studies using DNA methylation has not
been explored, and this analysis is beyond the scope of this thesis but is something that should
be noted when assessing the reliability of such MR studies.
Availability of data for MR
Another advantage of MR is the data it uses. Thousands of GWAS have been conducted giving
researchers ample instruments for a wide variety of traits and many of these instruments are eas-
ily accessible through databases such as the GWAS Catalog (103) and IEU OpenGWAS Project
(104,105). Furthermore, it isn’t necessary to use individual-level data to conduct MR studies;
summary statistics from GWAS are all that is needed to provide data in a two-sample MR frame-
work (126,127). This is especially valuable to conducting MR studies using DNA methylation
data as DNA methylation is not widely measured across cohorts and case-control studies. Thus,
without a method to combine summary data from both GWAS of DNA methylation and GWAS
of other complex traits, well-powered MR studies would not be possible to assess the potential
effect of DNA methylation on complex traits (and vice versa).
Assumptions of MR
In order for MR analyses to be valid, they must satisfy three instrumental variable assumptions,
these are illustrated in Figure 1.3. Testing assumption one, the instruments associate with the
exposure of interest, is simple, but the other two assumptions cannot technically be proven to be
true. Horizontal pleiotropy, where genetic variants associate with more variables than just the
exposure of interest, can lead to violations in assumptions two and three. Ideally, MR would be
performed in the context where the genetic effect on the exposure had been characterised such
that the mechanism of action was understood clearly. This would help give evidence against
assumptions two and three being broken. Unfortunately, this is rarely possible. However, a
plethora of methods have now been developed to test for pleiotropic effects, given the exposure
of interest has multiple independent genetic variants reliably associated with it.
Applying MR in a DNA methylation context
MR can be applied to studies of DNA methylation by using methylation quantitative trait loci
(mQTL), genetic variants associated with changes in DNA methylation levels, as proxies for
DNA methylation variation (57,85,128). As mentioned previously, using a two-sample MR







Figure 1.3: Mendelian randomization. Mendelian randomization can be used to test the causal
nature of exposure-outcome relationships provided the assumptions are met. Assumption 1.
There is an association between the instrument and the exposure. Assumption 2. There are no
associations between the instrument and outcome, except through the exposure. Assumption 3.
The instrument is not associated with any factors that confound the exposure-outcome relation-
ship.
methylation site few independent mQTLs have been identified (129), which prevents the use of
various tests to examine whether the instruments are likely to be pleiotropic. Further, without re-
liable associations between SNPs and DNA methylation at some sites, MR cannot be conducted.
Both cis-mQTLs (mQTLs within 1Mb of the DNA methylation site) and trans-mQTLs (mQTLs
over 1Mb away from the DNA methylation site) have been identified in GWAS of DNA methyla-
tion variation. As genetic architecture of DNA methylation changes is also not well understood,
the mechanism of action for each mQTL can only be speculated at present. Cis-mQTLs are
thought to be less likely to be pleiotropic than trans-mQTLs as the mechanism of action seems
more likely to be related to the binding of regulatory machinery that may influence DNA methy-
lation levels (85,130). For example, a genetic variant may decrease the affinity of a transcription
factor for that region and so the transcription factor will bind less frequently and/or for a shorter
period, this would lead to increased methylation at that site (131). On the contrary, the mecha-
nism of trans-mQTL action, especially those on separate chromosomes to the DNA methylation
site of interest, is more likely to be pleiotropic (130), for example a trans-mQTL could influence
gene expression of a transcription factor that binds many sites and alters their DNA methylation
(132), this would make the trans-mQTL associate with multiple DNA methylation sites. There-
fore, if one limits mQTLs to those in cis, this gives greater confidence that horizontal pleiotropy
isn’t biasing results.
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Due to the complexity of cellular regulatory mechanisms (Section 1.2), it may be impossible to
identify the exact cause of changes in complex traits, even with replicated MR results that give
strong evidence of an effect of DNA methylation on a complex trait.
As mentioned, DNA methylation varies both temporally and across cell types. If the instru-
ments used to represent DNA methylation are viewed as influencing life-time differences in
DNA methylation between individuals, then temporal variation can be ignored. However, cell
type-specific effects are likely to occur for some mQTLs. In some cases genetic variation may
influence proximal DNA methylation by altering the binding affinity of transcription factors for
that region. In cells for which chromatin structure prohibits binding of transcription factors to
that region, genetic variation would have no impact on DNA methylation. Thus, genetic variation
would have an impact with DNA methylation in some cells but not others.
With all this in mind, it is important to maintain the idea that making strong conclusions of
causality in the context of DNA methylation is difficult, but triangulating evidence from multiple
sources could be key to understanding the role of DNA methylation in underlying trait biology
(133).
Such evidence can come from different sources of statistical methodology that can be used to
assess causality in observational studies (134–136). One that has been applied in EWAS includes
taking advantage of temporal measurements (137). If DNA methylation is measured before the
trait of interest, then chances of reverse causation are greatly diminished, although confounding
may still be an issue. DNA methylation associations may also be tested across different, relevant
tissue types and molecular biology can be used to augment epidemiological evidence. Tools exist
to experimentally manipulate DNA methylation at specific regions of the genome in cultured
cells or in model organisms (99,100). Using a negative control design, one could follow up any
findings from an epidemiological study like an EWAS, in the laboratory by assessing if changes
in the DNA methylation sites identified have any intracellular impact. This could be done for a
variety of tissue types of interest.
To truly provide strong evidence that changes in DNA methylation are causally related to a trait,
one must take a cross-disciplinary approach.
1.5 Overview of thesis aims
DNA methylation has great potential for use in an epidemiological sense and as samples with
DNA methylation data continue to grow it is important to understand the limitations of EWAS
and how to maximise its potential. My thesis aims to address this by exploring what information
has been gained from EWAS (Chapters 3 and 4), what information is still to gain from EWAS
(Chapter 5), whether EWAS might add to our biological understanding of complex traits above
GWAS (Chapter 6) and by applying MR in a particular case, the potential for confounding in
EWAS (Chapter 7). See the flowchart in Figure 1.4 for a graphical depiction.
In Chapter 3 a database of published EWAS is curated and made publicly available, which will
be used in later chapters. The aim of Chapter 4 is to analyse the results present in this database
jointly to allow the discovery of commonalities across methylome-trait associations and provide
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a platform to explore what is driving these commonalities. Further, the chapter explores the
extent to which published results are reliable by assessing replication rate and whether sites
measured by unreliable probes are prominent.
After exploring the information already gained from EWAS, Chapter 5 investigates the infor-
mation still to gain from EWAS. The aim of the chapter is to apply methods developed to assess
SNP-heritability to estimate the proportion of complex trait variation that is associated with sites
commonly measured in EWAS. Quantifying the total covariation of DNA methylation measured
in EWAS and complex traits enables an evaluation of whether study design should be altered to
maximise understanding of complex traits through DNA methylation.
Chapter 6 will then aim to assess whether the discoveries of EWAS may provide extra biological
insight for traits of interest on top of those from GWAS. Tests will be applied to assess whether
there is more overlap between the sites, genes or pathways identified by some large EWAS (N >
4500) and their corresponding GWAS than expected by chance.
Finally, Chapter 7 will apply MR to explore the causal nature of associations between DNA
methylation and lung cancer. This application case-study will compare and contrast findings to
conventional EWAS estimates to give an example of the potential residual confounding that can
be present in EWAS.
18
What information has been
gained from EWAS?
What information is still to
gain from EWAS?
Does EWAS give increased
biological insight to what is
gained from GWAS?
Are EWAS associations likely
to be causal?
Chapter 3
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Figure 1.4: Thesis flowchart. Flowchart showing questions being asked in the thesis and the





I utilize multiple data sources throughout this thesis and in this chapter, each of these sources will
be described in relevant detail so that they can be referenced for future results chapters. Table
2.1 gives a list of the data sources used, which results chapters they appear in and what type
of data I extracted from each source. It should be noted that I also use databases of molecular
and genomic annotations, for example the Gene Ontology resource that brings together evidence
across fields to annotate genes based on proposed function, pathways they are involved in and
where the gene products are active in the cell (138,139). These are not described here, but are
described in the chatpers they were used.
2.1 Accessible Resource for Integrated Epigenomic Studies
(ARIES)
2.1.1 Summary
ARIES is a subsection of the Avon Longitudinal Study of Parents and Children (ALSPAC)
prospective birth cohort (140). This data source contains dense phenotypic data, DNA methy-
lation data measured by the HM450 array, and genotype data from 1018 mother–child pairs.
Whole blood samples were collected for DNA methylation measurement at three timepoints in
children and two in their mothers, the timepoints with mean ages in years (in brackets) are as fol-
lows for children: birth, childhood (7.5), adolescence (17.1) and for mothers: during pregnancy
(28.7), and at middle age (46.9). Within this thesis, data from mothers at middle age was used
for all the analyses and after exclusion of individuals during quality control steps, this lead to a
maximum of 940 mothers used in any analyses.
2.1.2 ALSPAC description
ALSPAC recruited pregnant women in the Bristol and Avon area, United Kingdom, with an ex-
pected delivery date between April 1991 and December 1992 (http://www.bris.ac.uk/a
lspac/). Over 14,000 pregnancies have been followed up (both children and parents) through-
out the life-course. Full details of the cohort have been published previously (141,142).
Ethical approval for ALSPAC was obtained from the ALSPAC Ethics and Law Committee and
from the UK National Health Service Local Research Ethics Committees. Written informed
consent was obtained from both the parent/guardian and, after the age of 16, children provided
written assent. The study website contains details of all the data that is available through a fully
searchable data dictionary (http://www.bristol.ac.uk/alspac/researchers/a
ccess/).
Study data were collected and managed using REDCap electronic data capture tools hosted at
ALSPAC (143,144). REDCap (Research Electronic Data Capture) is a secure, web-based soft-
ware platform designed to support data capture for research studies, providing 1) an intuitive in-
terface for validated data capture; 2) audit trails for tracking data manipulation and export proce-
dures; 3) automated export procedures for seamless data downloads to common statistical pack-
ages; and 4) procedures for data integration and interoperability with external sources.
2.1.3 ALSPAC genetic data
Mothers were genotyped using the Illumina human660W-quad genome-wide single nucleotide
polymorphism (SNP) genotyping platform (Illumina Inc., San Diego, CA, USA) at the Centre
National de Génotypage (CNG; Paris, France). SNPs were removed if they displayed more than
5% missingness or a Hardy-Weinberg equilibrium P value of less than 1.0e-06. Additionally,
SNPs with a minor allele frequency of less than 1% were removed. Samples were excluded
if they displayed more than 5% missingness, had indeterminate X chromosome heterozygosity
or extreme autosomal heterozygosity. Samples showing evidence of population stratification
were identified by multidimensional scaling of genome-wide identity by state pairwise distances
using the four HapMap populations as a reference, and then excluded. Cryptic relatedness was
assessed using a IBD estimate of more than 0.125 which is expected to correspond to roughly
12.5% alleles shared IBD or a relatedness at the first cousin level. Related subjects that passed all
other quality control thresholds were retained during subsequent phasing and imputation.
Imputation of mother’s genotype data in ALSPAC was done with ALSPAC children’s data. So,
genotypes in common between the sample of mothers and sample of children were combined.
SNPs with genotype missingness above 1% due to poor quality were removed along with sub-
jects due to potential ID mismatches. Haplotypes were estimated using ShapeIT (v2.r644) which
utilises relatedness during phasing. A phased version of the 1000 genomes reference panel
(Phase 1, Version 3) was obtained from the Impute2 reference data repository (phased using
ShapeIt v2.r644, haplotype release date Dec 2013). Imputation of the target data was performed
using Impute V2.2.2 against the reference panel (all polymorphic SNPs excluding singletons),
using all 2186 reference haplotypes (including non-Europeans).
2.1.4 ARIES DNA methylation data
Following DNA extraction samples were bisulfite converted using the Zymo EZ DNA Methyla-
tion kit (Zymo, Irvine, CA). Genome-wide methylation was measured using the HM450 array.
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The arrays were scanned using an Illumina iScan, with initial quality review using GenomeS-
tudio. During the data generation process, a wide range of batch variables were recorded in a
purpose-built laboratory information management system (LIMS). The LIMS also reported qual-
ity control (QC) metrics from the standard control probes on the HM450 array for each sample.
Methylation data were normalised in R with the wateRmelon package (145) using the Touleimat
and Tost (146) algorithm to reduce the non-biological differences between probes.
Cell proportions (CD8+ and CD4+ T cells, B cells, monocytes, natural killer cells, and granulo-
cytes) were estimated using an algorithm proposed by Houseman et al. (86).
2.2 Gene expression omnibus (GEO)
The GEO database is an online repository that allows deposition of functional genomics datasets
that are made publically available. It contains individual participant data from various EWAS
and so was queried to recruit additional datasets for entry into The EWAS Catalog (Chapter 3).
More details of how the database was queried for The EWAS Catalog can be found in Section
3.3.3.
2.3 UK Biobank
The UK Biobank is a prospective cohort study that recruited over 500,000 people aged 37-73
years were recruited for the study between 2006 and 2010. Phenotype and genotype data were
collected from assessment centres all over the United Kingdom. The quality control and the
participants have been described in detail elsewhere (147–149).
Importantly, this data was made easily accessible to researchers, which has lead to multiple
efforts to perform hundreds of GWAS in parallel and make the summary data from these openly
available. This can be found on platforms such as the IEU OpenGWAS Project (Section 2.4).
The GWAS summary statistics from these efforts were utilized in Chapters 5 and 6. Further,
the Neale Lab (http://www.nealelab.is/uk-biobank/) calculated h2SNP using LD-
score regression for the traits for which they performed GWAS and made this data publically
available. This was used in Chapter 5. More details can be found in those chapters.
2.4 IEU OpenGWAS Project
A team at the IEU recently produced a database of full GWAS summary statistics, the IEU
OpenGWAS Project (104,105). This is accompanied by a website and packages to extract the
data and perform various analyses (104,105). There are thousands of GWAS present in the
database. For each GWAS, the database stores meta-data such as sample size, participant ances-
try and sex, as well as full association statistics (betas, standard errors, P values) for all genetic
variants assayed in the GWAS, i.e. not just those surpassing a given P value threshold.
There are thousands of GWAS with this data present in the database. These come from studies
which the authors have released full summary statistics and from many GWAS performed in
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large-scale biobanks by members of the IEU OpenGWAS Project team or by other groups.
The IEU OpenGWAS Project was used in Chapters 5 and 6. More details of why summary
level GWAS statistics were required can be found in those chapters.
2.5 Summary data for an EWAS of lung cancer
In Chapter 7, I assess the association between DNA methylation and lung cancer by meta-
analysing summary data from four case-control studies nested within prospective cohorts. In
total 918 case-control pairs were used in the analyses. Below I give a description of the cohorts
and how DNA methylation was measured for this meta-analysis of EWAS, referencing an earlier
study where the methods are described in more detail (137).
At the various laboratory sites, samples were distributed into 96-well plates and processed in
chips of 12 arrays (8 chips per plate) with case-control pairs arranged randomly on the same
chip. Methylation data were pre-processed and normalized in each study, and probe filtering
was performed as previously described (137), leaving 465,886 CpGs suitable for the analy-
sis in EPIC-Italy, 485,330 CpGs in MCCS, 450,890 CpGs in NOWAC and 482,867 CpGs in
NSHDS.
2.5.1 European Prospective Investigation into Cancer and Nutrition-Italy (EPIC-
Italy)
EPIC-Italy includes 47,749 volunteers (32,579 women) aged 35–70 years at the time of recruit-
ment (1992–1998). Anthropometric measurements and lifestyle variables including detailed in-
formation on smoking history were collected at recruitment through standardized questionnaires,
together with a blood sample. Within EPIC-Italy a nested case-control study was conducted uti-
lizing incident cases diagnosed within follow-up and healthy controls individually matched to
cases by sex, date of birth (±5 years), date of inclusion in the study and study centre. Analysis
was performed for 185 incident cases diagnosed within follow-up and matched controls. Lab-
oratory procedures were carried out at the Human Genetics Foundation (Turin, Italy) and DNA
extracted from buffy coats as previously described (137). All participants signed an informed
consent form, and the ethical review boards of the International Agency for Research on Cancer
and of each local participating centre approved the study protocol.
2.5.2 Melbourne Collaborative Cohort Study (MCCS)
The MCCS is a prospective cohort study of 41,514 volunteers (24,469 women) aged between 27
and 76 years at baseline (1990-1994). At baseline attendance, participants completed question-
naires that measured demographic characteristics and lifestyle factors. Height and weight were
directly measured, and a blood sample was collected and stored. Incident cases of lung cancer
were identified through linkage with the State and National Cancer Registries during follow-up
up to the end of 2011. The MCCS sample included 367 cases and 367 matched controls selected
from MCCS participants who were lung cancer free at the age of diagnosis of the matching case
(density sampling). Matching variables included sex, date of blood collection (within 6 months),
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date of birth (within 1 year), country of birth (Australia and UK versus Southern Europe), type of
biospecimen (lymphocyte, buffy coat and dried blood spot) and smoking status (never smokers;
short-term former smokers: quitting smoking less than 10 years before blood draw; long-term
former smokers: quitting smoking 10 years or more before blood draw; current light smokers:
less than 15 cigarettes per day at blood draw; and current heavy smokers: 15 cigarettes or more
at blood draw). For the MCCS, laboratory procedures were carried out at the Genetic Epidemi-
ology Laboratory, the University of Melbourne according to manufacturers’ protocols. DNA
extraction from lymphocytes and buffy coats was performed as previously described (137). The
Cancer Council Victoria’s Human Research Ethics Committee approved the study protocol. Sub-
jects gave written consent to participate and for the investigators to obtain access to their medical
records.
2.5.3 Norwegian Women and Cancer (NOWAC)
The biobank of the NOWAC cohort was established in the years 2003-2006. Those who filled in
an eight-page questionnaire and accepted the invitation to donate blood were sent blood drawing
equipment together with a two-page epidemiological questionnaire. Around 50 000 women re-
turned two tubes of blood to the Institute of Community Medicine at UiT The Arctic University
of Norway and data linkage to the National Cancer Registry of Norway was performed. During
follow-up to the end of 2011, 132 eligible cases of lung cancer were identified and were used for
the EWAS. For each case, one control with an available blood sample was selected and matched
on time since blood sampling and year of birth in order to control for effects of storage time
and ageing. The cases and the controls were processed together for all laboratory procedures in
order to reduce any batch effect. Laboratory procedures were carried out at the Human Genetics
Foundation (Turin, Italy). DNA extraction from buffy coats was performed as previously de-
scribed (137). All participants gave informed consent. The study was approved by the Regional
Committee for Medical and Health Research Ethics in North Norway. Data storage and linkage
was approved by the Norwegian Data Inspectorate.
2.5.4 Northern Sweden Health and Disease Study (NSHDS)
NSHDS is an ongoing prospective cohort and intervention study intended for health promotion
of the population of Västerbotten County in northern Sweden. All residents were invited to par-
ticipate by attending a health check-up at their local health care centre at 40, 50 and 60 years of
age. At the health check-up, participants were asked to complete a self-administered question-
naire covering various factors such as education, smoking habits, physical activity and diet. In
addition, height and weight were measured and participants were asked to donate a blood sample.
Incident lung cancer cases were identified through linkage to the regional cancer registry. One
control was chosen at random for each lung cancer case from appropriate risk sets consisting of
all cohort members alive and free of cancer (except non-melanoma skin cancer) at the time of
diagnosis of the index case. Matching criteria were the same as for the MCCS except there was
no matching for type of biospecimens as DNA was extracted from whole blood for all samples.
After quality control, a total of 234 incident lung cancer cases and 234 individually matched
controls were available for this analysis. Laboratory procedures for NSHDS were carried out
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at two sites. DNA extraction from the buffy coat was conducted at Umeå University, Sweden,
as previously described. Illumina Infinium HumanMethylation450 BeadChip analysis was con-
ducted at the ALSPAC/IEU Laboratory at the University of Bristol. All study subjects provided
written informed consent at time of the recruitment into the NSHDS.
2.6 Transdisciplinary Research in Cancer of the Lung and The In-
ternational Lung Cancer Consortium (TRICL-ILCCO)
To perform the two-sample MR analyses in Chapter 7, summary statistics from a large lung
cancer GWAS were required. This was taken from a GWAS using data from the TRICL-ILCCO
consortium. Transdisciplinary Research in Cancer of the Lung and The International Lung Can-
cer Consortium (TRICL-ILCCO)
In the consortium there are 26 cohorts, which provide data on 29,863 lung cancer cases and
55,586 controls. These individuals were genotyped using various different methods, with the
most recent and largest cohort being genotyped by the Illumina Infinium OncoArray-500K Bead-
Chip (Illumina Inc. San Diego, CA). This data went through extensive quality control and har-
monsiation before the meta-analysis was performed. Detailed information on the genotyping,
quality control, and cohorts can be found in the original study (150).
2.7 Copenhagen City Heart Study (CCHS)
To clarify the association between DNA methylation and lung cancer in Chapter 7, a one-
sample MR analysis was conducted using data from the Copenhagen City Heart Study (CCHS),
a prospective study of the general population (151). Copenhagen residents were invited to com-
plete a questionnaire and undergo a physical examination and are followed through a unique
person identifier in the Danish health registries. All participants gave written informed consent,
and a Danish ethics committee approved the study (KF100.2039/91). Phenotype, genotype and
DNA methylation data were required for the analyses. Details of how these were collected and
some quality control are below.
2.7.1 Phenotypic data
Participants were asked whether they smoked at the day of attendance or previously. If they
answered affirmative to either of these questions, they were asked about their current and former
smoking behaviour, including age of smoking initiation, age of smoking cessation, and number
of daily consumed cigarettes, cheroots, cigars, and weekly grams of pipe tobacco. Based on these
answers, participants were categorized as never, former, and current smokers. In addition, par-
ticipants reported on alcohol consumption, occupational exposure to dust and/or welding fumes,
exposure to passive smoking, education, and familial cases of lung cancer. The answers were
reviewed together with an examiner at the day of attendance. Body mass index was calculated
as measured weight in kilograms divided by measured height (in meters) squared.
For lung cancer (ICD7, codes 1624 or 4624 until 1977, and ICD10, code C34 from 1978 and
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onwards), the date of first diagnosis was taken from the national Danish Cancer Registry from
1943 to December 2012.
2.7.2 DNA methylation data
At the physical examination, blood samples were drawn for DNA from which AHRR methy-
lation extent was measured (114). The AHRR cg05575921 methylation extent was measured
in duplicate samples of bisulphite treated DNA from peripheral blood from 9,234 individuals.
A Taqman assay was used that was developed in the CCHS laboratory, and included standard
curves, as well as internal controls in each 384-well plate. Coefficients of variation at the methy-
lation level of 71% varied from 5.0 to 6.7%. Laboratory technicians were blinded to smoking
and disease status of the individuals. Results were validated with pyrosequencing on a subset of
samples (114).
2.7.3 Genotype data
Genotypes from the iCOGs array (152) and prospective data on lung cancer incidence were also
available for these participants. Of the 9234 individuals, genotype data from iCOGS on 8778
were available. In short, DNA isolated from leukocytes was genotyped with a custom Illumina
iSelect genotyping array, designed to test genetic variants related to breast, ovary and prostate
cancer, comprising roughly 211,000 SNPs after rigorous quality control (152).
Table 2.1: Overview of data used in this thesis
data-source chapters-used-in data-type data
ARIES 3, 4, 5, 7 individual and summary DNAm, genotypic, phenotypic, GWAS
EWAS Catalog* 3, 4, 6 summary EWAS
GEO 3 individual DNAm, phenotypic
IEU OpenGWAS Project 5, 6 summary GWAS
EPIC-Italy 7 summary EWAS
MCCS 7 summary EWAS
NOWAC 7 summary EWAS
NSHDS 7 summary EWAS
TRICL-ILCCO 7 summary GWAS
CCHS 7 individual DNAm, genotypic, phenotypic
GTEx 7 summary GWAS
ARIES = Accessible Resource for Integrated Epigenomic Studies
GEO = Gene Expression Omnibus
IEU = Integrative Epidemiology Unit
EPIC-Italy = Italian strand of the European Prospective Investigation into Cancer and Nutrition study
MCCS = Melbourne Collaborative Cohort Study
NOWAC = Norwegian Women and Cancer
NSHDS = Northern Sweden Health and Disease Study
TRICL-ILCCO = Transdisciplinary Research in Cancer of the Lung and The International Lung Cancer Consortium
CCHS = Copenhagen City Heart Study
GTEx = Genotype-Tissue Expression (project)
DNAm = DNA methylation




The EWAS Catalog: a database of
epigenome-wide association studies
3.1 Chapter summary
Before investigating the properties of DNA methylation-trait associations, I sought to bring to-
gether published EWAS results to help identify studies for use in future chapters and to allow
joint analysis of currently available EWAS results in Chapter 4. To this end, I led a project to
produce The EWAS Catalog. This database contains manually curated CpG-trait associations (at
P<1x10-4) from published EWAS, each assaying over 100,000 CpGs in at least 100 individuals.
The database currently contains these 582,801 associations from 218 published studies as well
as summary statistics for 392,773 associations from 428 EWAS using data from ARIES (Section
2.1.1) and GEO (Section 2.2). This database provides a platform for future chapters in this thesis
and will give researchers the opportunity to quickly and easily query EWAS associations to gain
insight into the molecular underpinnings of disease as well as the impact of traits and exposures
on the DNA methylome.
3.1.1 Contributions statement
I developed the website (after its original production), conducted all EWAS in ARIES and GEO,
extracted the most published data, have led the project for the past 18 months and wrote every-
thing presented in this chapter, however I was not the sole contributor. Contributions by others
are listed below:
• James Staley produced the original website and R package and originally led the project
• Matthew Suderman re-formatted and developed the website. Relative contributions to this
development can be found here: https://github.com/ewascatalog/ewascat
alog2/graphs/contributors
• Paul Yousefi extracted GEO data
• Matthew Suderman and Paul Yousefi are part of the core development team (along with
myself) and continue to provide expert guidance
• James Staley, Gemma Crawford, Claire Prince, Mahsa Sheikhali Babaei, Charlie Hatcher,
Maria Vega-Salas, Sahar Khodabakhsh, Oliver Whitehurst, Luke Mahoney all extracted
some published data
3.2 Introduction
In recent years, there has been a dramatic increase in the number of EWAS being performed and
published due to technological advancements making it possible to measure DNA methylation
at hundreds of thousands of CpG sites cheaply and effectively (56,77,153,154). Curating these
EWAS results and making them freely available would enable researchers to use the data to
inform or enhance studies on specific traits of genomic regions of interest. Furthermore, the
joint analysis of these data could provide insights into the properties of DNA methylation-trait
associations, potentially leading to an understanding of how to improve design of EWAS. The
latter is explored in Chapter 4.
At the time of making the database, to my knowledge, there were no databases that had collected
well-curated EWAS on all traits (not just diseases) in an online database accessible to researchers.
During production one database fulfilled those metrics: EWAS Atlas (107). Other databases are
available but are limited to certain diseases (e.g. MethHC (155)). The EWAS Atlas provides a
website with annotated CpG sites and information on traits. Ideally a database of EWAS results
will provide summary statistics, including betas, standard errors and p-values where provided
from publications, in an easily accessible manner, this enables researchers to explore various
aspects of the published data without having to retrieve the published article. For example,
researchers might compare effect estimates between studies in the database or check to see if
their results are replicated in another published study. At the time of writing, the EWAS Atlas
platform did not enable users to download effect estimates and standard errors.
A clear caveat with using data from published EWAS is that the data reported is governed by
the authors of those papers; not all published EWAS include full summary statistics. Performing
EWAS in a systematic way in available cohorts and enabling user upload of results allows for
more in-depth results to be included in an EWAS database.
The EWAS Catalog aims to improve upon current databases to 1) allow easy and programmatic
access to summary statistics for downstream analyses by researchers and 2) provide full summary
statistics from a range of EWAS conducted in multiple cohorts. To this end The EWAS Catalog
has been produced, a manually curated database of currently published EWAS, 387 EWAS per-
formed in ARIES (Section 2.1.1) (141,142) and 41 EWAS performed from data from the Gene
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Figure 3.1: EWAS Catalog project flowchart. On the left is a brief description of how the
CpG-phenotype associations were assembled from published works and on the right is a brief
description of the EWAS performed using individual participant data.
3.3 Methods
3.3.1 Implementation
The EWAS Catalog web-app was built using the Django Python package (https:
//djangoproject.com). The data is stored in a combination of MySQL databases
and fast random access files (27) and can be queried via the web app or the R package
(www.github.com/ewascatalog/ewascatalog-r/).
3.3.2 Overview of publication data extraction
To identify publications, periodic literature searches are performed in PubMed using the search
terms: “epigenome-wide” OR “epigenome wide” OR “EWAS” OR “genome-wide AND methy-
lation” OR “genome wide AND methylation.”
To try and maximise quality and usefulness of data, and minimize computational burden, criteria
for inclusion of a study into The EWAS Catalog were developed. These criteria and reasons for
them are as follows:
1. The EWAS performed must contain over 100 humans. Limiting the sample size to 100
or more individuals was done to try and remove EWAS that would be highly underpow-
ered, but make sure EWAS of rarer phenotypes and in smaller cohorts (for example non-
European cohorts) were not excluded.
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2. The DNA methylation data must be genome-wide. As discussed, published candidate gene
studies are at risk of publication bias and thus were excluded.
3. The analysis must contain over 100,000 CpG sites. Similarly to the previous criterion, this
was to avoid studies performing more targeted DNA methylation measurements.
4. The study must include previously unpublished EWAS summary statistics. This was to
prevent duplication of results.
CpG-phenotype associations are extracted from studies at P<1x10-4. A P-value cut-off was im-
posed to avoid a large computational burden from storing millions of associations. This threshold
was chosen to be more lenient than the conventional EWAS P-value threshold as there is potential
information from associations reported with P-values above P<1x10-7, for example when trying
to replicate associations in a study with a smaller sample size.
All these criteria along with the variables extracted are documented on the website
(www.ewascatalog.org/documentation). Experimental factor ontology (EFO) terms were
mapped to traits to unify representation of these traits. These EFO terms were manu-
ally entered after looking up the trait in the European Bioinformatics Institute database
(www.ebi.ac.uk/efo).
Based on these criteria, from 2021-05-25, The EWAS Catalog contained 582,801 associations
from 218 published studies.
3.3.3 New EWAS performed
Overview of GEO data extraction
To recruit additional datasets suitable for new EWAS analysis, the geograbi R package (https:
//github.com/yousefi138/geograbi) was used to both query GEO for experiments
matching The EWAS Catalog inclusion criteria (described above) and extract relevant DNA
methylation and phenotype information. The GEO database is briefly described in Section 2.2.
The query of this database was performed on 2020-10-12 and identified 136 such experiments
with 32,555 samples where DNA methylation and phenotype information could be successfully
extracted. From these, the aim was to repeat the analyses performed in the publications linked
by PubMed IDs to each GEO record. Thus, I looked up the corresponding full texts for each
dataset and identified the main variables of interest. Of the 136 putative GEO studies, only 41
(30%) contained sufficient information to replicate the original analysis.
Overview of ALSPAC data used
EWAS were conducted for 387 continuous and binary traits in peripheral blood DNA methylation
of ALSPAC mothers in middle age (N = 940), generated as part of the ARIES project (140). All
phenotypes used in this chapter were measured at the same time blood was drawn for DNA
methylation measurement. The ARIES dataset is summarised and is described in more detail in
Section 2.1
Ancestry principal components were used as covariates in the EWAS. These were generated
within ALSPAC mothers using PLINK (v1.9). Quality control and imputation of the genetic
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data are described in Section 2.1.3. After quality control and imputation, independent SNPs (r2
< 0.01) were used to calculate the top 10 ancestry principal components.
As discussed, batch effects and cell type heterogeneity may account for a large proportion of co-
variation observed between DNA methylation and a phenotype of interest. In an attempt to com-
bat this, surrogate variables were generated from the DNA methylation data using the smartsva
R package (156). Surrogate variables capture variation in DNA methylation that are orthogonal
to the relationship between the trait of interest and DNA methylation (94,156). When used in
an EWAS model, they capture the largest portion of DNA methylation variation that is not due
to the trait of interest. Thus, if batch effects and cell type heterogeneity are causing substan-
tial variation in the DNA methylation data, this should be captured by the surrogate variables
(94).
Values of continuous phenotypes were defined as outliers if greater than three multiplied by the
interquartile range (IQR) or if less than three multiplied by the IQR and set to missing, then
all phenotypes with 100 or more non-missing values were kept for further analysis. To ensure
all phenotypes were approximately normal, each of their distributions were examined and then
transformed. If a variable was deemed right-skewed, it was log-transformed then its distribution
was re-assessed by eye. Square-roots and cube-roots were used to try and approximate normality
if log-transformation did not work. If a variable was deemed left-skewed, it was squared, and
the distribution re-assessed by eye.
EWAS statistical models
For all EWAS using ARIES and GEO data, linear regression models were fitted with DNA
methylation at each site as the outcome and the phenotype as the exposure. DNA methylation
was coded as beta values between 0 and 1. For a particular site, a beta value of 0 represents
no methylation being detected in all cells measured and a value of 1 represents all cells being
methylated at that site. For the 387 EWAS conducted using participant data from ARIES, covari-
ates included age, the top 10 ancestry principal components, and 20 surrogate variables. For the
41 EWAS conducted using data extracted from GEO, just 20 surrogate variables were included
as covariates. For GEO other covariates were considered, but surrogate variables only were used
for two reasons: 1) to help automate the process and 2) because covariates used in the original
EWAS were not included with many of the GEO datasets.
Statistical analyses were conducted in R (Version 3.6.2). The smartsva package (156) was used
to create surrogate variables and the ewaff R package (https://github.com/perishky/
ewaff) was used to conduct the EWAS, all p-values are two-sided.
3.4 Results
3.4.1 Database interface and use
There are two ways to access this large, curated database: through the main website
www.ewascatalog.org or by using the R package “ewascatalog.” The website provides a simple
user interface, whereby there is one simple search bar and an advanced search bar to explore the
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database and links to tabs that contain documentation on the contents and how to cite its use
(Figure 3.2). Users may enter a CpG, gene, genome position, trait, EFO term, author name, or
PudMed ID into the search bar and it will rapidly return detail for relevant EWAS associations,
including CpG, trait, sample size, publication and association (effect size and P value) (Figure
3.2). This information along with additional information such as ancestry, outcome, exposure
units, and tissue analysed are available for download as a tab-separated value (tsv) text file.
Unlike other EWAS databases, the option is provided to download summary results for both the
user’s search and for the entire database. Further, users may upload their own data which will be
parsed by a pipeline designed to check the data and format it for input into The EWAS Catalog
MySQL database.
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Figure 3.2: Using The EWAS Catalog. On the left hand side is the home page. On the top
right hand side are examples of searches possible: 1. CpG sites, 2. genes and 3. traits. Below
the searches shows the pages directed to after searching for “Vitamin B6 intake.” Circled in red
is the download button, this button enables the user to download the results of their search as a
tab-separated value file. This file will contain the information shown on the website as well as
additional analysis information.
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The R package, along with installation instructions and examples are available at https:
//github.com/ewascatalog/ewascatalog-r/. Once installed, the database can be
queried directly in R using the “ewascatalog()” function similar to the website: simply supply
the function with a CpG site, gene, genome position or trait and the function returns the same
output as is downloadable from the website.
3.5 Discussion
In this chapter, a database of previously published EWAS and the full summary statistics of 428
newly performed EWAS within ALSPAC and GEO has been established. This is freely available
for all researchers to use and provides a platform to explore what information has been gained
from EWAS as well as a platform that can be used to pool all existing data to gain new insights
into both the EWAS study itself and how DNA methylation associates with traits. Despite the
fact The EWAS Atlas has similar aims to The EWAS Catalog, the latter provides full summary
statistics, extra information, a user-friendly platform to enable more downstream analyses, and a
pipeline for users to upload their own data and receive a citable DOI for it.
The EWAS Catalog team will continue to collate and upload newly published EWAS and further
increase the number of full summary statistics on the website by performing additional EWAS
on available datasets and by inviting EWAS authors to provide full summary statistics. Currently
work is ongoing to include additional functionality to allow users to easily and systematically
compare their EWAS findings to EWAS in the database. With this full summary data, it is
possible to make greater strides into discovering the epigenetic architecture of traits.
In this chapter, a platform has been generated that enables us to examine 1) what information has







The EWAS Catalog database developed in Chapter 3 contains thousands of associations from
hundreds of studies. By far the most common method of measuring DNA methylation amongst
these EWAS is in blood using the Illumina Infinium HumanMethylation450 BeadChip (HM450
array). This platform assays fewer than 2% of CpG sites in the human genome, and those selected
are ascertained for regions hypothesised to be relevant to gene regulation. Understanding what
drives the associations found by measuring DNA methylation in this way could help prioritise
CpG sites or regions of the genome to target for future technologies used in EWAS and further,
it could guide current EWAS study design (for example by discovering sites which could be
removed before analysis).
In this chapter I use the data collected for The EWAS Catalog to evaluate the characteristics of
known DNA methylation associations. Of the data in the EWAS Catalog, 9.9% of reported asso-
ciations are from CpGs measured by probes recently reported as unreliable and 21% of studies
did not account for both batch effects and cellular composition, suggesting some associations
may be false positives. However, after removal of these potentially false positive results, char-
acteristics of DNA methylation still associated with EWAS results. An increase in heritability
by 10% associated with a decrease in the modulus of the standardised effect size by 8% [95%
CI: 8.3% decrease, 7.7% decrease]. It was also observed that the modulus of the standardised
effect size decreased by 26% [95% CI: 26% decrease, 25% decrease] per one standard devia-
tion increase in the variance of DNA methylation. Differentially methylated positions (DMPs)
were found to be present in actively transcribed promoter regions, enhancer regions and in over
100 transcription factor binding sites more than expected by chance. DMPs were also found
to be depleted for heterochromatic regions, poised and bivalent promoters, regions repressed by
polycomb proteins and quiescent regions. Targeting genomic regions for measurement of DNA
methylation that are enriched for EWAS results, and avoiding regions that are depleted for EWAS
results, may increase probability of identifying DMPs in future EWAS. These enrichment and
depletion analyses were conducted across 25 distinct tissues and the strongest associations were
found in blood, suggesting conducting EWAS in different tissues will likely yield tissue-specific
results.
The results presented in this chapter (and later chapters) are using data from The EWAS Catalog
when published data present in the database was from before 2019-01-01.
4.1.1 Contributions statement
I wrote all the sections and performed all analyses except the the enrichment analyses using
LOLA, which was performed by Charlie Hatcher. I performed the downstream analyses from
LOLA output (visualisation of the results and some further statistical analyses).
4.2 Introduction
Hundreds of EWAS have been conducted in the last 10-15 years, yet no systematic evaluation of
published EWAS across complex traits has been conducted. By exploring the patterns of associa-
tion across a large group of EWAS, one can discover potential explanations for the results found,
that may shed light on technical issues affecting previous studies as well as shared epigenetic
architectures across traits.
Since the inception of EWAS, it has become clear that batch effects and cellular heterogeneity
can generate false positives and bias effect sizes (87,90,91). Also, as discussed in Section 1.3.4,
characterisation of probes used by common arrays (e.g. the HM450 array and the HMEPIC array)
has shown that unreliable methylation measurements may occur because of cross-hybridisation
of probes, non-specific probe mapping and SNPs being present at the binding sites of probes
(92,93). Despite this, there are examples of replication amongst EWAS results, (113,157–
162). Further functional characterisation of EWAS results, such as new experimental studies
or the application of existing gene function knowledge, can also be used to bolster evidence that
changes in DNA methylation estimated are unlikely due to bias (56,163). By way of an exam-
ple, changes in DNA methylation at AHRR have been replicated across multiple smoking EWAS
(1,113,114,164) and as functional research has implicated this gene in handling toxic substances
found in tobacco smoke (165), it seems unlikely these findings are chance occurrences.
The characteristics of the DNA methylome may also explain some EWAS findings. Heritability
varies across DNA methylation sites [VanDongen2016; (166); (167)], and so if genetic effects
are driving EWAS associations, either through confounding or with DNA methylation as a me-
diator, one would expect heritable sites to be commonly identified in EWAS. Variance is also
heterogenous across sites (18) and at sites where variation is low, the ratio of noise to signal
may be greater. Thus, some studies have advocated removing these sites to prevent generating
false positives and to reduce the multiple testing burden (153,168). However, it is unclear how
variance in DNA methylation relates to the magnitude of effect estimates.
Experimental studies have shown DNA methylation changes at different locations of the genome
correlate with different regulatory functions. For example, an increase in DNA methylation
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at transcriptional start sites is correlated with a decrease in gene expression (23,41,42), but an
increase in DNA methylation within a gene body shows the opposite association (43,44). As dis-
cussed in Section 1.3.3, the understanding that the genomic contexts in which DNA methylation
occurs is related to gene regulation likely contributed to the design of contemporary arrays that
measure DNA methylation. Yet, it is not known whether targeting protein-coding regions and
enhancers has likely led to an increase in discovery of DNA methylation-trait associations.
Understanding underlying factors that drive EWAS results is essential for future study design.
This may come in the form of consideration of potential biasing factors, or by selecting certain
DNA methylation sites based on their specific characteristics. Further, the HM450 and HMEPIC
arrays both capture less than 5% of the total number of CpG sites in the genome, therefore
understanding the characteristics of DNA methylation-trait associations could provide vital in-
formation when designing future studies targeting the other 95%.
Also, by examining the commonalities of EWAS results, one has the potential to uncover links
between traits that have not previously been made or to identify new potential mediating factors
between traits.
In this chapter I first describe the data present in The EWAS Catalog going on to explore the
factors that predict EWAS hits.
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4.3 Methods
4.3.1 Epigenome-wide association studies data
All the data for the analyses were extracted from The EWAS Catalog (Chapter 3). Data were
extracted when The EWAS Catalog had published EWAS data from before the start of 2019
(i.e. the data do not completely reflect that presented in Chapter 3). Studies were removed that
compared DNA methylation levels between tissue, race, and age. This was done because these
variables are not complex traits and thus the properties of those study results are unlikely to
be informative when attempting to understand how to best design EWAS. Overall, this left 614
EWAS, including 387 EWAS from the ARIES subsection of ALSPAC (Section 2.1) (140–142)
and 40 EWAS performed using data from the gene expression omnibus (GEO) resource (Section
2.2). See Chapter 3 for more details on the EWAS.
Description of catalog data
DMPs, unless otherwise stated, will be defined as DNA methylation sites associated with a trait
at P<1x10-7. Each of the CpGs in the Catalog are annotated to genes, using data from the meffil
R package (169).
T-statistics (t) were calculated using P-values, sample sizes (n) and the qt() function in R. r2
values were calculated from t-statistics as follows
r2 = t
2
t2 + n− 1 (4.1)
To identify which traits for which r2 values might be inflated, r2 values were first summed and
divided by the sample size (N). The base 10 log of these values were taken to approximate a
normal distribution. Then a z-test was performed to assess for which studies the sum of r2 values
divided by N were greater than the mean of summed r2 values divided by N across all studies.
From the z-test, those with a FDR-corrected P-value of less than 0.05 were labelled as having
inflated r2 values.
4.3.2 Identifying faulty probes
By far the most common method to measure DNA methylation across the studies in The EWAS
Catalog is using the HM450 array. Since its development, the array has been extensively char-
acterised (87,90–92) and it was found not all probes measure DNA methylation reliably. Some
probes map to CpG sites that are influenced by SNPs, others are non-specific and some are prone
to cross-hybridisation. Probes were assigned to be ‘potentially faulty’ if they were characterised
as such by Zhou et al. (92).
4.3.3 Replication
A study-wide significant association (P<1x10-7) was deemed to be replicated if it had been iden-
tified by another study at P<1x10-4 (i.e. it was replicated if reported by another study in The
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EWAS Catalog). It should be re-iterated that the published data collected for The EWAS Cata-
log was scraped from the journal articles and even though the threshold for inclusion into The
EWAS Catalog remained constant at P<1x10-4, there is heterogeneity in reporting of EWAS as-
sociations. Therefore, some studies would not have reported any results with a P-value lower
than the conventional EWAS P-value threshold (P<1x10-7), making power a key limitation for
attempts to assess replication. The replicability of EWAS within the database was assessed using
two methods. Firstly, replication within studies is recorded in the EWAS Catalog, thus a simple
lookup for any studies that performed a replication or meta-analysed discovery and replication
datasets was conducted. Secondly, a lookup of results for any traits for which multiple EWAS
had been conducted was performed.
The Catalog also contains results from studies that have uploaded their data to GEO as well as
results from the re-analysis of that data (details in Section 3.3.3). These re-analyses adjusted for
20 surrogate variables only as many studies did not provide a complete set of covariates to GEO.
To assess the potential reliability of these EWAS, the original EWAS results were looked up in
the results of the re-analysed data.
4.3.4 Selecting data to assess DNA methylation characteristics
Before further analyses, all potentially faulty probes and probes that mapped to sex chromosomes
were removed. Studies that did not include batch and cell composition as covariates in at least
one EWAS model were also excluded, and studies for which re-analysis of the data replicated
less than 10% of the findings were removed.
4.3.5 DNA methylation characteristics
The relationship between the characteristics, heritability and variance, of DNA methylation at
each CpG site and EWAS effect size was assessed. To allow this across traits, beta coefficients




where β = beta coefficient, σ = standard deviation, x = independent variable, y = dependent
variable. As individual participant data were not available to us, the variance in DNA methy-
lation sites was approximated by the variance in DNA methylation at sites as supplied by the
Genetics of DNA Methylation Consortium (GoDMC) (170) and the trait variance was estimated
by rearranging equation (4.3) depending on whether DNA methylation was the independent (x)




GoDMC (170) also provided the mean levels of DNA methylation at each site. Heritability of
DNA methylation at each site has been previously estimated by McRae et al. 2014 (166) and Van
Dongen et al. 2016 (171). These values were kindly made publically available by the authors of
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those studies, in this chapter the estimates of heritability from twin data (Van Dongen et al. 2016
(171)) were used.
Relationships between each characteristic and effect size were assessed using linear regression,
fitting the absolute value of the standardised effect size as the dependent variable and the char-
acteristic as the independent variable. The absolute values of standardised effect sizes were
transformed using the natural log to approximate normality.
The relationship between tendency for a DMP to replicate and heritability and variance were also
assessed. Logistic regression models were fitted with the binary variable of a DMP replicating
in at least one study (yes or no) used as the outcome measure and heritability and variance fitted
as the dependent variable.
It was also tested whether heritability and variance could predict whether a CpG site was likely
to be identified as a DMP in EWAS by generating receiver operating characteristic (ROC) curves
and quantifying the area under these curves (AUC).
4.3.6 Enrichment tests
Assessment of enrichment of DMPs amongst various genomic regions was carried out to help
understand whether selecting regions to measure could maximise EWAS yield. Locus Overlap
Analysis (LOLA) (172) was used to assess whether DMPs identified in the EWAS Catalog were
enriched for 25 chromatin states and 167 transcription factor binding sites in 127 different cell
types comprising 25 distinct tissues. These data were generated by the Roadmap Epigenomics
Project (173) and ENCODE (174).
Five different groups of DMPs were defined for the enrichment analyses:
• Group A - all sites associated with any complex trait at the conventional P-value threshold
used in EWAS, P<1x10-7.
• Group B - a subset of group A, all sites associated with any complex trait at a more strin-
gent threshold, P<1.6x10-10. Multiple EWAS were conducted to produce the results in the
database and so the stricter threshold of group B aimed to limit the false discovery rate by
taking into account the multiple EWAS.
• Group C - DMPs replicated at P<1x10-4 in any other EWAS of the same trait.
• Group D - a subset of group A, but restricted to results from studies where DNA methyla-
tion was measured in whole blood.
• Group E - a subset of group B, but restricted to results from studies where DNA methyla-
tion was measured in whole blood.
To assess enrichment, LOLA performs Fisher’s exact test and generates an odds ratio that can
be interpreted as the odds of the DMPs being within an annotation divided by the odds of the
DMPs not being within an annotation. Genomic annotations may differ by CG content and thus
a differential CG content of regions containing the DMPs of interest and the background group
of CpG sites might bias enrichment estimates. Thus, background sites were matched on CG
content before the analysis.
All analyses were completed using R (version 3.6.2).
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4.4 Results
Description of the catalog
Before assessing the factors predicting DMPs, a brief summary of the data in The EWAS Catalog
(as used for this study, see Section 4.3.1 for details) is presented (Table 4.1).
The percentage of hypermethylated sites in relation to traits was 52% and there were five CpGs
that associated with more than ten traits (Figure 4.1). Here are those sites with gene names, as
mapped using Illumina-provided annotations, in brackets: cg01940273 (-), cg05575921 (AHRR),
cg00574958 (CPT1A), cg17901584 (DHCR24), cg06500161 (ABCG1). cg06500161 (ABCG1)
was associated with more traits than any other site - 71 traits. These correspond mostly to
metabolites, weight-related traits, and type two diabetes. Next estimates of the trait variance
Table 4.1: Description of data present in the EWAS Catalog
study-trait value
Number of EWAS 614
Unique traits 556
Number of samples 389527
Median sample size (range) 536 (93 - 13474)
Number of associations 155976
Unique CpGs identified 129670
Unique genes identified 19305
Sex (%) Both (38.6), Females (52.0), Males (2.1)
Ethnicities EUR (75.3), Unclear (12.5), AFR (4.6), Other (3.6), ADM (1.6), EAS (1.4), SAS (1.0)
Age (%) Adults (72.5), Geriatrics (11.2), Children (4.9), Infants (4.4)
Number of tissue types 42
Most common tissues (%) whole blood (84.14), cord blood (4.34), cd4+ t-cells (2.60), placenta (1.24), saliva (0.99)
Identified associations were defined as those P < 1x10-7
Results for Sex, Ethnicities, Age, and Most common tissues were calculated per EWAS.
For example, if one EWAS (or meta-analysis) contained just Afican indviduals then that would be counted as one.
EUR = European, AFR = African, ADM = Admixed, EAS = East Asian, SAS = South Asian
(see equation (4.1)) explained by each association were assessed. This indicates the predictive
performance from EWAS, although it should be noted that winner’s curse will artificially inflate
the performance, even amongst EWAS with true positive results.
The proportion of trait variance (ranging from 0 to 1) that correlated with DNA methylation (r2)
at each site varied from 0.0011 to 0.97 with a median of 0.093 (Figure 4.2). The sum of r2 values
ranged greatly from 0.0055 to 23,879 (Figure 4.3), with a median of 1.2. There was evidence
that 54 studies had a total sum of r2 values greater than the mean (FDR < 0.05) and r2 values
from individual associations from these studies made up the majority of r2 values greater than 0.1
(Figure 4.2). When excluding those studies from the results, the median r2 value at individual
sites was 0.023.
These results suggest that some associations within the database are likely to be inflated, yet for
most traits, variation at individual DNA methylation sites captures little trait variance. Summing
the r2 values indicates a substantial proportion of trait variance can be captured by multiple
43
DNA methylation sites for some traits, but this can only be estimated by jointly modelling the
contribution of all sites to trait variance. This is explored in Chapter 5. Here, the sum of r2
values is used to indicate whether the results of a study are likely inflated and thus may not be
reliable.
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Figure 4.1: Number of unique traits associated with DNA methylation at each CpG. Sites
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Figure 4.2: Distribution of r2 values across all CpG sites in The EWAS Catalog. Each
EWAS can identify multiple differentially methylated positions, each of which will capture some
variance of the trait of interest for that EWAS (r2).
∑
r2 is the sum of r2 values, the distribution
of which is shown in Figure 4.3. Fifty-four studies were identified for which there was some
evidence that the sum of r2 values were greater than the mean across all studies. All of the













Figure 4.3: Distribution of the sum of r2 values across each study in The EWAS Catalog.
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4.4.1 Robustness of results
As discussed, cellular heterogeneity, batch effects and inclusion of faulty probes can lead to false
positives in EWAS. The extent to which this might be the case within EWAS included within The
EWAS Catalog was explored.
Each study may have reported results across multiple EWAS models, adjusting for different co-
variates. In at least one model, 579 studies adjusted for batch effects, 518 studies adjusted for
cell composition, and 489 adjusted for both. Of all DMPs identified, 9.3% were measured by po-











all other probes on sex chromosome potentially faulty
Figure 4.4: The percentage of DMPs that may have been identified by faulty probes and the
percentage of EWAS that reported identifying at least one of these probes. The left-hand bar
represents all DMPs reported across all EWAS that fit into the categories shown, the right-hand
bar represents the number of EWAS that include CpGs that fit into the categories shown. Some
CpGs are both on a sex chromosome and were identified as faulty by Zhou et al. They were
labelled as ‘potentially faulty.’
There were 30 studies that performed a meta-analysis of discovery and replication samples. A
further 48 studies performed a separate replication analysis. Together, this provides 1666 asso-
ciations within the EWAS Catalog that have been replicated at P < 1x10-4.
From the studies that uploaded their data to GEO, the association between DNA methylation
and the phenotype of interest from the original study was re-analysed, including 20 surrogate
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variables as covariates. Both the original study results and the results from the re-analysis of
the phenotype of interest are in The EWAS Catalog database for 9 studies. Across the studies,
between 0% and 96.875% of DMPs were replicated at P < 1x10-4 (Table 4.2). Some of these
EWAS reported very few DMPs (some only 1) and as they would have used different models,
replicating the single reported result was not expected.
Table 4.2: GEO re-analysis replication
Trait N-DMPs N-replicated Percent-replicated
Age at menarche 1 0 0.00
Arsenic exposure 12 0 0.00
Fetal alcohol spectrum disorder 19 1 5.26
Inflammatory bowel disease 14 13 92.86
Nevus count 1 0 0.00
Psoriasis 16 0 0.00
Rheumatoid arthritis 47,875 116 0.24
Smoking 32 31 96.88
Smoking 30 12 40.00
N-DMPs = number of differentially methylated positions identified at P < 1x10-7
N-replicated = number of DMPs replicated in the GEO re-analysis at P < P < 1x10-4
Using the catalog data, DMPs were examined to see if they were also associated with that
same trait in another study at P<1x10-4. There were 72 studies that shared a common
phenotype of interest. Replication rate, judged as the percentage of CpGs also present
in any other study of the same trait with P<1x10-4, varied from 0 to 100 between stud-
ies (Table 4.3, Table 4.4, Table 4.5). For many of the traits, the number of identified
DMPs was low (0 studies reported one DMP), therefore the low replication rate for these
studies is not completely unexpected given potential study heterogeneity in important
factors such as study power, age, sex, ancestry and study design. However, there were
also three studies that identified over 100 DMPs and none of them replicated, includ-
ing an EWAS of smoking for which there are many high-powered replication studies.
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Table 4.3: Replication rate
Trait N-DMPs N-replicated N-replication-studies Prop-replicated
glucose 4 1 1 0.25000
insulin 3 1 2 0.33333
insulin 1 0 2 0.00000
alzheimers 21 5 1 0.23810
alzheimers 25 7 1 0.28000
Birth weight 27 0 4 0.00000
Birth weight 1 0 4 0.00000
Birth weight 2 0 4 0.00000
Triglycerides 4 2 3 0.50000
Triglycerides 11 6 3 0.54545
Triglycerides 33 26 3 0.78788
Triglycerides 1 1 3 1.00000
Waist circumference 172 6 2 0.03488
Waist circumference 11 3 2 0.27273
Waist circumference 2 1 2 0.50000
Type II diabetes 11 2 2 0.18182
Type II diabetes 6 0 2 0.00000
Type II diabetes 1 1 2 1.00000
HOMA-IR 1 1 1 1.00000
HOMA-IR 5 1 1 0.20000
Schizophrenia 3 0 2 0.00000
Schizophrenia 163 0 2 0.00000
C-reactive protein 3 3 1 1.00000
C-reactive protein 226 17 1 0.07522
High-density lipoprotein cholesterol 2 2 1 1.00000
High-density lipoprotein cholesterol 63 5 1 0.07937
Serum high-density lipoprotein cholesterol 22 17 1 0.77273
Serum high-density lipoprotein cholesterol 213 11 1 0.05164
Serum low-density lipoprotein cholesterol 61 0 1 0.00000
Serum total cholesterol 1 0 2 0.00000
Serum total cholesterol 111 0 2 0.00000
Serum total cholesterol 1 0 2 0.00000
Serum triglycerides 46 38 1 0.82609
Serum triglycerides 99 33 1 0.33333
Rheumatoid arthritis 47,875 8 1 0.00017
Rheumatoid arthritis 6 0 1 0.00000
Depression 1 0 1 0.00000
Depression 2 0 1 0.00000
N-DMPs = number of differentially methylated positions identified at P<1x10-7
N-replicated = number of DMPs replicated in the GEO re-analysis at P<1x10-4
N-replication-studies = number of studies for which replication was examined
Prop-replicated = proportion of DMPs replicated.
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Table 4.4: Replication rate in EWAS of smoking
Trait N-DMPs N-replicated N-replication-studies Prop-replicated
smoking 1 1 21 1.00000
smoking 1 1 21 1.00000
smoking 10 10 21 1.00000
smoking 1,065 862 21 0.80939
smoking 1 1 21 1.00000
smoking 22 20 21 0.90909
smoking 30 9 21 0.30000
smoking 44 42 21 0.95455
smoking 32 31 21 0.96875
smoking 450 417 21 0.92667
smoking 37 28 21 0.75676
smoking 3 3 21 1.00000
smoking 60 57 21 0.95000
smoking 171 171 21 1.00000
smoking 258 257 21 0.99612
smoking 20 1 21 0.05000
smoking 2,780 1,117 21 0.40180
smoking 524 424 21 0.80916
smoking 192 0 21 0.00000
smoking 177 172 21 0.97175
maternal_smoking_in_pregnancy 19 19 4 1.00000
maternal_smoking_in_pregnancy 24 24 4 1.00000
maternal_smoking_in_pregnancy 1,591 413 4 0.25959
maternal_smoking_in_pregnancy 121 121 4 1.00000
maternal_smoking_in_pregnancy 4 4 4 1.00000
N-DMPs = number of differentially methylated positions identified at P<1x10-7
N-replicated = number of DMPs replicated in the GEO re-analysis at P<1x10-4
N-replication-studies = number of studies for which replication was examined
Prop-replicated = proportion of DMPs replicated.
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Table 4.5: Replication rate in EWAS of body mass index
Trait N-DMPs N-replicated N-replication-studies Prop-replicated
Body mass index 2 2 8 1.00000
Body mass index 133 83 8 0.62406
Body mass index 13 8 8 0.61538
Body mass index 14 12 8 0.85714
Body mass index 3 1 8 0.33333
Body mass index 5 3 8 0.60000
Body mass index 821 306 8 0.37272
Body mass index 182 113 8 0.62088
Body mass index 1 1 8 1.00000
N-DMPs = number of differentially methylated positions identified at P<1x10-7
N-replicated = number of DMPs replicated in the GEO re-analysis at P<1x10-4
N-replication-studies = number of studies for which replication was examined
Prop-replicated = proportion of DMPs replicated.
Before continuing to assess what CpG characteristics might, in part, explain some associations
found in EWAS, sites were removed that were identified by potentially faulty probes and were
on either of the sex chromosomes. Further, studies that did not include batch effects and cell
composition as covariates in at least one EWAS model were removed and studies for which fewer
than 10% of sites identified in the original analyses were identified in a re-analysis using the data
provided via GEO. Overall, this left 619 EWAS and 54961 associations (at P<1x10-4).
4.4.2 CpG characteristics
Using the selected EWAS results, it was investigated whether the characteristics of DNA methy-
lation at CpG sites explained associations found in EWAS.
It has previously been suggested that sites at which DNA methylation variability is low should
be removed (153,168). The rationale for this is that if total variation is low then the ratio of
variation due to technical effects to variation due to biological effects will be greater and thus
any association with a complex trait is more likely to be due to technical artefacts. However, it’s
unknown whether this may be removing sites pertinent to complex trait variation.
When assessing whether variance at a CpG site was associated with the odds of a DMP being
replicated in at least one other study, it was found that an increase of variance by one standard
deviation associated with a decreased odds of a DMP replicating (OR = 0.83 [95% CI: 0.79,
0.87] per sd increase in CpG variance). This contrasts with the notion that removing sites with
lower variance will reduce the chances of identifying sites due to technical artefacts.
There was also strong evidence of an inverse association between variance at a CpG site and
effect size. It was observed that an increase in the variance of DNA methylation by one standard
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deviation was associated with a decrease in absolute standardised effect size by 26% [95% CI:
26% decrease, 25% decrease]. This suggests that removal of sites with little variation may
reduce the chances of discovering changes in DNA methylation that have larger effects, whilst
not removing more unreliable sites.
DNA methylation changes are heritable (166,171), and DNA methylation could mediate the
effects of genotype on complex traits or genotype might confound the association between DNA
methylation and complex traits.
It was found that an increase in heritability by 10% was associated with an increased odds of a
DMP replicating (OR = 1.9 [95% CI: 1.9, 2]). An increase in heritability by 10% also associ-
ated with a decrease in absolute standardised effect size by 8% [95% CI: 8.3% decrease, 7.7%
decrease].
Heritability also had a capacity to predict whether a site would be identified as a DMP in at least
one study (AUC = 0.76), whereas variability only had a modest ability to do so (AUC = 0.59)
and further did not add to the predictive capacity of heritability (combined AUC = 0.76).
4.4.3 Enrichment of DMPs for genomic annotations
As the position of DNA methylation relative to genes is pertinent to its association with gene
expression (Section 1.2.3) (23,41–44), the enrichment of DMPs identified in The EWAS Catalog
across genomic regions and chromatin states were assessed (Figure 4.5). Across all tissues,
there was a trend for sites to be enriched for promoter regions (OR > 1). Evidence of enrichment
across different enhancer types was mixed and there was a trend towards depletion of sites within
heterochromatic regions, poised and bivalent promoters, regions repressed by polycomb proteins
and quiescent regions (Figure 4.5, OR < 1).
The DMPs identified by EWAS were also enriched for transcription factor binding sites. Of
the 167 transcription factor binding sites tested, there was evidence that identified DMPs were
enriched in 158 of them in at least one tissue type (FDR < 0.05). The strongest enrichments were
found for transcription factor binding sites as measured in blood (median OR ranged from 1.5
to 1.7 based on how DMPs were defined - see Section 4.3.6 for details) and varied from tissue
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Figure 4.5: Enrichment of DMPs for 25 chromatin states. Chromatin states across the genome
of 127 cell types comprising 25 distinct tissues were available from the Roadmap Epigenomics
Project. Using LOLA, the enrichment of DMPs from across all data in The EWAS Catalog for
chromatin states were assessed. DMPs were divided into five categories as detailed in Section
4.3.6. The x-axis show the 25 chromatin states: TssA, Active TSS; PromU, Promoter Upstream
TSS; PromD1, Promoter Downstream TSS with DNase; PromD2, Promoter Downstream TSS;
Tx5’, Transcription 5’; Tx, Transcription; Tx3’, Transcription 3’; TxWk, Weak transcription;
TxReg, Transcription Regulatory; TxEnh5’, Transcription 5’ Enhancer; TxEnh3’, Transcription
3’ Enhancer; TxEnhW, Transcription Weak Enhancer; EnhA1, Active Enhancer 1; EnhA2, Ac-
tive Enhancer 2; EnhAF, Active Enhancer Flank; EnhW1, Weak Enhancer 1; EnhW2, Weak
Enhancer 2; EnhAc, Enhancer Acetylation Only; DNase, DNase only; ZNF/Rpts, ZNF genes &
repeats; Het, Heterochromatin; PromP, Poised Promoter; PromBiv, Bivalent Promoter; ReprPC,































































































































DMP group A B C D E
Figure 4.6: Enrichment of DMPs for 167 transcription factor binding sites. Using LOLA,
the enrichment of DMPs from across all data in The EWAS Catalog for 167 transcription factor
binding sites confirmed across 25 distinct tissues were assessed. DMPs were divided into five
categories as detailed in Section 4.3.6. The x-axis show the 25 distinct tissues. All transcription
factor binding sites have not been confirmed across all tissues. For some tissues (e.g. “Eye” and
“Gingiva”) only five have been confirmed, but in blood over 131 have been confirmed.
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4.5 Discussion
Understanding the nature of EWAS associations is imperative for biological inference. Using
data from The EWAS Catalog this chapter shows that many CpGs associate with multiple dif-
ferent unique traits and the magnitude of these associations are partly explained by the charac-
teristics of DNA methylation levels. False positives may also explain a proportion of EWAS
associations. Roughly 10% of the DMPs identified were measured by potentially faulty probes
and the median percentage of CpGs that could be replicated across studies was 52%.
4.5.1 Identifying mediators
Identifying modifiable molecular traits that mediate the effect of complex traits on disease is
something that motivates a substantial portion of molecular epidemiology research (57,85). Hav-
ing a database of associations between DNA methylation and various traits and diseases may
enable easy identification of potential mediators that warrant follow-up. Overall, DNA methy-
lation at 126,673 CpGs are associated with multiple traits. The CpG that was identified in the
most EWAS, cg06500161 (ABCG1), had evidence from multiple studies that methylation at that
site associated with weight-related traits such as body mass index (3,69,175,176) and waist cir-
cumference (176), roughly 60 metabolites (160,161,177–179) and with type 2 diabetes (180).
Some studies have explored these associations further, for example, two studies used Mendelian
randomization (MR) to provide evidence that body mass index caused changes in methylation at
this site (3,175). However, full characterisation and assessment of whether methylation at that
site mediates the effect of adverse adiposity on any diseases has not been undertaken and could
be followed-up.
4.5.2 Biased results
The potential biases in EWAS have been well documented (6) and were discussed at length
in Section 1.3.4. It is encouraging that the majority of studies include batch effects and cell
composition in at least one of their models (79%). However, there are still some studies including
probes that have been characterised as faulty.
Differences in cell composition, sample ethnicity, covariates used and other differential biases
between studies might explain the low replication rate in some cases. However, studies only tend
to report associations below the conventional EWAS P-value threshold, P<1x10-7, so differences
in study power could also be a major factor.
4.5.3 Understanding CpG characteristics
Characteristics of DNA methylation discovered in experimental studies, such as its association
with gene expression, were used to select sites to measure DNA methylation for array-based
technology used in many EWAS (77). Individual studies may also select CpGs to analyse from
those assayed based on statistical characteristics such as high variance (153,168).
Our results suggest removing CpG sites with low variances may make it more likely to remove
sites with greater effects. Variance had a modest ability to predict whether or not a CpG site
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was likely to be identified in an EWAS, and it did not add to the predictive ability of heritability,
despite explaining a higher proportion of variance in effect estimates. This may be explained by
two things. Firstly, having a lower variance in the independent or dependent variable increases
the standard error of the beta coefficient in a linear regression. Secondly, heritability will in part
determine variance of DNA methylation.
4.5.4 Choosing sites to measure
As discussed in Section 1.3.3, the HM450 array was designed to capture DNA methylation in
various regions of the genome. The probes of the array target roughly only 2% of CpG sites in
the genome, yet target over 99% of protein coding genes and predominantly target the promoter
regions of these genes (77). The newer HMEPIC array captures much of what the HM450 array
does, and further covers 58% of FANTOM5 enhancers (181).
The trend for DMPs to be enriched for promoter regions (compared to regions of similar CG
density) suggests there may have been some justification for the chosen sites. However, not all
promoter regions were enriched with DMPs and bivalent promoters were depleted for DMPs.
Enrichment of enhancers was also seen, but the magnitude of enrichment was smaller. When
designing future arrays, these results suggest that continuing to target promoters and enhancers,
whilst avoiding gene regions that are less likely to be actively transcribed may yield more asso-
ciations in EWAS.
Despite the tissue specific nature of DNA methylation, the regions for which DMPs identified in
The EWAS Catalog were found to be enriched were fairly consistent across tissues. However, en-
richment of DMPs tended to be greater for blood-based genomic annotations, perhaps reflecting
the fact the majority of EWAS in The EWAS Catalog were conducted using DNA methylation
measured in whole blood.
4.5.5 Limitations
Individual participant data were not available and thus to calculate standardised betas, the vari-
ance of the trait had to be estimated from external measures of DNA methylation. If the GoDMC
sample is not representative of the sample used for the study EWAS then these estimates may be
substantially biased. Further, many studies do not report the effect estimates from their statistical
analyses. If there is a marked difference in the studies that do not report effect sizes and those
that do, then any associations between standardised effect estimates and DNA methylation site
characteristics are likely to be biased.
Like other observable phenotypes, DNA methylation varies under many contexts. Age, sex,
tissue type, population, socioeconomic position and many other factors may influence the results
of EWAS (6,57,85). The majority of EWAS conducted have used DNA methylation measured
in whole blood from European adults making the results not necessarily apply broadly outside
those bounds. The need for tissue-specific data has been discussed previously in Section 1.3.4.
Differences in DNA methylation between ethnic groups has been shown previously (182) and the
predictive value of a smoking-related methylation score was shown to differ between Europeans
and South Asians (164). This suggests any biological insight and population health benefits that
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may be the result of EWAS is likely to to be maximised by diversifying populations. It is unclear
from the work in this chapter whether the CpG characteristics and genomic annotations that show
evidence that they influence EWAS results, will also influence EWAS results in the same way
within a more ethnically diverse selection of samples.
4.6 Conclusion
This chapter demonstrates the potential for using large-scale EWAS databases to understand
DNA methylation-trait associations. It was found that study design flaws can help explain some
associations. However, it is noteworthy that the vast majority of studies have accounted for
some potential biasing factors, for example 79% of studies adjusted for batch effects and cell
composition. Further, there was an invese association between DNA methylation variability and
effect size, suggesting that studies that remove variable sites prior to analysis could be excluding
important regions from the analysis. Finally, cg06500161 ABCG1 was identified as being associ-
ated with 71 traits that share known biological relationships. This highlights the potential to use




Exploring the variance in complex
traits captured by DNA methylation
assays
5.1 Chapter summary
In Chapter 4, various aspects of DNA methylation were shown to correlate with the chances of
a CpG site being identified in epigenome-wide association studies (EWAS). However, whether
these identified CpG sites, or those that do not associate with with traits at a given P-value thresh-
old, capture much complex trait variance is unclear. Quantifying the total covariation between
the DNA methylation marks most commonly measured in EWAS and complex traits may reveal
how much more information is to gain from the current EWAS design by increasing sample sizes.
By re-purposing methods developed to estimate SNP-heritability, I estimated the proportion of
phenotypic variation captured by 421,693 blood derived DNA methylation markers (h2EWAS)
across 400 independent traits (1 - [r] > 0.4). The mean h2EWAS was zero, with evidence for reg-
ular cigarette smoking exhibiting the largest association with all markers (h2EWAS = 0.42) and
the only one with evidence of h2EWAS > 0 (FDR < 0.1). Though underpowered to determine the
h2EWAS value for any one trait, h2EWAS was predictive of the number of EWAS hits across the
traits analysed (AUC=0.7). Modelling the contributions of the methylome on a per-site versus
a per-region basis gave varied h2EWAS estimates (r=0.47) but neither approach obtained substan-
tially higher model fits across all traits. Our analysis indicates that most complex traits do not
heavily associate with the markers commonly measured in EWAS within blood. However, it is
likely DNA methylation does capture variation in some traits and h2EWAS may be a reasonable
way to prioritise these traits that are likely to yield associations in EWAS.
5.1.1 Contributions statement
I performed all analyses and wrote everything in this chapter.
5.2 Introduction
Epigenome-wide association studies (EWAS) aim to assess the association between phenotypes
of interest and DNA methylation across hundreds of thousands of CpG sites throughout the
genome (6,56). As seen in Chapter 4, many recent EWAS yielded few sites across the genome
with strong evidence for association. The proportion of total trait variance associated with each
of these sites tended to be small (Figure 4.2), but when modelled together, may be large. There
is a need to have a global view of the contribution of DNA methylation to complex traits in order
to interpret these results.
There are multiple possible reasons for there being few EWAS signals. Firstly, DNA methylation
varies between cells and tissues, thus any changes related to a trait may occur in any number of
tissues. Currently, because of ease of access and cost, the most common tissue used for EWAS
is blood, which may not capture changes in DNA methylation related to the trait of interest
(6,56). Secondly, the commonly used technologies probe a small percentage of the total number
of potentially methylated sites. In the absence of full knowledge of the correlation structure
across methylation site variation, it is therefore difficult to fully understand coverage in current
measures. Two more possibilities are that DNA methylation variation is actually not associated
with the traits studied or that the associations are many but individually too small to detect with
current sample sizes (Box 1).
Interpretation of the paucity of EWAS hits is difficult because there is no knowledge of the
total contribution of methylation variation to the trait. However, analogous to the calculation
of genetic heritability estimates, which have now been expanded to make inference across non-
familial population-level data (SNP heritability), the total contribution of methylation markers to
complex traits can potentially be estimated. This could give insight into the underlying patterns
of association between DNA methylation markers and complex traits (See Box 2 for a simple
explanation of SNP heritability (or h2SNP) and its application to DNA methylation).
SNP heritability estimates are sensitive to assumptions of the underlying genetic architecture and
there are different ways in which to model the contribution of each SNP to the overall genetic
component. The original model of calculating h2SNP introduced by Yang et al. assumes that each
variant has an effect that is independent of the regional linkage disequilibrium (LD) structure
as each variant is unweighted (the blanket model), and this effectively assumes regions of high
LD contribute more to phenotypic variance (108). Speed et al. proposed a new model, which
considered the LD between SNPs so that each region of high LD can effectively be counted as a
singular effect (the grouping model) (109). Finding which models fit the data better helps ensure
a more accurate estimation of the proportion of DNA methylation association with a trait, further
contrasting these models could also be biologically informative.
Gene regions are methylated in a coordinated fashion, which is associated with changes in gene
expression (23,183), with a tendency for promoter regions to be unmethylated and gene body
regions to be methylated when gene expression is activated (23). This, amongst other complex
patterns of gene regulation, induces a correlation structure within EWAS data, and it is not clear
whether a single site is driving an association and neighbouring sites are consequentially corre-
lated, or if the cumulative contributions of all neighbouring sites associate with the regulatory
60
process. In EWAS, a common strategy is to collapse DNA methylation sites into groups based
on proximity and if they share the same direction of association and potentially magnitude of
association, this is often called differentially methylated region (DMR) analysis (184). This,
however, does not explain whether the sites within groups are acting independently and cumula-
tively or as a set of distinct influences. Figure 5.1 shows a representation of how the differences
in models apply to DNA methylation data at a single small region using in one specific example.
Of course, there are far more scenarios possible and furthermore, the models aren’t restricted to
a single small region in the genome. They apply to all sites, as do the DMR methods used in
EWAS. Thus, by applying both methods to DNA methylation data across multiple phenotypes
and comparing their utility insight can be gained into how DNA methylation operates across
gene regions. Furthermore, it is important to find the model that best fits the data to help prevent
biased estimates.
This chapter aims to estimate h2EWAS values across a plethora of traits and assesses whether this
estimate may be useful in identifying traits for which EWAS will likely yield successful identi-
fication of associated DNA methylation sites. To do this I perform hundreds of EWAS studies
and evaluate if h2EWAS estimates are predictive of the number of sites identified by the EWAS
at various P value thresholds. I also compare the performance of different models underlying
h2EWAS estimates to infer likely methylation architecture of complex traits.
Box 1
The need for larger sample sizes in GWAS has been empirically demonstrated across a broad
range of traits. For height and body mass index (BMI), the number of associations dramatically
increased from 12 to 3290 and from one to 941, respectively after increasing sample sizes by
~670,000 (185–187). This trend can be seen for many traits. Similar to early GWAS, many
EWAS are discovering few sites strongly associated with complex traits. However, an example
that suggests promise for increasing sample sizes for EWAS is seen with BMI, where an EWAS
of 459 individuals identified just five sites, but increasing the sample size to over 5,000 led to
identification of 278 sites (3,188). While we can continue to improve sample sizes in EWAS,
there is a need to determine the upper limit of the information we can obtain from EWAS of
complex traits like BMI. Furthermore, the BMI EWAS example may be unrepresentative of
other traits, so having a corollary test for estimating h2SNP for DNA methylation would help
us understand if we’re capturing relevant information from the current arrays we are using in
EWAS. Such information could inform future study designs in terms of growing sample sizes
with the current assays available versus designing new assays.
Box 2
Methods used to estimate h2SNP use restricted maximum likelihood (REML) tests to estimate the
proportion of variance attributable to these genetic variants. Essentially this assesses whether
individuals that are genetically similar are more likely to be phenotypically similar. If those
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individuals that have a high genetic overlap tend to correlate strongly phenotypically compared
to those that don’t have high genetic overlap, then the phenotype of interest will have a high
h2SNP. Unlike genetic variants, DNA methylation is responsive to the environment (6) and de-
termining causal directionality between DNA methylation markers associated with traits is not
trivial (57,189,190). Therefore, estimating the proportion of trait variation captured by DNA
methylation variation (which will henceforth be denoted as h2EWAS) using the same techniques
will ascertain effects going in both directions as well as associations due to confounding. The
combination of these mechanisms may increase power to detect trait-DNA methylation associa-
tion, and could be the reason that so many DNA methylation markers are found in small EWAS





















Grouping model Blanket model
Figure 5.1: Comparison of the grouping and blanket models in the context of the relation-
ship between DNA methylation and gene expression. Both regions are exactly the same, the
only difference is how each model assumes the methylation sites should be treated. The group-
ing model down-weights the contribution of correlated CpGs, effectively grouping them, and
the blanket model assumes each CpG independently associates with a trait. As seen here, the
grouping of correlated CpG sites may not be the correct thing to do as some of the sites may be




All data used in this chapter came from the ARIES subsection of the ALSPAC cohort (see Sec-
tion 2.1 for study details). This chapter uses phenotypic and DNA methylation data from 940
mothers at middle age for which data could be extracted. Not all individuals had data on the
various covariates used in the analyses, thus the sample size varied with each analysis (mean of
805 and range of 491 to 940).
Continuous and binary phenotypes measured in mothers were extracted from the cohort using
the ‘alspac’ R package (github.com/explodecomputer/alspac) and went through extensive quality
control. Originally over 15,000 traits that were related to the mothers were extracted from the
database. After the quality control process, which is detailed in Figure 5.2, there were 2408
traits left for analysis.
All continuous traits were rank-normalised for further analyses. A Shapiro-Wilk test of nor-
mality was performed on these rank-normalised traits and for those with some evidence of non-
normality (P < 0.05), the distribution of those traits was re-examined by eye to ensure it was
approximately normal. It was found that any non-normality of phenotype distributions corre-
sponded to an inflation of zero values. These traits were removed and overall there were 2408
traits left for analyses. These traits do not necessarily represent independent phenotypes and as
such I wanted to prevent correlated traits skewing results. The absolute Pearson’s correlation co-
efficient between each trait was subtracted from one (1 –[r]). Then traits were greedily selected
where 1 – [r] > 0.4 with any other trait. This left 400 traits, which consisted of ~30% clinically
measured variables (including roughly 50 metabolites and some anthropometric traits), ~25%
health related questions (for example “have you ever had asthma?”), ~40% behavioural and so-
cial traits (for example educational attainment variables, use of pesticide, and having pets), and
~5% of traits were related to the partner or child of the participant (for example the employment
status of the partner).
5.3.2 DNA methylation data
The DNA methylation data also came from ARIES. Measurement, quality control of this data
are found in Section 2.1.4
Probes were excluded if they were present on either of the sex chromosomes, a SNP/control
probe, had a detection p value > 0.05 across over 10% of samples or were identified as problem-
atic by Zhou et al. (92). This left 421,693 CpG sites for analyses.
Before analysis a linear regression model was fitted with beta values for methylation (which
ranges from 0 (no cytosines methylated) to 1 (all cytosines methylated)) as the outcome against
batch variables (plate ID in ALSPAC) modelled as a random effect to help remove the effects of
batch in the subsequent analyses.
5.3.3 REML analysis
Using LDAK (191) the relationship between the methylomes (as measured by the HM450 array)
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Figure 5.2: A summary of the data cleaning steps. Binary variables with fewer than 100 cases
or controls were removed. Variables with “no clear relevance” to the mothers were identified
manually, most were descriptive of how samples were measured, for example the fieldworker
that examined the mother several months or years after blood draw. Normality of traits after rank
normal transformations were assessed using a Shapiro-Wilk test. Those with some evidence of
non-normality (P < 0.05), were re-examined by eye and removed if thought to be non-normal.
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This matrix was used as input for the REML analysis to estimate the proportion of a trait’s
variation that was explained by DNA methylation (h2EWAS). Age, the top 10 ancestry principal
components, and derived cell proportions were added as covariates to the model.
When producing the MRM, probes were scaled by their observed variance and the weighting
of each probe was based on the variance of DNA methylation at that site using the formula
below:
fj(1 − fj)(α/2) (5.1)
where fj(1 − fj) is the variance of methylation at CpG j. The higher the alpha value the more
weight is given to probes with greater variance; an alpha value of -1 gives equal weight to probes
with low and high variance. The alpha value of -0.25 was chosen because previous analysis by
Speed et al. (191) suggested that this value was optimal for measuring h2SNP. Furthermore, it
was hypothesised that probes with a greater variance would contribute more to trait variance.
As the method was applied to DNA methylation data in this chapter, sensitivity analyses were
conducted. MRMs were created specifying the alpha value at increasing increments of 0.25 from
-2 to 0. The association between h2EWAS and number of EWAS hits.
The mean of the MRM diagonal should be 1 and the variance close to 0, as the diagonal values
essentially represent the correlation between an individual’s methylome with itself. Although
values are expected to vary slightly from 1. For the MRMs it was identified that some diagonal
elements were very high (> 2), which caused the diagonal to have a high variance (0.13). To
assess whether these values could skew results, sensitivity analyses were conducted, removing
individuals with varying diagonal value cut-offs.
Like h2SNP estimates, h2EWAS estimates should range from zero to one. If a trait has a true
h2EWAS value of zero, there is no association between the methylome and that trait, and if h2EWAS
equals one then DNA methylation has the capacity to completely predict that trait. However,
estimation of h2EWAS can be fairly imprecise and without constraining the software it’s possible
to get estimates of h2EWAS that are outside 0-1 due to large standard errors. These point estimates
have to be erroneous by definition.
Even though the grouping model effectively groups sites together, it is actually likely to in-
crease the number of parameters because without the weightings imposed by this model, the
blanket model essentially ignores sites that are not neighbouring others. Therefore, larger stan-
dard errors are expected with the grouping model. The grouping model applies a sliding window
approach, with windows of 100kb, to capture the correlation between neighbouring sites and
weight sites according to the correlation structure of the region. When applying the grouping
model, the number of sites that were weighted were 45,863 (out of 421,693) and the number of
sites neighbouring any single CpG site ranged from 29 to 28,217.
5.3.4 Generating genetic principal components
Ancestry principal components were generated within ALSPAC mothers using PLINK (v1.9).
Before analysis, genetic data went through quality control and were imputed, full details can be
found in Section 2.1.3. After quality control and imputation, independent SNPs (r2 < 0.01) were
used to calculate the top 10 ancestry principal components.
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5.3.5 Epigenome-wide association studies
EWAS were conducted for 400 selected traits (see Section 5.3.1 for selection process) within
the ALSPAC cohort. For all traits, linear regression models were fitted with beta values of DNA
methylation as the outcome and the phenotype as the exposure. Covariates included age, the top
10 ancestry principal components and cell proportions.
5.3.6 Association between h2EWAS and epigenome-wide association studies
results
DMPs were extracted from the EWAS at P value thresholds ranging from 10-3 to 10-7. It was
assessed whether h2EWAS could predict that the number of identified DMPs in an EWAS was
greater than number of DMPs expected to be identified at a given P threshold defined as the
number of sites tested multiplied by the threshold. The traits were also “pruned” in the same
way as described above, to prevent including overly correlated traits and biasing results. The
sensitivity and specificity of this prediction was calculated and a receiver operating characteristic
(ROC) curve was plotted. At p-value thresholds of 10-6.5 and 10-7 there were fewer than 100 traits
for which EWAS identified any sites, so these thresholds were removed from the analysis.
The association between the number of DMPs identified at P<1x10-5 and h2EWAS values was
assessed using a negative binomial hurdle model with the number of DMPs identified fitted as
the outcome and h2EWAS as the exposure. The negative binomial hurdle Poisson regression model
results are twofold. The first of which assesses whether there is an association between the binary
trait of whether a DMP was identified by EWAS (dependent variable) and h2EWAS (independent
variable). The second is a zero-truncated model, i.e. the zero values are removed from the model
and the association between number of DMPs (dependent variable) and h2EWAS (independent
variable) is assessed.
The same method was applied to estimate the association between the number of SNPs iden-
tified in GWAS at P<5x10-8 and h2SNP. SNPs associated with 485 traits in UK Biobank (see
Section 2.3 for a brief description of the cohort) were extracted using the IEU OpenGWAS
Project (105). The h2SNP estimates were extracted from http://www.nealelab.is/uk-
biobank/.
All analyses were conducted in R (version 3.3.3) or using the command line software LDAK
(191), GCTA (192), and PLINK (193). For the EWAS analyses, the meffil R package was used
(169). A one-sided P value was used to assess if the h2EWAS for a trait was > 0, and two-sided P
values were used for everything else.
5.4 Results
A flowchart showing our study design and giving a summary of the results is shown in Figure
5.3.
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2408 traits from ALSPAC after QC
400 independent traits ([r] < 0.4)
EWAS
340 traits with at least one EWAS hit
at P<1x10-5
Estimate h2EWAS using the
grouping and blanket models
Comparison of models
Neither model fits the data better
(has a higher likelihood across traits)
Association between h2EWAS and
number of EWAS hits
Sensitivity analyses:
assessing outliers in the
MRM and variability of DNA
methylation sites
Removing outliers and
changing the weight given to
highly variable DNA
methylation sites did not
impact the distribution of
h2EWAS estimatesh2EWAS has a modest ability to predict
the number of EWAS hits
(AUC = ~0.7)
An increase of 0.1 h2EWAS was
associated with an increase of 0.63
[95%CI 0.41, 0.84] EWAS hits when
the number of EWAS hits > 0
Figure 5.3: Study design with a summary of the results. ALSPAC = Avon Longitudinal Study
of Parents and Children, QC = quality control, EWAS = epigenome-wide association study,
MRM = methylation relationship matrix, AUC = area under curve.
5.4.1 Estimating the proportion of phenotypic variance associated with DNA
methylation
Two models were used to estimate the total contribution of all DNA methylation sites to the
variation (h2EWAS) for each of 400 traits within up to 940 individuals. The mean for both models
was zero with ranges of -0.4 to 0.4 and -0.5 to 0.4 for the blanket and grouping models respec-
tively Figure 5.4. The estimates were imprecise, the mean standard error was 0.03 and 0.05 for
the blanket and grouping models respectively. The trait with the greatest evidence for h2EWAS
estimates being above zero was having smoked cigarettes regularly (FDR-corrected P = 0.06 and
0.10 for the blanket and grouping models respectively). The correlation between the h2EWAS
estimates of the two models was 0.47 and there was evidence that on average the estimates of
the grouping model were higher (Paired t-test P = 1.8x10-5, Figure 5.4), and the mean difference
between estimates was 0.018.
There was little evidence that either of the models fit the data better (had higher likelihoods)
across the 400 traits tested (difference in median likelihoods = 0.19, Wilcoxon’s paired ranked











































































































































































































































Figure 5.4: A comparison of h2EWAS estimates given by applying REML using the blanket
and grouping models across 400 traits. The blue dashed line is at x=y. Values with h2EWAS
lower than 0 are due to imprecision in h2EWAS estimates as the true estimate cannot be negative.
Smoked_cigs_reg = smoked cigarettes regularly. The h2EWAS of this phenotype has the greatest
evidence for being above 0 for both the blanket and grouping model (Uncorrected P = 1.44x10-4
and P = 2.61x10-4, respectively).
5.4.2 Sensitivity analyses when estimating the proportion of phenotypic variance
associated with DNA methylation
After examination of the MRMs required to produce the h2EWAS estimates, for both the blanket
and grouping model some unexpected values were observed. Ninety-six diagonal elements had
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values over 1.5 when using the blanket model, with the maximum value being 3.562. When
assessing the impact of these potential outliers in the MRM to results it was found that the
median and range of h2EWAS estimates varied little (Figure 5.5). The likelihood of the models
tended to be greater as more outliers were removed (lower threshold for classing a diagonal
element as an outlier), but it still did not vary greatly (Figure 5.5).
The weight of predictors used to produce the MRMs was also examined. As more weight was
given to sites where methylation variation was greater (increasing alpha value) the h2EWAS es-
timates were slightly higher (Figure 5.5). However, the likelihood varied little, the median
likelihood had a range of 2 across the alpha values (Figure 5.5).
5.4.3 EWAS analyses
In order to assess the association between h2EWAS and EWAS results, EWAS of 400 traits were
performed. No associations were found at the strict P value cut-off of P<2.5x10-10 (conventional
EWAS P-value threshold, 1x10-7, divided by the number of traits, 400). A total of 29 associations
between traits and CpGs were identified at the conventional EWAS P value cut-off – P<1x10-7.
Of the traits tested, 16 had at least one EWAS hit, with the maximum number of CpGs associated
with a trait being 13 (smoked cigarettes regularly). As there were so few traits with any identified
hits, I took forward results from the lenient P value threshold of P<1x10-5, at which 340 traits had
at least one EWAS hit. Table 5.1 shows each trait and the number of differentially methylated
positions identified at varying P value thresholds.
As the distributions of hit count data was heavily right skewed with an inflation at 0 and 1 (Figure
5.6), to test the association between h2EWAS and number of DMPs I opted to test goodness of fit
for variations of Poisson models. Of the 6 models tested, the negative binomial hurdle Poisson
regression model fit the data best (had a higher likelihood). It was found there was some evidence
for an association between number of EWAS hits and h2EWAS (Figure 5.7). There was some
evidence of association between the presence of DMPs and h2EWAS (beta = 6.2, [95%CI 2.5,
10]) as well as some evidence of an association between number of DMPs (when the number is
above 0) and h2EWAS (mean increase of 0.63, [95%CI 0.41, 0.84] DMPs when h2EWAS increases
by 0.1). Applying the same method to GWAS data, it was found evidence that the presence
of identified SNPs associated with h2SNP (beta = 21.9 [95%CI 19.6, 24.1]) and the association
between number of SNPs identified (when the number is above 0) and h2SNP (mean increase of














































































































































































































































































































































































































































































































































































































































Figure 5.5: Boxplots summarising of sensitivity analyses. A and B Analyses estimating
h2EWAS were repeated after removing individuals who had high diagonal values in the methy-
lation relationship matrix (MRM). Varying thresholds were used to define individuals as an out-
lier, NA indicates that no individuals were removed from the analysis. A shows the likelihood
estimate (model fit) variation and B shows the variation in h2EWAS estimates. Analyses were also











Figure 5.6: The distribution of the number of DNA methylation sites identified at P<1x10-5























































































































































































































































































































Figure 5.7: Association between h2EWAS and number of DMPs identified in EWAS. The
correlation between DNA methylation and the variance of traits (h2EWAS) was calculated using
REML analysis using the blanket and grouping models. EWAS were conducted on all the same
traits and the distribution of the number of DMPs identified at P<1x10-5 and h2EWAS are plotted
above. Any traits where the h2EWAS estimate is below 0 are coloured grey. The true h2EWAS
value of a trait cannot be negative, but sample sizes in this analysis are small so the estimates are
imprecise.
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Table 5.1: Summary of how well models fit to test the association between h2EWAS and the
number of differentially methylated positions identified across 400 traits at P < 1x10−5.
Model Log(likelihood) DF
Poisson -1561 2
Negative binomial -972 3
Hurdle-negative binomial -954 5
Hurdle -1500 4
Zero-inflated negative binomial -972 5
Zero-inflated Poisson -1501 4
DF = degrees of freedom.
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The ability of h2EWAS estimated by both models to predict whether the number of DMPs iden-
tified was greater than expected was assessed at varying P value thresholds. ROC curves were
produced and the area under the curve (AUC) ranged from 0.65 and 0.67 at P<1x10-6 to 0.79
and 0.71 at P<1x10-3 for the blanket and grouping models respectively and the predictive ability




































Figure 5.8: The ability of h2EWAS values to predict whether the number of differentially
methylated positions identified in an EWAS is higher than expected by chance. ROC curves




The global contribution of DNA methylation to complex trait variance can inform researchers of
how to design future studies that seek to discover new DNA methylation sites associated with
their trait of interest. In this chapter I apply methods designed to estimate the predictive capacity
of variants across a SNP-chip (h2SNP), to DNA methylation data measured in blood with the
HM450 array across 400 independent traits, giving a distribution of the contribution of all sites
typically measured in EWAS to complex trait variance. Although sample size was too small to
reliably estimate h2EWAS for any one trait, the distribution of estimates suggest little complex
trait variation is captured by DNA methylation at the sites measured and h2EWAS may be a good
measure to identify traits for which EWAS will yield associations.
5.5.1 Estimation of h2EWAS
The true h2EWAS of a trait gives the total predictive capacity of DNA methylation for that trait,
which is equivalent to the proportion of that trait’s total variance that is associated with changes in
DNA methylation. Knowing this information can help design future EWAS studies. A low value
of h2EWAS doesn’t necessarily mean there is little correlation between DNA methylation and a
trait, it could transpire that unmeasured sites contribute more to the association. It is important
to remember that roughly 1.5% of CpG sites are targeted by the HM450 array and DNA can be
methylated elsewhere (not at cytosine bases). Therefore, whole genome bisulphite sequencing, or
a similar technique, may show that the variance of complex traits captured by DNA methylation
is far higher. Furthermore, even if h2EWAS is low and the sites discovered already do not explain
all of the h2EWAS estimate, there may still be value in increasing sample size to identify more
DMPs as well as increase the precision of h2EWAS estimates. DMPs discovered may not be
highly correlated with a trait, but this doesn’t mean the potential biological information gained
isn’t valuable. For example, if a change in a the levels of protein X has a large effect on a trait
and change in DNA methylation has a small effect on the levels of protein X, then the effect of
that DNA methylation change on the trait will be small, but identifying that DMP could lead to
discovering the importance of the protein. Another thing to consider is that DNA methylation
is tissue and cell specific. This means, that h2EWAS may vary a lot depending on what tissue the
methylation is measured in.
The true underlying genetic architecture of complex traits is still unknown, and therefore it is dif-
ficult to know the appropriate model to choose when estimating the contribution of all measured
SNPs to phenotypic variance amongst unrelated individuals and arguments for each model de-
pending on this underlying genetic architecture are still being put forward (191), (194–196), thus
the attempts made in this study to re-purpose genomic REML are likely to suffer the same flaws
that are trying to be overcome in genetic data. With this in mind, in addition to the imprecise
estimates of h2EWAS presented here (due to the small sample sizes of available data), individual
trait h2EWAS values should be treated with caution. This doesn’t exclude the possibility that es-
timating h2EWAS may be useful and other methods are already being developed to measure the
association between DNA methylation at all sites and complex traits (197).
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5.5.2 Future EWAS
Heritability estimates from family-based studies gave an a priori justification for the pursuit of
gene mapping endeavours that eventually gave rise to GWAS, as they demonstrated variation in
complex traits had a substantial genetic component. However, the evidence DNA methylation
contributed to trait variation was not ascertained before EWAS were first conducted. To justify
collecting more samples and continuing with EWAS research in the current vein, methods such
as the one presented in this study should be used to show DNA methylation does substantially
contribute to trait variance.
It has become clear from the GWAS era of genetics, that for complex traits, such as coronary
artery disease, many common genetic variants with small effects make up the genetic component
of the trait (198,199). This suggests a large number of molecular pathways contribute to these
traits. DNA methylation at CpGs is heritable (129,171), thus it would be expected that the DNA
methylation architecture of a trait will somewhat reflect the genetic architecture of the trait,
although this has not been empirically tested.
Despite uncertainty of h2EWAS estimates for individual traits, I show h2EWAS has a modest ability
to predict whether the number of EWAS hits will be greater than expected by chance at a given
P value threshold. This predictive ability remained stable as the P value threshold for detection
increased from P<1x10-6 to P<1x10-3. These results suggest that increasing sample sizes for
traits which truly associate with DNA methylation should result in the discovery of more DMPs.
Furthermore, these results support a model for which small changes in methylation at many
CpGs across the genome are related to complex traits.
5.5.3 Contributions of individual CpG sites
The original model for measuring h2SNP assumed all genetic variants contributed the same effect
on a trait (108), Speed et al. offered an alternative model assuming a different underlying genetic
architecture, whereby genetic variants in regions of high LD contributed less to the variance
of a trait than more independent variants. Both groups have shown that the performance of
the models depends on the alignment of the trait’s architecture with the models’ underlying
assumptions. Previous literature has suggested that it is the methylation across groups of CpGs
that may affect how other molecules interact with DNA and influence cellular functions such as
gene expression (23). Furthermore, CpGs are not randomly distributed throughout the genome –
many exist in close proximity within “islands” or other regions, suggesting that grouping of the
CpGs may have functionality. However, the most common method used in EWAS is to treat CpG
sites as independent. Here, the models proposed by Speed et al. (the grouping model) and Yang
et al. (the blanket model), when estimating h2EWAS were tested across 400 traits. The model fit
the data better (had a higher likelihood) 207 times for the blanket model and 193 times for the
grouping model. Thus for over half the traits treating DNA methylation sites as independent
seems to be preferable and even though there is correlation between CpG sites, which allows
them to be grouped, it might be that in some groups of correlated sites, individual sites within
the group contribute separately to trait variance.
It’s important to note that the grouping method takes into account correlation between CpGs
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within 100Kb of each other. Differential methylation at CpG sites may be correlated for a variety
of biological reasons, for example, CpGs lying within a transcription factor binding site will be
regulated together, but also, they will be correlated with CpGs that lie in other binding sites for
that same transcription factor and these may be many megabases away. This is relevant to the
relationship between DNA methylation and complex traits because transcription factor regulation
might be the link between complex traits and DNA methylation. Even though grouping CpG sites
might yet be the best way to model the relationship between DNA methylation and complex
traits, the optimum way to group sites is unknown and will likely change depending on the trait
of interest.
5.5.4 Limitations
The main limitation of the chapter is the small sample size (maximum N = 940) to estimate the
h2EWAS. This meant the precision of our h2EWAS estimates were very low and so our power to
assess their ability to predict number of DMPs and find individual trait h2EWAS values was low.
To circumvent this problem, trends across multiple traits are assessed and I do not make strong
conclusions for any one trait.
As mentioned previously the HM450 array captures a small percentage of the total DNA methy-
lome and h2EWAS estimates will likely vary upon assaying more DNA methylation sites. Fur-
thermore, when measuring more sites, it might be that one of the models fits the data better.
Nevertheless, the results of this study can still give evidence towards the hypothesis that dif-
ferential methylation at many sites across the genome each contribute minimally to the overall
association between the methylome and a complex trait.
Unlike germline genetic variants, there is intra-individual (between tissue and time dependent)
DNA methylation variation (6,56). Thus, it is to be expected that the variation of h2EWAS esti-
mates across traits is partly a product of the tissue and timepoint of choice. However, within the
tissue biologically pertinent to the complex trait of interest, the number of pathways that asso-
ciate with variation in that trait is likely to remain high, for example there are many processes
affecting, or affected by, cancer development (200). Thus, it would still be expected that differ-
ential methylation at many CpG sites each associate with a trait, but the effect sizes are small.
The same can be said when estimating h2EWAS at various timepoints.
Estimates of h2EWAS will be a product of their environment and genetic make-up of the partici-
pants it’s measured in. Therefore, the results here may vary by population and by sex. However,
participants used in this study are considered to be representative of the larger ALSPAC cohort
(201), which is itself considered to be representative of a large majority of women from the UK
and potentially other high-income countries (141). This suggests the results will be generalisable
to a large group of samples for which EWAS are conducted, but replication in these samples as
well as in different populations would provide greater confidence in the generalisability of the
results.
A wide range of complex traits was used in the analysis, but there are some notable absences.
Rarer diseases and diseases that predominantly impact the elderly are not present in this study.
The results presented here cannot be generalised to those traits.
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The factors important for the correlation structure of DNA methylation data are less known
than those for linkage disequilibrium structure of genetic variants. Therefore, when applying
models, such as the grouping model here, that aim to account for correlation of neighbouring
DNA methylation sites, some of the important structure captured may be missed for example
by trans-correlations (over 1Mb). A model that estimates h2EWAS by incorporating all of the
underlying correlation of DNA methylation data may therefore outperform both models tested
here.
5.6 Conclusion
Overall, the number of traits with good evidence for h2EWAS > 0 was low (only smoking be-
haviour met the threshold of FDR < 0.1) and mean h2EWAS value across both models was roughly
0, suggesting that for many traits DNA methylation variation as measured on the HM450 array in
blood is of little relevance. However, these estimates varied greatly and therefore DNA methy-
lation measured in this way will likely have relevance for some traits, for example smoking
cigarettes regularly. Further, these estimates were correlated with the number of DMPs identi-
fied, suggesting that for traits whose variance associates with DNA methylation then increasing
sample size will yield an increase in the number of CpGs identified in EWAS. I also provide ev-
idence that there is value in assessing individual CpG-trait associations as opposed to groups of
correlated CpG sites within 100Kb. However, this does not preclude the possibility that a more
complex model of CpG site correlation may provide a better fit.
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Chapter 6
A comparison of the genes and genesets
identified by EWAS and GWAS of eight
complex traits
6.1 Chapter summary
Despite little evidence that DNA methylation correlates highly with complex trait variation
(Chapter 5), it is of interest to understand whether the DNA methylation sites identified may
be valuable in understanding the underlying biology of complex traits. Identifying the genes,
properties of these genes and pathways to understand the underlying biology of complex traits
responsible for differential health states in the population is a common goal of EWAS and GWAS.
Genetic variants identified in GWAS will not be caused by phenotypic variation and their asso-
ciations with complex traits are unlikely to be confounded. Whilst DNA methylation changes
identified in EWAS do not share the same properties, the goal of identifying facets of genomic
change that cause differential health states among the population remains the same for both stud-
ies. A simple method, routinely applied, to aid in this goal involves mapping regions of the
genome identified by the study to genes and genesets. In this chapter I use data from The EWAS
Catalog (Chapter 3) and the IEU OpenGWAS Project to assess whether EWAS are identifying
similar genes and genesets to GWAS, which indicates if EWAS is capturing the same underlying
biology of a trait.
Across eight different traits with large EWAS (N > 4500), the number of 500kb genomic re-
gions with both an associated genetic variant (P<5x10-8) and differentially methylated position
(P<1x10-7) identified was a small percentage of the total number variants and differentially
methylated positions identified (ranging from 0% to 9%). Fisher’s exact test was used to es-
timate whether genes identified by EWAS were more likely to be also identified by GWAS. The
overlap was found to be no more than expected by chance across all the traits (P > 0.05 in all
cases). Further, correlation between Gene Ontology term enrichment scores was no higher than
expected by chance. Overall, the EWAS findings for these eight traits are vastly different to
the GWAS findings and implicate different biological genesets. By way of example, the GWAS
of alcohol consumption identified genes enriched in the ethanol catabolism pathway (FDR <
0.1), whereas the corresponding EWAS identified no genes in this pathway. Simulations sug-
gested these results were likely due to the majority of EWAS signal being the consequence of
trait variation or confounding. However, they did not preclude the possibility that some of the
differentially methylated positions may be pertinent to the aetiology of the traits. Currently, in-
terpreting EWAS is difficult, but even if only a small proportion of the DNA methylation sites
identified are causally related in some way to the traits of interest here, it is likely they are acting
through distinct biological pathways.
6.1.1 Contributions statement
I conducted all analyses and wrote everything in this chapter.
6.2 Introduction
Often in EWAS, the potential biological implications of differentially methylated positions or
regions (DMPs or DMRs) will be investigated further through genomic annotations (5,202–204).
As discussed in Section 1.2.3, previous studies have demonstrated a relationship between DNA
methylation levels and proximal genes (23,40). This observation has lead to it being common
place to map sites identified in EWAS to nearby genes and these genes and their function are
often probed to ascertain their relevance to the trait of interest (5,202–204). Further, genes can
be grouped with others into “genesets” that have similar functionality or lie within the same
pathway. Over-represented genesets may provide an insight into the molecular biology of a trait,
for example, DNA methylation sites identified in an autoimmune disease EWAS might tag genes
within immunological pathways more than expected by chance. Other assessments may be made
to infer potential biological understanding, including enrichment of other epigenetic marks at the
regions identified (205) and follow-up experimental studies (56). However, using open access
databases to investigate tagged genes and genesets is a simple and potentially effective approach
to further biological understanding.
GWAS often use similar approaches to EWAS to help infer function from the signals identified
(56,206). However, the properties of genetic variants and DNA methylation differ making po-
tential inferences from EWAS and GWAS diverge. Importantly, DNA methylation is responsive
to environmental stimuli, thus making associations identified in EWAS potentially attributable to
reverse causation and to confounding (6,57,201). It should be noted GWAS may be susceptible
to confounding, but it is reasonable to assume it is less pervasive amongst GWAS associations
(101,102).
Given what is known about the properties of genetic variants, a direct comparison between
EWAS and GWAS results can provide insight into what biological information EWAS is cap-
turing. If EWAS are highlighting a similar set of genes and genesets, it suggests changes in DNA
methylation are identifying facets of trait aetiology. In the event that GWAS and EWAS are not
highlighting similar genes and genesets, it is plausible that EWAS may still be identifying facets
of trait aetiology. If DNA methylation mediates non-genetic effects and if sites are mapped to
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genes or genesets incorrectly then overlap will not be guaranteed even if DNA methylation iden-
tified is aetiologically relevant. When DNA methylation mediates the effect of genetic variants
distal to their genomic position on complex traits, the genes identified by GWAS and EWAS will
also differ, but the genesets would likely overlap. The lack of overlap could also reflect the fact
associations in EWAS may be driven by confounding and reverse causation. Despite the caveats
mentioned, one might still expect to detect overlap in genes and genesets identified by EWAS
and GWAS of corresponding traits in the absence of confounding and reverse causation. The
extent to which this expectation holds is discussed in more detail in the Section 6.4.
In this chapter, the overlap between genes and genesets identified by GWAS and EWAS of eight
complex traits is explored and the scenarios in which one would and would not expect to find
overlap are modelled through simulations.
6.3 Results
6.3.1 Study data
Traits were selected for which EWAS had been conducted with over 4500 samples and for which
corresponding GWAS summary data were available. At the time of conducting these analyses,
traits were identified using data from The EWAS Catalog (Chapter 3) that contained EWAS
published before 2019. The EWAS of glucose and insulin were also added at a later date. Traits
and study data information is in Table 6.1.
Table 6.1: Study data
trait ewas-author ewas-pmid ewas-n gwas-author gwas-pmid gwas-n
current versus never smoking Joehanes R 27651444 9,389 Liu M 30643251 632,802
former versus never smoking Joehanes R 27651444 13,474 Elsworth B NA 424,960
alcohol consumption per day Liu C 27843151 9,643 Liu M 30643251 537,349
c-reactive protein Ligthart S 27955697 8,863 Ligthart S 30388399 204,402
body mass index Wahl S 28002404 10,238 Yengo L 30124842 681,275
educational attainment Karlsson Linner R 29086770 10,767 Lee JJ 30038396 766,345
insulin Liu J 31197173 4,740 Manning AK 22581228 51,750
glucose Liu J 31197173 4,808 Manning AK 22581228 58,074
Where gwas-pmid = NA, the GWAS were conducted as part of a UK Biobank GWAS pipeline within the Univeristy of Bristol’s Integrative Epidemiology Unit and can be found on the OpenGWAS Project website (see Methods for more)
6.3.2 Genomic position overlap
The genome was divided into 5591 500kb non-overlapping regions and mapped EWAS and
GWAS signals for each trait to these regions (see Section 6.6 for more details). The number of
regions that were identified by one study type and not the other was higher for each trait than
the number of overlapping regions (Figure 6.1). Further, the magnitude of the greatest GWAS
effect estimate in each region had little ability to predict whether or not a DNA methylation site















Figure 6.1: Overlap between genomic positions identified by corresponding EWAS and
GWAS. The genome was divided into 500Kb regions. Those where no probes on the HM450
array measured DNA methylation were excluded from the analysis. Regions were counted as
being identified by a GWAS if one or more SNPs associated with the trait and as being identified
by an EWAS if one or more CpGs associated with the trait. Neither = no EWAS or GWAS sites
identified in the region, GWAS = GWAS sites only were identified, EWAS = EWAS sites only
were identified, Both = Both EWAS and GWAS sites were identified, AC = alcohol consumption
per day, BMI = body mass index, CRP = c-reactive protein, CsNs = current smokers vs never




















Figure 6.2: Can genetic variant associations predict the presence of DNA methylation as-
sociations in the same region?. For each 500kb region in the genome, the largest SNP-trait
effect size was extracted. ROC curves were produced to determine whether these could predict
whether a differentially methylated position related to the same trait was present in the same
500kb region. The area under these curves (AUC), with their confidence intervals, are plotted
for each trait. The red dashed line is at AUC = 0.5, which represents a prediction no better than
chance. AC = alcohol consumption per day, BMI = body mass index, CRP = c-reactive protein,
CsNs = current smokers vs never smokers, EA = educational attainment, FsNs = former smokers
vs never smokers. Note: insulin is not present in this plot as there were GWAS and EWAS signal
that overlapped across all the 500kb regions.
6.3.3 Assessing power to detect shared annotations between GWAS and
EWAS
Genomic function and trait biology are not divided into discrete 500kb genomic chunks, thus
GWAS and EWAS could still be identifying similar facets of trait biology without identifying
the same genomic regions.
I sought to assess whether the genes and genesets identified overlapped more than expected by
chance, thus genomic positions were mapped to genes and genes to genesets (details in Section
6.6). Overlap between genes identified was assessed using Fisher’s exact test. Two methods for
testing overlap between genesets were considered, one simply mapped genes to genesets and
used Fisher’s exact test in the same way as assessing overlap between identified genes. The other
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generated ‘enrichment scores’ for each geneset and assessed correlation between the geneset
enrichment scores across studies.
Assuming all genetic effects on DNA methylation are proximal. If all DMPs that associated with
a trait were on the pathway from SNP to disease, then EWAS and GWAS would be identifying
genes from the exact same geneset (i.e. genes that caused changes in the trait). The more DMPs
that are identified because of confounding effects or reverse causation, the smaller the chance of
overlap, assuming that causal and responsive genesets are distinct. As mentioned, the presence
of trans-mQTLs would make the overlap of genes identified by GWAS and EWAS less likely
despite both studies identifying aetiologically relevant factors. However, geneset overlap will be
more likely to be maintained regardless of trans-mQTL presence. In a scenario where no DMPs
are causing phenotypic changes, any overlap in genes and genesets found would be entirely
attributable to chance (ignoring potential feedback loops whereby the trait causes changes in
genesets that it is affected by). Simulations were run to assess which scenarios the enrichment
and annotation methods had power to detect whether there was more overlap than expected by
chance. Power was also assessed across different annotation methods. A schematic of how the
simulations were set up can be found in Figure 6.3.
Under each scenario, the ability to predict whether EWAS were identifying, in part, the same set
of genes as GWAS (‘causal genes’) compared to a random set of genes (‘associated genes’) was
tested. As expected, predictive capacity increased as study power and the proportion of causal
DMPs increased (Figure 6.4, Figure A.1). Predictive ability tended to increase as the number of
identified genes increased, but this parameter was largely inconsequential when the proportion
of causal DMPs was low (Figure A.1). Performance was similar across annotation methods and
between methods attempting to assess geneset overlap, with assessment of gene overlap perform-
ing better (Figure 6.4). Overall there was more power to detect overlap in genes than overlap in
genesets. Between the geneset methods, there was more power to detect correlation between en-
richment scores than direct overlap in genesets. Therefore, gene overlap and correlation between
geneset enrichment scores were taken forward for the empirical analyses. Assessing correlations
of GO term genesets had slightly more power (Figure 6.4) than other geneset databases, so these
geneset annotations were taken forward.
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Figure 6.3: Flowchart demonstrating how the first set of simulations were set up. The
flowchart (under the title “Generating simulated data”) shows how the simulated data were gen-
erated. The boxes under “Analysis” show the analyses performed with the simulated data. Un-



















































































































































































































































































B.  The proportion of causal EWAS genes =  1
Figure 6.4: Power to detect overlap between genes and genesets identified by corresponding
EWAS and GWAS. Simulations were set up as illustrated in Figure 6.3. The area under receiver
operator curves (AUC) was used to estimate the ability to distinguish between results generated
when EWAS and GWAS were sampling, in part, from the same set of causal genes and results
generated when EWAS were sampling random genes from the genome. The header of each set
indicates the proportion of genes identified by the simulated EWAS that were set to be causal.
or_g = assessing overlap of genes, or_p = assessing overlap of genesets, rho_p = assessing corre-
lation between geneset enrichment scores. go = Gene Ontology, ppi = protein-protein interaction
database from EpiGraphDB. This is a summary of the results, full results can be found in Figure
A.1.
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6.3.4 Gene and geneset overlap between GWAS and EWAS
For the eight traits used, the number of genes identified by EWAS and GWAS that overlapped
was low and for two traits no genes identified by the studies overlapped (Table 6.2). The number
of genesets that overlapped was higher, peaking at 1,243 for GWAS and EWAS of body mass
index (Table 6.3).
There was no strong evidence that the number of overlapping genes identified was more
than expected by chance (Table 6.2). Although, power was low in most cases to detect a
high level of gene overlap in most cases. There was also little evidence that correlation
between enrichment scores of the GO terms was greater than expected by chance (Table
6.3). As suggested by the previous simulations, this does not preclude the possibility that
EWAS are identifying changes in DNA methylation that are upstream of phenotypic change.
Table 6.2: Overlap of genes identified by EWAS and GWAS
trait n-ewas-genes n-gwas-genes gene-overlap obs-OR exp-gene-overlap exp-OR p-diff
current versus never smoking 1,933 312 27 2.9 39 3.42 0.322
former versus never smoking 282 320 9 6.4 7 3.43 0.022
alcohol consumption per day 361 196 3 2.6 3 2.44 0.908
c-reactive protein 189 302 3 3.2 1 0.91 0.121
body mass index 232 3,221 23 2.0 39 3.04 0.052
educational attainment 25 1,594 1 1.5 3 3.00 0.430
insulin 36 5 0 0.0 0 0.00 1.000
glucose 15 50 0 0.0 0 0.00 1.000
exp = expected, obs = observed
odds ratios (ORs) can be interpreted as the odds of an gene being identified by EWAS and a GWAS over the odds of a gene being identified by an EWAS but not by a GWAS.
exp-OR = the mean OR after repeating the analysis 1000 times, randomly sampling EWAS genes equal to the number identified in the empirical analysis.
Table 6.3: Correlation of geneset enrichment scores between EWAS and GWAS
trait n-ewas-genes n-gwas-genes geneset-overlap obs-cor exp-cor p-diff
current versus never smoking 1,933 312 1,053 0.200 0.22 0.034
former versus never smoking 282 320 661 0.298 0.30 0.994
alcohol consumption per day 361 196 562 0.259 0.27 0.575
c-reactive protein 189 302 600 0.265 0.26 0.798
body mass index 232 3,221 1,243 0.187 0.20 0.229
educational attainment 25 1,594 215 0.105 0.13 0.173
insulin 36 5 16 0.093 0.12 0.376
glucose 15 50 49 0.153 0.16 0.809
For each geneset, odds of study genes being in the geneset divided by the odds the study genes not being in the geneset were assessed and correlation between these odds ratios are given here.
expected-cor = the mean correlation between odds ratios after repeating the analysis 1000 times, randomly sampling EWAS genes equal to the number identified in the empirical analysis
geneset-overlap indicates the number of gene ontology terms that map to both genes identified by the EWAS and GWAS.
There were 16 GO term genesets that were commonly enriched (FDR < 0.1) for both the EWAS
and GWAS traits. Of these zero were specific (contained under 100 genes). There were 51
specific genesets (geneset size < 100 genes) that did not overlap between studies of corresponding
traits, for example, the genes identified by the GWAS of alcohol consumption were enriched for
the “ethanol catabolism” pathway (geneset size = 12 genes), however none of the genes identified
by the EWAS were present in this pathway.
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6.3.5 Understanding architecture from geneset overlap
The total number of genes and genesets that can be identified by GWAS and EWAS are unknown
and the proportion of causal and non-causal genes EWAS will identify is also unknown. Thus
it is uncertain how much overlap there will be between genes and genesets of corresponding
GWAS and EWAS as sample sizes increase and more genes and genesets are discovered. Using
the empirical data from Table 6.3 to inform simulations, I sought to identify the proportion of
overlap between causal and associated genes (genes that may or may not be causal) and how this
is related to the number of genes yet to be discovered.
For the simulations, three sets of genes were linked to each trait: genes identified by the GWAS
(known GWAS genes), genes identified by the EWAS (known EWAS genes) and a random set
of genes sampled from the total set of Ensembl gene IDs (excluding the genes identified by the
EWAS and GWAS). Those genes identified by the GWAS and a number of the randomly selected
set of genes was assigned as “causal” and the genes identified by the EWAS and the rest of the
randomly selected set of genes was assigned as “associated.” The overlap between the causal and
associated genes as well as the number of total genes (causal and associated) was pre-determined.
From these pools of causal and associated genes, X genes were sampled randomly to represent
GWAS genes and Y genes were sampled randomly to represent EWAS genes. The number of
genes, X and Y , sampled was equal to the number identified in the empirical GWAS and EWAS,
respectively.
Having generated the GWAS and EWAS genes, enrichment of GO terms was performed and
the correlation between enrichment scores across all the terms was estimated. Under a single
simulation scenario, the number of total genes and the proportion of causal and associated gene
overlap was pre-determined. The known GWAS and EWAS genes was determined by those
discovered from the empirical results, thus the random set of genes was varied to alter the total
number of genes and proportion of overlap. The proportion of overlap was 0, 0.01, 0.1, 0.5 or
1 and the total number of genes was split evenly into causal and associated genes. The number
of associated genes (and causal genes) equalled the total number of EWAS and GWAS genes
discovered multiplied by 1, 2, 3, 5, 10 or 20. For each scenario, the analyses were repeated 1000
times for each trait. A schematic of the methods for these simulations can be found in Figure



















Simulated GWAS Simulated EWAS
Geneset enrichment Geneset enrichment
Spearman's Rank correlation
Figure 6.5: Flowchart demonstrating how the second set of simulations were set up for
each trait. Phenotypic variation may be caused by changes in gene/protein polymers (causal
genes) and can be associated with changes in gene/protein polymers via other routes such as
confounding or reverse causation (associated genes). In these simulations the causal genes were
a mix of genes identified by GWAS, known GWAS genes (KGG), and a random set of genes,
simulated GWAS genes (SGG). The associated genes were a mix of genes identified by EWAS,
known EWAS genes (KEG), and a random set of genes, simulated EWAS genes (SEG). The level
of overlap in the causal and associated genes was modified by changing the overlap in the SGG
and SEG. The number of causal and associated genes was kept the same for each simulation,
but this number varied between simulations. The minimum number of causal genes and the
minimum number of associated genes was equal to the sum of KGG and KEG. The “simulated
GWAS” step in the simulation simply equates to randomly sampling from the causal genes.
The number of genes sampled was equal to the number of KGG. The “simulated EWAS” step
was identical except the number of KEG from the associated genes. Geneset enrichment was
performed as described in Section 6.6. The simulations were repeated 1000 times for each set of
parameters.
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From the simulations it was determined that, for seven of eight traits, it is likely that if the number
of genes discovered currently is near to the total genes to discover for these traits, the proportion
of overlap between causal and associated genes is low. However, for former vs. never smoking,
there was greatest evidence for a scenario where the causal and consequential gene overlap was
high. The results from the analysis of former vs. never smoking and c-reactive protein (repre-
senting simulations for the other traits) are shown in Figure 6.6. Figure A.2 shows the same
results for the other traits. Each simulation was repeated 1000 times. Evidence for a difference
in the empirically determined correlation of geneset enrichment scores and the mean correlation
of geneset enrichment scores across simulations was assessed using a z-test for difference. There
was some evidence against 53 simulation scenarios (FDR < 0.05). Across the traits, the scenar-
ios that were least likely tended to be when the number of genes yet to discover was low, and
the overlap between causal and associated genes was high, except for former vs. never smoking,
highlighting architecture differences between traits.
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Figure 6.6: Simulations to understand the likely number of genes still to identify in EWAS
and GWAS of c-reactive protein and former vs. never smoking under different trait archi-
tectures. Simulations were set up as illustrated in Figure 6.5. Correlation of geneset enrichment
scores from empirical data (Table 6.3), is shown as a red dashed line. Box plots show the range
of enrichment score correlations from 1000 simulations using the parameters indicated. The
number of causal and associated genes, as well as the overlap between these genes were var-
ied. NKEG = number of known EWAS genes, NKEG = number of known GWAS genes, NKTG =
number of known total genes (NKEG + NKGG). By way of an example, when NKTG = 491 and
the ratio of causal and associated genes relative to NKTG is 1:1, the number of causal genes in
the simulations will be 491 and the number of associated genes in the simulations will be 491.
Scenarios which lie close to the empirical result (red dashed line) are more likely to reflect the
true underlying number of genes related to a trait and the true overlap between the causal and
associated genes. Where there is some evidence that the empirical results are different to the
simulations (z-test FDR < 0.05) the box outline is grey.
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6.3.6 Overlap of non-corresponding EWAS and GWAS
It may be the case that EWAS of one trait are actually more closely related to GWAS of another
trait. For example, if DNA methylation changes related to BMI were mediating the effect of
BMI on changes in metabolites, then one could expect to see greater correspondence in identified
genes and genesets with GWAS of those metabolites.
To test if this was the case for any of the EWAS in this study, 1886 GWAS with SNPs asso-
ciated at 5x10-8 with a sample size above 5000 from the IEU OpenGWAS Project (104) were
extracted. For each GWAS and the eight EWAS, enrichment scores were calculated using geneset
enrichment analysis and correlation between the enrichment scores was calculated, as in previous
analyses.
Across all pairwise comparisons, correlations between enrichment scores ranged from -0.014
to 1 and had a mean of 0.12. The mean correlation between GWAS traits and EWAS traits
was 0.23, which was higher than the correlations between just GWAS traits (0.12). Amongst
just GWAS results, there was evidence that 14653 pairwise enrichment score correlations were
greater than the the mean (FDR < 0.05). However, there was little evidence that any pairwise
correlations between enrichment scores derived from EWAS and GWAS were greater than the
mean correlation (FDR > 0.05).
This suggests that the signal from EWAS is not capturing aspects of any specific factor that
impacts the aetiology of any of the eight traits of interest.
6.4 Discussion
Several EWAS papers have compared their findings with those of the corresponding trait GWAS
(203,207–210), but it’s unknown if any overlap that might occur should be attributed to shared
underlying genetic and epigenetic architectures or if it occurs by chance. In this study, the genes
and genesets identified by eight large EWAS (N>4500) were not identified in their corresponding
GWAS any more than expected by chance. Simulations suggested these EWAS could still be
identifying aspects of trait aetiology, but it is likely most DMPs identified are due to confounding
or reverse causation. Further simulations suggested that the overlap between genes that impact
phenotypic variation and those that might be identified through confounded analyses or reverse
causation is likely to be low. However, if the number of genes still to identify in EWAS and
GWAS is high, it is possible that the overlap between “causal” and “associated” genes could be
high also.
6.4.1 Overlap expected
GWAS identifies the effects of genetic variation on complex traits. These effects are less likely to
be confounded than associations estimated between observational phenotypes (101,102). Thus,
one would expect overlap between genes and genesets identified by EWAS and GWAS of the
same trait if the DMPs identified are also of aetiological relevance. Assuming mapping of DMPs
and SNPs to genes is correct, the genes identified by EWAS may cause variation in complex
traits without overlapping with genes identified in GWAS. Under the scenario where the effect
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of a SNP on a complex trait is mediated by a distal DNA methylation site (or the gene that site is
tagging), GWAS and EWAS may identify genes that do not overlap, but that are along the same
causal pathway from genome to complex trait. One plausible mechanism for which trans-mQTLs
may act is via transcription factors. A trans-mQTL may influence the transcription of a nearby
transcription factor then the transcription factor could cause a change in DNA methylation at
distal sites. One study has provided evidence this may occur frequently (132). In this scenario
the genes proximal to the identified SNP and DMP would lie on the same causal pathway and
so would likely be part of the same genesets. This is likely not the only plausible mechanism of
trans-mQTL function though. DNA methylation may also mediate non-genetic effects, allowing
for causal DMPs to be identified at genes not near pertinent genetic variation. However, there
is strong evidence that the majority of DNA methylation sites have a heritable component. As
such any effect of DNA methylation on a trait could be influenced by genetic variation. If DNA
methylation is influenced by proximal genetic variants then the discovery of the same gene(s)
will be a function of GWAS and EWAS power. If only distal genetic variants influence the
DNA methylation site, then the overlap of genesets is a function of regulatory mechanisms and
power. These two issues, and likely others, may introduce noise into the results. However,
there is overwhelming evidence that confounding and reverse causation are pervasive across
observational epidemiology (84,211–213) as well as within EWAS (6,214). This suggests that
the evidence that EWAS and GWAS are not identifying any more overlapping genes and genesets
than expected by chance, is likely due to identified DMPs being mostly the result of reverse
causation or confounding.
As the simulations showed, even if an EWAS identifies DMPs that cause a change in the trait,
if the majority of DMPs identified are due to confounding or reverse causation then the overlap
will be indistinguishable to the overlap expected by chance. Thus, our empirical results do not
preclude the possibility that some DMPs identified by the EWAS are pertinent to trait aetiol-
ogy.
For body mass index, work has already suggested the traits cause changes in DNA methylation
rather than vice versa (3,79), supporting our findings here. Further, one study suggested DNA
methylation changes capture different components of body mass index variance than genetic
variation (69) and another estimated the percentage of trait variance captured by DNA methyla-
tion was 75.7% when accounting for genotype (197).
Simulations involving empirical data from former vs. never smoking EWAS and GWAS sug-
gested that overlap between causal and associated genes was high. This is surprising for two
reasons. Firstly, it differs from the current vs. never smoking results, suggesting distinct genetic
or epigenetic architectures of those traits. Secondly, there is evidence that for DNA methylation
changes identified in relation to smoking, smoking is likely causing DNA methylation variation
and not vice versa. Although the statistical tests suggested that it was unlikely that the propor-
tion of causal and associated genes is 0.1 or lower, it should be noted that the absolute difference
between simulated results and empirical results were not great.
If EWAS is discovering some DMPs that influence genes that cause changes in the trait of in-
terest, study power is the limiting factor for detecting overlap. For traits with a weak polygenic
architecture (few genes explain most of the heritability), such as gene expression (215,216),
93
discovering almost total overlap would be inevitable even with modest sample sizes.
6.4.2 Little overlap with any GWAS
Little correlation was found between geneset enrichment scores for EWAS and GWAS of non-
corresponding traits. In a scenario where DNA methylation was capturing a specific facet of a
trait one might expect correlation between EWAS of the original trait and GWAS of that facet.
For example, if changes in DNA methylation associated with smoking were mostly responsible
the effect of smoking on lung cancer then one would expect to observe an overlap between
the genes and pathways identified by an EWAS of smoking and GWAS of lung cancer. This
specific example is explored, in part, in Chapter 7 under a Mendelian randomization framework
and has been examined before, with a study suggesting methylation at two sites (of over 1000
smoking-related sites) mediate over 30% of the effect of smoking on lung cancer (217). The
results of either study suggest most sites will not mediate the effect of smoking on lung cancer
and thus there would be little overlap between genes and pathways of an EWAS of smoking
and a GWAS of lung cancer. This is corroborated by the results of our study: there was little
evidence that correlation of pathway enrichment scores between the two, 0.15, was greater than
the mean correlation enrichment score across all GWAS-GWAS and GWAS-EWAS correlations,
0.12 (FDR > 0.05).
It is important to note that overlap between EWAS and GWAS genesets may be missed even if
this mediation model is true for various traits. As shown in the simulations, detecting this overlap
depends on individual study power as well as the underlying genetic and epigenetic architecture
of the trait. There are further things that may limit detection of geneset overlap that is discussed
later on.
6.4.3 Information gained from EWAS
The fact that genes and pathways identified from GWAS and EWAS of the same traits are seem-
ingly very separate suggests we are gaining new information from EWAS, even if interpreting
the new information may be difficult. Key to interpreting the EWAS results would be to try and
disentangle whether the EWAS results are likely due to confounding (as is explored in Chapter
7). Interpreting EWAS can also be difficult due to cell type heterogeneity and the complexity of
mechanisms which mediate DNA methylation changes (6,23,53,86,87). Due to these difficulties
it should not be concluded that EWAS definitely help increase our biological understanding of
complex traits. Rather, DNA methylation is capturing different biological information. Regard-
less of biological insight gained, translational impact may still be gleaned from DNA methylation
studies; DNA methylation may aid diagnoses by acting as a reliable biomarker or could help pre-
dict various health outcomes (57).
There are also benefits to understanding the biological consequences of a trait, something that
EWAS might help identify and GWAS will not (at least not directly). This does depend on
further research to understand how changes in DNA methylation downstream to complex trait
variation is relevant to human health. Further, establishing where exactly DNA methylation may
lie on the causal pathway may be difficult and work is ongoing to discover this for various traits
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(130). Use of causal inference methods such as Mendelian randomization (85,101,102) can be
applied (and are in Chapter 7), but this still comes with various caveats, as discussed in Section
1.4.4 (85,130). Some studies also try and confirm effects experimentally (56) and use previous
biological knowledge of the trait to try and understand EWAS results.
However, some of the biological knowledge of complex traits relating to genes and pathways
comes from GWAS of those traits. This study suggests that EWAS is unlikely to identify many
genes proximal to genetic variation pertinent to the trait of interest and further the genesets are
unlikely to overlap with those identified in GWAS. Therefore, comparison of EWAS results to
those of a corresponding GWAS is unlikely to explain a large proportion of DNA methylation-
trait associations observed in EWAS. This may make inference from EWAS difficult, yet it seems
likely the interpretability of DNA methylation studies will continue to improve over the coming
years, as understanding the underlying epigenetic architecture of complex traits could still pro-
vide translational benefits (57).
6.4.4 Limitations
As discussed, detecting gene or pathway overlap depends on the genetic and DNA methylation
architecture of the trait. Here only eight traits, two of which are smoking behaviour traits, have
been studied. This means the results cannot be generalised to all or even the majority of complex
traits. These analyses could be repeated by setting a less restrictive sample size limit, but it was
felt that would make the results less reliable and impossible in many circumstances where too
few DNA methylation sites had been discovered by EWAS. As sample sizes increase and tech-
nologies measuring more DNA methylation sites become more common, it would be interesting
to repeat the analysis.
Often in GWAS and EWAS, prioritisation of SNPs and DMPs identified occurs before functional
mapping. Prioritisation for both studies may be informed by prior knowledge of the trait, prior
understanding of molecular biology, predicted consequences of observed variation (for example
using Ensembl’s Variant Effect Predictor (218)), replication of findings or a number of other
methods. In this study, I did not perform any prioritisation (besides the conventional P value
threshold cut-offs) and thus may have increased the amount of “noise” in the signal taken for-
ward for functional annotation. Unfortunately, this extra prioritisation of sites is not tractable
when comparing many different association studies and may reduce power to detect any over-
lap between genes and pathways. However, added noise is unlikely to prevent detection of true
overlap if that true overlap is substantial, as shown by the simulations (Figure 6.4).
The nearest gene, by chromosomal position, to a DMP or SNP is not necessarily the gene of
interest. SNPs may have effects on genes distal to their position (219). Also, the correlation be-
tween genetic variants inflates associations of variants proximal to the true causal variant, which
may map to unrelated genes. Further, the correlation structure in DNA methylation data may
induce associations between complex traits at a site far from where variation in DNA methyla-
tion causes complex trait changes (219). Therefore, the mapping of DMPs and SNPs to genes
in this study could likely be improved. The “correct” method for this mapping has not yet been
established though and even though some tools are available (such as eQTL studies), there are
caveats to them too (220,221).
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Our understanding of molecular pathways is not complete and thus attributing genes to certain
pathways or functionalities may be erroneous. However, the results remained consistent across
four different methods that annotate genes to pathway, suggesting differences in mapping genes
to genesets should not impact our conclusions.
Biological information gained from EWAS and GWAS may be defined in various ways and
depending on the interpretation of this, one could alter methods used to extract biological in-
formation. However, first exploring the genomic regions identified and then mapping these to
potentially relevant biological genesets is common amongst GWAS and EWAS (5,187,199,202–
204,222) and gave a simple way to compare the information from the two study types.
6.5 Conclusion
Overall this chapter provides evidence that, for eight complex traits, there is little overlap be-
tween genes and genesets identified by EWAS and GWAS of the same trait. Given the differ-
ences in properties between DNA methylation and genetic variants the results presented in this
study may apply to other traits, but this is still to be confirmed. Where lack of overlap between
genes and genesets is found, it suggests EWAS may be providing new biological information,
however, the interpretability of EWAS is still in question and with current methods it is hard
to determine if EWAS results are attributable to confounding or reverse causation. Regardless,
as causal inference within epigenetic epidemiology improves, it seems likely we will be able to
interpret this apparent gain in biological information.
6.6 Methods
6.6.1 Samples
EWAS summary data and GWAS summary data were extracted from the EWAS Catalog
(Chapter 3) and the IEU OpenGWAS Project (104,105) respectively. The data was extracted in
July 2019, when the EWAS Catalog contained data published before 2019. For traits that had
multiple EWAS with a sample size of greater than 4500, the EWAS with the largest sample size
was used, the same was applied to the GWAS. The sample size, first authors and PubMed IDs
can be found in Table 6.1.
6.6.2 Overlapping genomic regions
Each chromosome was divided into 500Kb blocks, each block that did not contain a DNA methy-
lation site measured by the HM450 array was removed. For each trait, the genome blocks that
had one or more EWAS sites and one or more GWAS sites that reached the set p-value threshold
were tallied. The p-value threshold was set at a lenient P<1x10-5 or if it was lower, the maximum
reported p-value in the EWAS of that trait.
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6.6.3 Mapping sites to genes and genesets
The R package biomaRt (223) was used to extract Ensembl gene ids along with chromosome po-
sitions of all genes. The package was also used to extract Gene Ontology (GO) terms (138,139)
and map these to the Ensembl gene ids. The R package limma (95) was used to extract KEGG
terms (224,225,225) and these were mapped to Ensembl gene ids.
Protein-protein interaction data, which includes data from StringDB (226) and IntAct (227), and
terms from the Reactome database (228) were extracted from EpiGraphDB (229).
CpG sites associated with traits at P<1x10-7 and SNPs associated with traits at P<5x10-8 were
taken forward to be mapped to genes. The correlation structure present in genetic and DNA
methylation data makes it difficult to ascertain the precise site driving any signal observed. Thus,
no filtering based on correlation between variants or CpG sites was performed.
For each CpG site identified by EWAS and used in the analyses, it was mapped to the nearest
gene (Ensembl gene ID) by chromosome position. If a CpG site lay within the bounds of multiple
genes then the site was mapped to all of those genes. Therefore, one CpG site could map to
multiple genes and one gene could map to multiple CpG sites. The same gene mapping approach
was used for variants identified in GWAS. The positions of CpG sites were extracted using the R
package meffil (169).
6.6.4 Methods for assessing overlap





where oddsEG is the odds of a gene being identified in EWAS and GWAS and oddsEnG is the
odds of a gene being identified in EWAS, but not in GWAS.
Genes may map to genesets by chance. Often in EWAS and GWAS, enrichment for any gene-
sets are tested by assessing whether the genes identified are more common in any geneset than
expected by chance. Power was compared between mapping genes to genesets and directly
assessing overlap like in Equation (6.1) and correlation between enrichment scores for each






where oddsGS is the odds of a gene being annotated to the geneset and oddsnGS is the odds of a
gene not being annotated to the geneset.
For many genesets, genes annotated to that geneset would not be identified in an EWAS or
GWAS, causing the enrichment score for many genesets to be zero. Further, some genesets
would have very large enrichment scores. This made the relationship between enrichment scores
generated for the EWAS results and the enrichment scores generated for the GWAS non-normal.
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Thus, to examine the relationship between the two, Spearman’s rank correlation coefficients of
the logarithm of enrichment scores was used.
6.6.5 Testing power to detect overlap
Simulations were setup as seen in Figure 6.3. The simulations iterated over each set of param-
eters 1000 times. For each iteration, two sets of genes, GWAS genes and EWAS genes, were
sampled from the total set of genes. Each iteration assessed gene overlap and geneset overlap
between these gene sets using Equation (6.1). Equation (6.2) was used to generate enrichment
scores for each gene set and then correlation between the enrichment scores was assessed.
GWAS genes were only sampled from a set of “causal” genes and a proportion of EWAS genes
were sampled from the set of causal genes and the rest from the set of “associated” genes. Re-
ceiver operator characteristic (ROC) curves were generated to assess whether it was possible to
predict the gene overlap, geneset overlap and enrichment score correlations for scenarios where
the proportion of causal EWAS genes was greater than zero from the scenario where the propor-
tion of causal EWAS genes was zero. The area under these ROC curves were then calculated in
each case.
These simulations were repeated for each geneset and protein-protein interaction database.
The protein-protein interaction and Reactome databases all map only to protein coding genes,
whereas the GO and KEGG databases map to all Ensembl gene IDs. To compare predictive
ability across annotation methods, Ensembl gene IDs that were not protein coding genes were
excluded. A comparison between the performance of models when mapping to all Ensembl gene
IDs or to protein coding genes was made for GO and KEGG databases. (Figure A.3).
From these simulations, the best method to assess geneset overlap, and the best geneset anno-
tation method to assess that overlap and the scenarios (i.e. study power required, proportion of
DMPs that need to be causal) in which it could be expected to be able to detect overlap could be
deduced.
6.6.6 Empirical analyses
The DNA methylation sites identified in the EWAS at P<1x10-7 and the SNPs identified in the
GWAS at P < 5x10-8 were mapped to genes and genesets. Overlap between genes was calcu-
lated as before (Equation (6.1)), enrichment scores were generated and correlated as described
above.
Expected overlap was generated to compare to the observed results. For this, random positions
were chosen in the genome equal to the number of DMPs identified in the EWAS. These genes
were then used to assess gene and geneset overlap as for the observed results. This was repeated
1000 times to generate a null distribution and a z-test was used to assess whether there was a
difference between the observed results and the mean of the null distribution.
There is a correlation structure within DNA methylation data (230), and it was hypothesised this
might contribute to the observed results. By randomly sampling positions from the genome, a
new correlation structure between DMPs would be generated. I tested whether sampling the
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genome in a non-random way, aimed at keeping some correlation structure, altered the results.
To generate new data whilst attempting to keep a similar correlation structure, a fixed number of
base pairs were added to each of the DMPs identified in the empirical analysis such that
BPnew = BPdmp +max(G) × I (6.3)
where BPnew = base pair of new site, BPdmp = base pair of DMP identified in the EWAS, G =
gene size, and I = iteration.
If BPnew extended beyond the end of a chromosome, the position moved onto the next chro-
mosome, with positions moving past the end of chromosome 22, being moved to chromosome
1.
Overall, the overlap between genes and genesets identified by EWAS and GWAS did not change
across null distribution sampling methods.
6.6.7 Understanding architecture from geneset overlap
Simulations were setup as illustrated in Figure 6.5. Here I describe simulations for a single trait.
These were repeated for all traits. Firstly, SNPs identified in GWAS and DMPs identified in
EWAS were mapped to genes as described in Section 6.3.4. Genes were then randomly sampled
from Ensembl gene IDs and were assigned as either “causal,” meaning changes in that gene effect
variation in the phenotype across individuals, or “associated,” meaning changes in the gene are
associated with the phenotype across individuals, but the nature of association is not known.
The empirically identified (or “known”) GWAS genes (KGG) were added to the list of causal
genes and the empirically identified (or “known”) EWAS genes (KEG) were added to the list
of associated genes. These combined set of causal and associated genes can be thought of as
all the genes related to the trait of interest. A number of genes, equal to the number of KGG
(NKGG), was sampled from the causal set of genes and assigned to be the “GWAS genes” in the
simulations. A number of genes, equal to the number of KEG (NKEG), was sampled from the
associated set of genes and assigned to be the “EWAS genes” in the simulations. Then geneset
enrichment analyses for both the EWAS and GWAS genes were performed (equation (6.2)) and
correlation between the enrichment scores was assessed as previously. In these simulations, the
number of total genes was varied and the number of causal and associated genes was always set to
be half of the total number of genes related to a trait. The total number of genes was proportional
to the total number of known genes (NKTG = NKGG + NKEG). The smallest number of total
genes for any simulation was double the number ofNKTG and the greatest number of total genes
was 40 times NKTG. The other variable set to vary between simulations was the proportion of
overlap between causal and associated genes. This varied between zero and one, where zero
represented the scenario where only the overlap in KGG and KEG would be present in the
overlap between causal and associated genes and one represented the scenario where all causal
and associated genes were the same. For each simulation scenario, the simulations were repeated
1000 times and box plots show the range of output from those 1000 repeats.
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6.6.8 Assessing the correlation between geneset enrichment results
GWAS were extracted from the IEU OpenGWAS Project (104) with the following criteria:
• Sample size > 5000
• European population
• For binary traits, cases and controls had to be greater than 500
• Full genome-wide results, i.e. not just associations between a molecular trait and variants
in cis.
For each GWAS, all SNPs that associated with the trait at P<5x10-8 were extracted. CpGs as-
sociated with the eight EWAS at P<1x10-7 were then extracted and mapped to genes. For each
study, enrichment scores were generated for GO terms as before (Equation (6.2)) and correlation
between them assessed.
When assessing whether gene overlap or geneset enrichment score correlations were greater than
the mean, a z-test was performed. As multiple tests were performed the false discovery rate was
limited by applying the Benjamini-Hochberg method (231).
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Chapter 7
Appraising the causal relevance of
DNA methylation for risk of lung
cancer
7.1 Chapter summary
The results of Chapter 6 suggested that epigenome-wide association studies (EWAS) might be
identifying differential facets of complex trait biology when compared to genome-wide asso-
ciation studies (GWAS) of corresponding traits. As discussed in Section 1.3.4, observational
studies such as EWAS suffer from issues of reverse causation and confounding, which could
have explained the results in Chapter 6.
In this chapter I attempt to explore the extent to which EWAS results may be confounded by
examining EWAS of one trait, lung cancer, and comparing these to corresponding results from
Mendelian randomization analyses. DNA methylation has been postulated to mediate over 30%
of the effect on smoking on lung cancer (217), making this case of particular interest to potential
lung cancer preventative strategies.
I first performed a meta-analysis of four lung cancer EWAS (918 cases, 918 controls). Next, I
conducted a two-sample MR analysis, using genetic instruments for methylation at CpG sites
identified in the EWAS meta-analysis, and 29,863 cases and 55,586 controls from the TRICL-
ILCCO lung cancer consortium, to generate estimates of the causal relationship between methy-
lation at these sites and lung cancer.
Sixteen CpG sites were identified from the EWAS meta-analysis (FDR < 0.05), 14 of which were
associated with genetic variants at P<5x10-8, which could be used as instruments. MR provided
little evidence that DNA methylation in peripheral blood at the 14 CpG sites play a causal role in
lung cancer development (FDR > 0.05), including for cg05575921 (AHRR) where methylation
is strongly associated with both smoke exposure and lung cancer risk.
The results contrast with previous observational and mediation analysis, which have made strong
claims regarding the causal role of DNA methylation on lung cancer risk. Yet, they add evidence
to the conclusions of Chapter 6 - that findings in EWAS may not be of aetiological relevance.
Previous suggestions of a mediating role of methylation at sites identified in peripheral blood,
such as cg05575921 (AHRR), could be unfounded. However, these results do not preclude the
possibility that differential DNA methylation at other sites is causally involved in lung cancer
development, especially within lung tissue.
7.1.1 Contributions statement
I performed the main analyses: the meta-analysis of the EWAS, the MR using mQTLs identi-
fied in ARIES, the replication of mQTLs in the NSHDS cohort and the supplementary analyses
assessing the association between mQTLs and gene expression using GTEx data. I also wrote
the majority of the text. Some supplementary analyses, which provided more clarity on the rela-
tionship between DNA methylation and lung cancer were performed by others. Stig E. Bojesen
performed analysis in the CCHS cohort (see Sections 7.3.4 and 7.4.2) and Rebecca Richmond
wrote these sections. Andrew E. Teschendorff analysed differences in lung tumour and adjacent
healthy tissue (see Sections 7.3.4 and 7.4.3).
7.2 Introduction
Lung cancer is the most common cause of cancer-related death worldwide (232). Several DNA
methylation changes have been recently identified in relation to lung cancer risk (137,217,233).
However, these epigenetic marks are sensitive to reverse causation, being affected by cancer
processes (234), and are also prone to confounding, for example by socio-economic and lifestyle
factors (164,235).
One CpG site, cg05575921 within the aryl hydrocarbon receptor repressor (AHRR) gene, has
been consistently replicated in relation to both smoking (1) and lung cancer (114,137,217)
and functional evidence suggests that this region could be causally involved in lung cancer
(165). However, the observed association between methylation and lung cancer might sim-
ply reflect separate effects of smoking on lung cancer and DNA methylation, i.e. the associa-
tion may be a result of confounding (120), including residual confounding after adjustment for
self-reported smoking behaviour (213,236). Furthermore, recent EWAS of lung cancer have re-
vealed additional CpG sites which may be causally implicated in development of the disease
(137,217).
As discussed in Section 1.4.4, Mendelian randomization (MR) can be used to help infer causal-
ity in associations between DNA methylation and complex traits (85,201,237) under a paradigm
that largely mitigates the problem of confounding if certain assumptions are met (Figure 1.3).
Briefly, MR uses genetic variants as proxies for the exposure of interest (here DNA methyla-
tion) under an instrumental variable framework. If the key assumptions of MR are met (Figure
1.3), any associations observed between the proxied exposure and outcome will reflect a causal
relationship.
In this study, I performed a meta-analysis of four lung cancer EWAS (918 case-control pairs)
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from prospective cohort studies to identify CpG sites associated with lung cancer risk and applied
MR to investigate whether the observed DNA methylation changes at these sites are causally
linked to lung cancer.
7.3 Methods
7.3.1 EWAS study details
A meta-analysis of four lung cancer case-control EWAS was conducted to identify DNA methy-
lation sites associated with lung cancer. In total there were 918 cases and 918 matched controls
for the analysis. A description of the studies, how controls were matched to cases and an outline
of the study populations, laboratory methods, data pre-processing and quality control methods
can be found in Section 2.5 and they described in detail elsewhere (137).
7.3.2 EWAS Meta-analysis
To quantify the association between the methylation level at each CpG and the risk of lung cancer
conditional logistic regression models were fitted for beta values of methylation (which ranges
from 0 (no cytosines methylated) to 1 (all cytosines methylated)) on lung cancer status for the
four studies. Surrogate variables were computed in the four studies using the SVA R package
(238) and the proportion of CD8+ and CD4+ T cells, B cells, monocytes, natural killer cells
and granulocytes within whole blood were derived from DNA methylation (86). The following
EWAS models were included in the meta-analysis: Model 1 – unadjusted; Model 2 – adjusted
for 10 surrogate variables (SVs); Model 3 – adjusted for 10 SVs and derived cell proportions.
EWAS stratified by smoking status was also conducted (never (N=304), former (N=648) and
current smoking (N=857)). For Model 1 and Model 2, the case-control studies not matched on
smoking status (EPIC-Italy and NOWAC) were adjusted for smoking.
An inverse-variance weighted fixed effects meta-analysis was performed of the EWAS (918 case-
control pairs) using the METAL software. Direction of effect, effect estimates and the I2 statistic
were used to assess heterogeneity across the studies in addition to effect estimates across smoking
strata (never, former and current). All sites identified at a false discovery rate (FDR) < 0.05 in
Model 2 and 3 were also present in the sites identified in Model 1. The effect size differences
between models for all sites identified in Model 1 were assessed by a Kruskal-Wallis test and
a post-hoc Dunn’s test. There was little evidence for a difference (P > 0.1), so to maximize
inclusion into the MR analyses sites identified in the unadjusted model (Model 1) were taken
forward.
7.3.3 Mendelian randomization
The relationship between sites identified in the meta-analysis of EWAS and lung cancer risk were
re-assessed under a two-sample MR framework to establish whether differential methylation at
these sites were likely to be causal (126,127).
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Sample 1: Accessible Resource for Integrated Epigenomic Studies (ARIES)
In the first sample, mQTL-methylation effect estimates (βGP ) for each CpG site of interest were
identified in an mQTL database from the Accessible Resource for Integrated Epigenomic Studies
(ARIES) (http://www.mqtldb.org). Details on the methylation pre-processing, genotyp-
ing and quality control (QC) pipelines are described in Section 2.1. ARIES data was used in
lieu of the larger Genetics of DNA Methylation Consortium (GoDMC) as GoDMC data was not
available at the time of this study. However, as mentioned in Section 7.4.2, using the smaller
sample from ARIES did not limit our power. Further discussion of this can be found in Section
7.5
If there was evidence for an mQTL-CpG site association in ARIES in at least one time-point,
it was assessed whether the mQTL replicated across time points in ARIES (FDR < 0.05, same
direction of effect). Further, this association was re-analysed using linear regression of methy-
lation on each genotyped SNP available in an independent cohort (NSHDS), using RVTESTS
(239). The same NSHDS samples on which DNA methylation was measured were genotyped
using the Illumina Infinium OncoArray-500k BeadChip (Illumina Inc. San Diego, CA) and qual-
ity control parameters were applied under the recently published TRICL-ILCCO GWAS study
on lung cancer (150). Genetic imputation was performed on these samples using the Haplotype
Reference Consortium (HRC) Panel (release 1) (233) through the Michigan Imputation Server
(240). Replicated mQTLs were included where possible to reduce the effect of winner’s curse
using effect estimates from ARIES.
The instrument strength of the mQTLs were assessed by the variance explained in methylation by
each mQTL (r2) as well as the F-statistic in ARIES Table 7.1.
Sample 2: Transdisciplinary Research in Cancer of the Lung and The International Lung
Cancer Consortium
In the second, independent, sample, summary data was extracted from a GWAS meta-analysis of
lung cancer risk conducted by the TRICL-ILCCO consortium (29,863 cases, 55,586 controls). A
brief description of the data can be found in Section 2.6. This summary data was used to obtain
mQTL-lung cancer estimates (βGD).
For each independent mQTL (r2 < 0.01), I calculated the log OR per SD unit increase in methy-
lation by the formula βGDβGP (Wald ratio). Standard errors were approximated by the delta method
(241). Where multiple independent mQTLs were available for one CpG site, these were com-
bined in a fixed effects meta-analysis after weighting each ratio estimate by the inverse vari-
ance of their associations with the outcome (the IVW method). Heterogeneity in Wald ratios
across mQTLs was estimated using Cochran’s Q test, which can be used to indicate horizontal
pleiotropy (242). Differences between the observational and MR estimates were assessed using
a Z-test for difference.
The power to detect the observational effect estimates in the two-sample MR analysis was as-
sessed a priori, based on an alpha of 0.05, sample size of 29,863 cases and 55,586 controls (from
TRICL-ILCCO) and calculated variance explained (r2).
104
Table 7.1: Instrument strength in ARIES
SNP CpG Beta SE P N F r2
rs1048691 cg23387569 0.35 0.053 3.9e-11 834 45 0.05
rs1939110 cg11660018 -0.40 0.048 2.6e-16 834 70 0.08
rs13087163 cg01901332 -0.19 0.035 5.8e-08 834 30 0.03
rs7927381 cg01901332 0.38 0.069 3.9e-08 834 31 0.04
rs878481 cg05951221 -0.32 0.042 5.9e-14 834 58 0.07
rs1048691 cg16823042 0.32 0.053 2.8e-09 834 36 0.04
rs734568 cg03636183 0.28 0.043 6.7e-11 834 44 0.05
rs72967500 cg23771366 -0.63 0.062 1.3e-22 834 102 0.11
rs3748971 cg21566642 -0.50 0.080 5.3e-10 834 39 0.05
rs9643220 cg25305703 0.34 0.049 7.1e-12 834 48 0.05
rs77433148 cg08709672 -0.80 0.137 6.3e-09 834 34 0.04
rs17518433 cg09935388 -0.33 0.046 1.8e-12 834 51 0.06
rs463924 cg26963277 -0.39 0.045 6.8e-18 834 78 0.09
rs56080708 cg27241845 0.72 0.070 2.4e-23 834 105 0.11
rs11744553 cg05575921 0.22 0.040 7.2e-08 834 30 0.03
rs11746538 cg05575921 -0.37 0.058 3.0e-10 834 41 0.05
SE = standard error, P = P value, N = sample size
F = F statistic, r2 = Variance explained
Lung cancer subtype analysis
MR analyses were also performed to investigate the impact of methylation on lung cancer sub-
types in TRICL-ILCCO: adenocarcinoma (11,245 cases, 54,619 controls), small cell carcinoma
(2791 cases, 20,580 controls), and squamous cell carcinoma (7704 cases, 54,763 controls). The
association in never smokers (2303 cases, 6995 controls) and ever smokers (23,848 cases, 16,605
controls) (150) was also assessed. Differences between the smoking subgroups were assessed
using a Z-test for difference.
Association of mQTLs and smoking
Smoking is known to be associated with DNA methylation changes at many CpG sites
(1,112,113) and causes lung cancer. Therefore, smoking was thought to be the most likely
confounder of any associations between DNA methylation and lung cancer. As discussed
in Section 1.4.4, the genetic variants associated with an exposure of interest tend not to be
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associated with confounders. To ensure that the mQTLs used in the MR analyses were not
exerting their effect on the exposure via smoking, the association between these mQTLs and four
smoking behaviours were tested. This analysis was performed using GWAS of four smoking
behaviours: number of cigarettes per day, smoking cessation rate, smoking initiation and age of
smoking initiation from the Tobacco and Genetics (TAG) consortium (N=74,053) (243).
7.3.4 Supplementary analyses
Assessing the potential causal effect of AHRR methylation: one sample MR
Given previous findings implicating methylation at AHRR in relation to lung cancer (137,217),
a one-sample MR analysis (244) was performed of AHRR methylation on lung cancer incidence
using individual-level data from the Copenhagen City Heart Study (CCHS) (357 incident cases,
8401 remaining free of lung cancer). A description of this study and details on the phenotyping,
measurement of DNA methylation and genotyping can be found in Section 2.7.
Identification of mQTLs for CCHS one-sample MR
mQTLs located within 1Mb of cg05575921 AHRR were identified in ARIES (FDR<0.05). Of
those mQTLs which replicated within the CCHS, an LD pruning step was performed using a less
stringent r2 threshold of 0.2 and generated an unweighted allele score, calculated by coding and
then summing the alleles to reflect the average number of methylation-increasing alleles carried
by an individual. Associations between the allele score and several potential confounding factors
(sex, alcohol consumption, smoking status, occupational exposure to dust and/or welding fumes,
passive smoking) were investigated. Then MR analyses were performed using two-stage Cox
regression, with adjustment for age and sex, and further stratified by smoking status.
Tumour and adjacent normal methylation patterns
DNA methylation data from lung cancer tissue and matched normal adjacent tissue (N=40 squa-
mous cell carcinoma and N=29 adenocarcinoma), profiled as part of The Cancer Genome Atlas
(TCGA), were used to assess tissue-specific DNA methylation changes across sites identified in
the meta-analysis of EWAS, as outlined previously (162).
mQTL association with gene expression
Gene expression at genes annotated to CpG sites identified in the lung cancer EWAS was ex-
amined in whole blood and lung tissue using data from the Gene-Tissue Expression (GTEx)
consortium (245).
Analyses were conducted in Stata (version 14) and R (version 3.2.2). For the two-sample MR
analysis the MR-Base R package TwoSampleMR (246) was used. An adjusted P value that




A flowchart representing the study design along with a summary of the results at each step is
displayed in Figure 7.1.
7.4.1 EWAS meta-analysis
The basic meta-analysis adjusted for study-specific covariates identified 16 CpG sites which
were hypomethylated in relation to lung cancer (FDR<0.05, Model 1, Figure 7.2). Adjusting for
10 surrogate variables (Model 2) and derived cell counts (Model 3) gave similar results (Table
7.2). The direction of effect at the 16 sites did not vary between studies (median I2=38.6) (Table
7.3), but there was evidence for heterogeneity of effect estimates at some sites when stratifying
individuals by smoking status (Table 7.2).
107
Figure 7.1: Study design with results summary. ARIES = Accessible Resource for Integrated
Epigenomic Studies, TRICL-ILLCO = Transdisciplinary Research in Cancer of the Lung and
The International Lung Cancer Consortium, MR = Mendelian randomization, CCHS = Copen-
hagen City Heart Study, TCGA = The Cancer Genome Atlas. * = 2000 individuals with samples
at multiple timepoints.
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Figure 7.2: Observational associations of DNA methylation and lung cancer: A fixed ef-
fects meta-analysis of lung cancer EWAS weighted on the inverse variance was performed
to establish the observational association between differential DNA methylation and lung
cancer. Left-hand side: Manhattan plot, all points above the solid line are at P < 1x10-7 and all
points above the dashed line (and triangular points) are at FDR < 0.05. In total 16 CpG sites are
associated with lung cancer (FDR < 0.05). Right-hand side: Quantile-quantile plot of the EWAS
results (same data as the Manhattan plot).
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Table 7.2: Meta-analyses of EWAS of lung cancer using four separate cohorts: 16 CpG sites
associated with lung cancer at false discovery rate < 0.05.
basic sv-adjusted sv-and-cell-count never-smokers former-smokers current-smokers
CpG Gene chr:pos OR SE P OR SE P OR SE P OR SE P OR SE P OR SE P
cg05575921 AHRR 5:373378 0.47 0.047 1.4e-16 0.45 0.053 6.3e-14 0.45 0.055 3.6e-13 0.93 0.22 0.717 0.46 0.084 6.1e-07 0.71 0.066 5.4e-05
cg21566642 ALPPL2 2:233284661 0.54 0.045 1.7e-15 0.53 0.050 2.5e-13 0.51 0.051 3.1e-13 0.89 0.14 0.418 0.52 0.081 1.4e-06 0.75 0.067 3.7e-04
cg06126421 IER3 6:30720080 0.58 0.046 2.1e-13 0.54 0.054 2.5e-11 0.51 0.054 3.9e-12 0.78 0.19 0.222 0.56 0.087 1.9e-05 0.73 0.112 1.8e-02
cg03636183 F2RL3 19:17000585 0.64 0.045 8.0e-12 0.61 0.053 8.2e-10 0.61 0.054 1.6e-09 0.91 0.17 0.553 0.62 0.084 7.5e-05 0.79 0.069 2.9e-03
cg05951221 ALPPL2 2:233284402 0.66 0.045 9.7e-11 0.64 0.051 1.8e-09 0.63 0.052 1.5e-09 0.87 0.18 0.409 0.63 0.082 7.2e-05 0.82 0.066 7.4e-03
cg01940273 ALPPL2 2:233284934 0.69 0.050 4.2e-08 0.68 0.058 7.3e-07 0.69 0.061 3.6e-06 1.14 0.23 0.428 0.57 0.086 2.6e-05 0.88 0.068 6.6e-02
cg23771366 PRSS23 11:86510998 0.77 0.040 1.1e-07 0.73 0.051 1.5e-06 0.71 0.052 5.6e-07 1.09 0.16 0.490 0.62 0.076 1.4e-05 0.86 0.061 2.0e-02
cg11660018 PRSS23 11:86510915 0.79 0.037 1.2e-07 0.70 0.051 2.0e-07 0.68 0.053 8.9e-08 0.94 0.13 0.586 0.75 0.071 1.0e-03 0.84 0.053 4.2e-03
cg26963277 KCNQ1 11:2722407 0.67 0.055 1.2e-07 0.64 0.068 3.8e-06 0.62 0.069 2.5e-06 0.54 0.17 0.014 0.72 0.110 1.5e-02 0.71 0.087 1.6e-03
cg27241845 ALPPL2 2:233250370 0.67 0.055 1.4e-07 0.68 0.067 1.7e-05 0.67 0.069 2.5e-05 0.75 0.21 0.193 0.68 0.108 5.0e-03 0.73 0.087 3.1e-03
cg23387569 AGAP2 12:58120011 0.71 0.049 1.5e-07 0.70 0.058 3.7e-06 0.68 0.059 1.9e-06 0.79 0.16 0.169 0.71 0.107 1.0e-02 0.75 0.079 2.5e-03
cg09935388 GFI1 1:92947588 0.68 0.055 2.5e-07 0.67 0.066 9.7e-06 0.67 0.070 3.0e-05 0.96 0.24 0.844 0.74 0.127 4.2e-02 0.68 0.075 1.1e-04
cg01901332 ARRB1 11:75031054 0.72 0.048 2.8e-07 0.69 0.064 1.1e-05 0.66 0.064 2.2e-06 1.02 0.21 0.922 0.60 0.093 1.5e-04 0.78 0.072 3.9e-03
cg25305703 CASC21 8:128378218 0.72 0.049 4.5e-07 0.72 0.067 1.1e-04 0.71 0.069 1.5e-04 0.80 0.17 0.210 0.76 0.106 2.6e-02 0.77 0.075 3.2e-03
cg16823042 AGAP2 12:58119992 0.74 0.049 1.1e-06 0.73 0.058 1.5e-05 0.70 0.059 5.9e-06 0.83 0.18 0.309 0.72 0.100 7.4e-03 0.80 0.080 1.3e-02
cg08709672 AVPR1B 1:206224334 0.75 0.048 1.4e-06 0.76 0.058 1.1e-04 0.74 0.060 5.3e-05 0.73 0.17 0.102 0.74 0.085 3.5e-03 0.82 0.079 2.1e-02
Meta-analyses of lung cancer EWAS adjusted for study specific covariates (basic, N = 1809),
basic model + surrogate variables (sv-adjusted, N = 1809), basic model + surrogate variables + derived cell counts (sv-and-cell-count, N = 1809).
Meta-analyses were also conducted stratified by smoking status (never-smokers (N = 304), former-smokers (N = 648), current-smokers (N = 857)) using the basic model
OR = odds ratio per SD increase in DNA methylation, SE = standard error, chr:pos = chromosome:position
110
Table 7.3: Heterogeneity between studies and smoker groups in the meta-analysis of EWAS in
four cohorts
basic sv-adjusted sv-and-cell-count never-smokers former-smokers current-smokers comp
CpG Dir I2 P Dir I2 P Dir I2 P Dir I2 P Dir I2 P Dir I2 P Dir I2 P
cg01901332 ---- 0 0.631 ---- 12 0.335 ---- 29 0.237 +--- 11 0.337 ---- 0 0.970 ---- 18 0.301 +-- 63 0.066
cg01940273 ---- 35 0.201 ---- 61 0.053 ---- 60 0.056 +--+ 59 0.064 ---- 7 0.356 ---+ 34 0.206 +-- 81 0.005
cg03636183 ---- 42 0.159 ---- 76 0.006 ---- 71 0.015 +-+- 26 0.254 ---- 30 0.231 ---- 0 0.540 --- 33 0.225
cg05575921 ---- 47 0.131 ---- 73 0.012 ---- 70 0.018 +--+ 0 0.481 ---- 0 0.433 ---- 34 0.207 --- 71 0.033
cg05951221 ---- 45 0.139 ---- 61 0.053 ---- 54 0.092 --++ 0 0.862 ---- 33 0.217 ---- 15 0.315 --- 44 0.168
cg06126421 ?--- 69 0.041 ---- 67 0.027 ---- 68 0.024 ?--- 0 0.464 ?--- 11 0.326 ?--- 0 0.400 --- 22 0.278
cg08709672 ---- 12 0.333 ---- 52 0.101 ---- 57 0.071 --++ 55 0.085 ---+ 0 0.584 ---+ 0 0.735 --- 0 0.657
cg09935388 ---- 20 0.291 ---- 50 0.110 ---- 29 0.241 ---+ 0 0.967 -+-- 60 0.056 ---- 0 0.729 --- 0 0.529
cg11660018 ---- 0 0.476 ---- 7 0.358 ---- 0 0.455 +-++ 0 0.699 ---- 9 0.349 ---- 0 0.557 --- 16 0.305
cg16823042 ---- 13 0.330 --+- 0 0.482 --+- 0 0.554 +-+- 19 0.293 ---+ 68 0.024 ---+ 0 0.919 --- 0 0.648
cg21566642 ---- 46 0.136 ---- 38 0.184 ---- 18 0.300 +-++ 0 0.681 ---- 0 0.798 ---- 65 0.035 --- 69 0.040
cg23387569 ---- 29 0.239 --+- 35 0.204 --+- 22 0.279 --+- 0 0.633 ---+ 76 0.005 ---+ 0 0.624 --- 0 0.890
cg23771366 ---- 42 0.161 ---- 75 0.007 ---- 72 0.013 ++++ 0 0.805 ---- 0 0.518 ---+ 27 0.249 +-- 81 0.006
cg25305703 ---- 53 0.096 ---- 0 0.461 ---- 4 0.373 ---- 0 0.780 ---- 28 0.246 ---- 0 0.793 --- 0 0.981
cg26963277 ---- 0 0.512 ---- 0 0.516 ---- 0 0.430 --++ 53 0.095 ---+ 0 0.466 ---- 17 0.308 --- 10 0.329
cg27241845 ---- 57 0.075 ---- 48 0.122 ---- 41 0.163 ---+ 0 0.643 ---+ 0 0.672 ---- 32 0.221 --- 0 0.846
Dir = Direction of effect
I2 = Heterogeneity I-squared value
P = Heterogeneity P value
chr:pos = chromosome:position
sv-adjusted = surrogate variables included as covariates in analysis
sv-and-cell-count = surrogate variables and derived cell counts included as covariates in analysis
never-smokers = basic model in never smokers only
former-smokers = basic model in former smokers only
current-smokers = basic model in current smokers only
comp = comparison of smoker groups.
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7.4.2 Mendelian randomization
I identified 15 independent mQTLs (r2<0.01) associated with methylation at 14 of 16 CpGs. Ten
mQTLs replicated at FDR<0.05 in NSHDS (Table 7.4). MR power analyses indicated >99%
power to detect ORs for lung cancer of the same magnitude as those in the meta-analysis of
EWAS.
There was little evidence for an effect of methylation at these 14 sites on lung cancer (FDR>0.05,
Table 7.5). For nine of 14 CpG sites the point estimates from the MR analysis were in the same
direction as in the EWAS, but of a much smaller magnitude (Z-test for difference, P<0.001)
(Figure 7.3).
For 9 of out the 16 mQTL-CpG associations, there was strong replication across time points
(Table 7.6) and 10 out of 16 mQTL-CpG associations replicated at FDR<0.05 in an independent
adult cohort (NSHDS). Using mQTL effect estimates from NSHDS for the 10 CpG sites that
replicated (FDR<0.05), findings were consistent with limited evidence for a causal effect of
peripheral blood-derived DNA methylation on lung cancer (Figure 7.4).
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Table 7.4: The SNP-exposure association estimates from ARIES and NSHDS
CpG CpG chr:pos Gene SNP SNP chr:pos A1 A2 MAF Beta (95% CI) P NSHDS Beta (95% CI) NSHDS P Trans
cg16823042 12:58119992 AGAP2 rs1048691 12:58152948 T C 0.207 0.321 (0.216, 0.426) 2.8e-09 0.176 (0.031, 0.322) 1.8e-02 N
cg23387569 12:58120011 AGAP2 rs1048691 12:58152948 T C 0.208 0.355 (0.251, 0.458) 3.9e-11 0.186 (0.04, 0.331) 1.2e-02 N
cg05575921* 5:373378 AHRR rs11746538 5:427466 A C 0.121 -0.369 (-0.482, -0.255) 3.0e-10 -0.062 (-0.315, 0.19) 6.3e-01 N
cg05575921* 5:373378 AHRR rs11744553 5:26366 C G 0.311 0.217 (0.139, 0.295) 7.2e-08 0.085 (-0.058, 0.228) 2.4e-01 N
cg27241845 2:233250370 ALPPL2 rs56080708 2:233274475 A C 0.078 0.716 (0.579, 0.852) 2.4e-23 0.464 (0.244, 0.684) 3.6e-05 N
cg05951221 2:233284402 ALPPL2 rs878481 2:233285872 G C 0.408 -0.319 (-0.401, -0.237) 5.9e-14 -0.182 (-0.313, -0.052) 6.0e-03 N
cg21566642* 2:233284661 ALPPL2 rs3748971 2:233250683 T C 0.074 -0.593 (-0.743, -0.443) 2.7e-14 0.111 (-0.115, 0.338) 3.4e-01 N
cg01901332* 11:75031054 ARRB1 rs7927381 11:67346743 T C 0.082 0.382 (0.247, 0.517) 3.9e-08 -0.191 (-0.4, 0.018) 7.3e-02 Y
cg01901332* 11:75031054 ARRB1 rs13087163 3:77329538 A C 0.390 -0.194 (-0.263, -0.124) 5.8e-08 0.11 (-0.019, 0.239) 9.4e-02 Y
cg08709672* 1:206224334 AVPR1B rs77433148 5:135967502 T A 0.018 -0.804 (-1.07, -0.535) 6.3e-09 -0.221 (-0.784, 0.342) 4.4e-01 Y
cg25305703 8:128378218 CASC21 rs9643220 8:128386926 A G 0.227 0.343 (0.247, 0.440) 7.1e-12 0.232 (0.078, 0.385) 3.0e-03 N
cg03636183 19:17000585 F2RL3 rs734568 19:17015685 T C 0.361 0.284 (0.199, 0.368) 6.7e-11 0.203 (0.074, 0.332) 2.0e-03 N
cg09935388 1:92947588 GFI1 rs17518433 1:92599172 A T 0.236 -0.330 (-0.421, -0.240) 1.8e-12 -0.186 (-0.339, -0.033) 1.7e-02 N
cg26963277 11:2722407 KCNQ1 rs463924 11:2717680 T C 0.304 -0.394 (-0.482, -0.307) 6.8e-18 -0.277 (-0.41, -0.145) 4.0e-05 N
cg11660018 11:86510915 PRSS23 rs1939110 11:86515072 T C 0.286 -0.404 (-0.498, -0.309) 2.6e-16 -0.229 (-0.385, -0.073) 4.0e-03 N
cg23771366 11:86510998 PRSS23 rs72967500 11:86505120 T C 0.132 -0.628 (-0.750, -0.506) 1.3e-22 -0.35 (-0.534, -0.166) 1.9e-04 N
* = SNPs used as an instrumental variables were not replicated in the independent dataset (NSHDS)
Trans = trans mQTL (Yes/No)
chr:position = chromosome:position
MAF = minor allele frequency
A1 = effect allele
P = P value
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Table 7.5: Full results for MR of DNA methylation of 14 CpG sites on lung cancer
Gene CpG N SNP Outcome OR (95% CI) P
AGAP2 cg16823042 1 Lung cancer 0.937 (0.858, 1.02) 0.149
AGAP2 cg23387569 1 Lung cancer 0.943 (0.871, 1.02) 0.149
AHRR cg05575921* 2 Lung cancer 0.936 (0.870, 1.01) 0.081
ALPPL2 cg27241845 1 Lung cancer 0.981 (0.926, 1.04) 0.522
ALPPL2 cg05951221 1 Lung cancer 1.02 (0.949, 1.10) 0.558
ALPPL2 cg21566642* 1 Lung cancer 0.922 (0.847, 1.00) 0.058
ARRB1 cg01901332* 2 Lung cancer 0.943 (0.871, 1.02) 0.146
AVPR1B cg08709672* 1 Lung cancer 1.08 (0.954, 1.21) 0.235
CASC21 cg25305703 1 Lung cancer 1.00 (0.924, 1.09) 0.956
F2RL3 cg03636183 1 Lung cancer 0.942 (0.864, 1.03) 0.172
GFI1 cg09935388 1 Lung cancer 1.03 (0.941, 1.12) 0.554
KCNQ1 cg26963277 1 Lung cancer 0.962 (0.903, 1.03) 0.236
PRSS23 cg11660018 1 Lung cancer 0.972 (0.912, 1.04) 0.372
PRSS23 cg23771366 1 Lung cancer 0.953 (0.901, 1.01) 0.086
N SNP = number of SNPs used in the analysis as instrumental variables
* = Instrumental variables for that CpG site did not replicate in an independent
dataset (NSHDS)
Where N SNP = 1, the Wald ratio estimate is used
Where N SNP > 1, the Wald ratio estimates were meta-analyzed and the estimates
were weighted by the inverse variance of the association with the outcome
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Figure 7.3: Mendelian randomization (MR) vs. observational analysis. Two-sample MR
was carried out with methylation at 14/16 CpG sites identified in the EWAS meta-analysis as the
exposure and lung cancer as the outcome. cg01901332 and cg05575921 had 2 instruments so the
estimate was calculated using the inverse variance weighted method, for the rest the MR estimate
was calculated using a Wald ratio. Only 14 of 16 sites could be instrumented using mQTLs
from mqtldb.org. * = instrumental variable not replicated in independent dataset (NSHDS). The
sites for which instrumental variables have not been replicated are cg01901332, cg21566642,
cg05575921 and cg08709672. OR = odds ratio per SD increase in DNA methylation.
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Table 7.6: The association between mQTLs and their CpG sites across the five timepoints in
ARIES
During pregnancy Middle age Birth Childhood Adolescence
CpG Gene SNP Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P
cg01901332 ARRB1 rs13087163 -0.007 0.003 4.1e-02 -0.004 0.003 2.5e-01 -0.003 0.002 1.1e-01 -0.003 0.003 1.7e-01 -0.015 0.003 2.9e-07
cg01901332 ARRB1 rs7927381 -0.003 0.006 5.9e-01 -0.005 0.006 4.2e-01 0.015 0.003 7.9e-07 0.000 0.004 9.8e-01 0.004 0.005 4.5e-01
cg03636183 F2RL3 rs734568 0.029 0.006 3.6e-07 0.027 0.005 4.7e-07 0.039 0.007 3.9e-08 0.031 0.005 2.1e-10 0.031 0.005 3.6e-10
cg05575921 AHRR rs11744553 0.002 0.004 5.9e-01 -0.005 0.004 2.0e-01 0.008 0.003 2.3e-03 0.009 0.002 1.3e-07 0.003 0.002 2.1e-01
cg05575921 AHRR rs11746538 -0.013 0.006 2.9e-02 -0.011 0.005 3.7e-02 -0.014 0.004 3.1e-04 -0.016 0.002 4.8e-11 -0.010 0.003 9.6e-04
cg05951221 ALPPL2 rs878481 -0.006 0.001 1.3e-06 -0.006 0.001 4.6e-06 -0.001 0.000 1.6e-03 -0.005 0.001 1.3e-08 -0.005 0.001 1.9e-12
cg08709672 AVPR1B rs77433148 -0.014 0.008 9.1e-02 -0.004 0.008 6.2e-01 0.010 0.008 2.3e-01 -0.032 0.006 6.9e-07 0.002 0.007 8.2e-01
cg09935388 GFI1 rs17518433 -0.037 0.009 3.6e-05 -0.024 0.010 1.6e-02 -0.028 0.010 6.0e-03 -0.054 0.010 4.2e-08 -0.063 0.010 9.9e-11
cg11660018 PRSS23 rs1939110 -0.017 0.003 6.5e-10 -0.014 0.003 1.2e-05 -0.004 0.003 1.9e-01 -0.014 0.003 8.0e-07 -0.012 0.003 1.0e-05
cg16823042 AGAP2 rs1048691 0.016 0.003 5.1e-08 0.013 0.003 1.0e-05 0.011 0.004 3.5e-03 0.019 0.003 1.3e-08 0.015 0.004 3.5e-05
cg21566642 ALPPL2 rs3748971 -0.009 0.006 1.6e-01 -0.011 0.006 6.9e-02 -0.007 0.003 6.2e-03 -0.034 0.004 9.2e-15 -0.024 0.004 2.4e-08
cg23387569 AGAP2 rs1048691 0.026 0.004 1.6e-10 0.020 0.004 2.2e-07 0.014 0.005 2.2e-03 0.027 0.004 2.6e-10 0.020 0.004 1.5e-06
cg23771366 PRSS23 rs72967500 -0.010 0.002 2.4e-06 -0.014 0.003 6.7e-07 -0.010 0.001 1.8e-16 -0.011 0.001 2.1e-13 -0.012 0.002 1.3e-12
cg25305703 CASC21 rs9643220 0.028 0.004 1.5e-10 0.023 0.004 1.6e-07 0.032 0.005 2.6e-09 0.020 0.003 1.1e-08 0.018 0.004 3.3e-06
cg26963277 KCNQ1 rs463924 -0.018 0.002 1.6e-14 -0.015 0.003 1.2e-08 -0.008 0.003 5.6e-03 -0.012 0.002 6.3e-09 -0.015 0.002 7.5e-12
cg27241845 ALPPL2 rs56080708 0.038 0.011 4.5e-04 0.052 0.012 2.5e-05 0.095 0.010 6.4e-22 0.102 0.010 8.4e-25 0.051 0.011 4.4e-06














































Figure 7.4: Comparison of two-sample Mendelian randomization results when using the
discovery (ARIES, n = 1018) and replication (NSHDS, n = 468). On the left-hand side of
each column the bracketed numbers represent the number of instrumental variables for that CpG
site.
There was little evidence of different effect estimates between ever and never smokers at in-
dividual CpG sites (Figure 7.5, Z-test for difference, P>0.5). There was some evidence for a
possible effect of methylation at cg21566642-ALPPL2 and cg23771366-PRSS23 on squamous
cell lung cancer (OR=0.85 [95% CI=0.75,0.97] and 0.91 [95% CI=0.84,1.00] per SD [14.4%
and 5.8%] increase, respectively) as well as methylation at cg23387569-AGAP2, cg16823042-
AGAP2, and cg01901332-ARRB1 on lung adenocarcinoma (OR=0.86 [95% CI=0.77,0.96], 0.84
[95% CI=0.74,0.95], and 0.89 [95% CI=0.80,1.00] per SD [9.47%, 8.35%, and 8.91%] increase,
respectively). However, none of the results withstood multiple testing correction (FDR<0.05)
(Figure 7.6). For those CpGs where multiple mQTLs were used as instruments (cg05575921-
AHRR and cg01901332-ARRB1), there was limited evidence for heterogeneity in MR effect es-
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Figure 7.5: DNA methylation – lung cancer Mendelian randomization effect estimates in
ever and never smokers. On the left-hand side of each column the bracketed numbers represent
the number of instrumental variables for that CpG site. * indicates that the SNP(s) being used to








































































0.6 0.8 1.0 1.2 1.4 1.6
OR (95% CI)
● ● ●Squamous Small Adeno
Figure 7.6: Mendelian randomization of DNA methylation on three lung cancer subgroups
On the left-hand side of each column the bracketed numbers represent the number of instrumental
variables for that CpG site. * indicates that the SNP(s) being used to instrument that CpG site
are more than 1MB away from the CpG site in the genome (trans). Squamous = squamous cell
carcinoma, Small = small cell carcinoma, Adeno = adenocarcinoma.
Single mQTLs for cg05575921-AHRR, cg27241845-ALPPL2, and cg26963277-KCNQ1 showed
some evidence of association with smoking cessation (former vs. current smokers), although
these associations were not below the FDR<0.05 threshold (Figure 7.7).
119
Table 7.7: Estimates of heterogeneity of MR estimates across multiple SNPs
CpG outcome N SNP Q P
cg05575921 Lung cancer (ever) 2 1.838 0.17
cg05575921 Small cell lung cancer 2 0.019 0.89
cg05575921 Lung cancer (never) 2 1.424 0.23
cg05575921 Lung adenocarcinoma 2 0.437 0.51
cg05575921 Lung cancer 2 0.003 0.96
cg05575921 Squamous cell lung cancer 2 1.168 0.28
cg01901332 Lung cancer (ever) 2 0.085 0.77
cg01901332 Small cell lung cancer 2 0.004 0.95
cg01901332 Lung cancer (never) 2 0.321 0.57
cg01901332 Lung adenocarcinoma 2 0.780 0.38
cg01901332 Lung cancer 2 0.965 0.33
cg01901332 Squamous cell lung cancer 2 1.266 0.26
N SNP = number of SNPs used in the analysis as instrumental
variables
Q = Cochrane’s Q statistic
Lung cancer (ever) = lung cancer in ever smokers
Lung cancer (never) = lung cancer in never smokers
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Beta Coef (95% CI)
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Figure 7.7: Associations of mQTLs and smoking behaviours. Some SNPs that were geno-
typed in the TRICL consortium were not within the TAG consortium, thus were not available
for analysis here. Units for the traits: AoI (age of smoking initiation) = log years, EvN (ever
vs. never smoked) = log odds, FvS (former vs current smoker) = log odds. CpD = cigarettes
smoked per day.
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Potential causal effect of AHRR methylation on lung cancer risk: one sample MR
In the CCHS, a per (average methylation-increasing) allele change in a four-mQTL allele
score was associated with a 0.73% [95% CI=0.56,0.90] increase in methylation (P<1x10-10)
and explained 0.8% of the variance in cg05575921-AHRR methylation (F-statistic=74.2).
Confounding factors were not strongly associated with the genotypes in this cohort (P>=0.11)
(Table 7.8). Results provided some evidence for an effect of cg05575921 methylation on total
lung cancer risk (HR=0.30 [95% CI=0.10,1.00] per SD (9.2%) increase) (Table 7.9). The
effect estimate did not change substantively when stratified by smoking status (Table 7.9).
Table 7.8: Association of AHRR methylation and methylation allele score with confounding
factors in the CCHS
Methylation Allele score
Confounder Beta 95 CI P Beta 95 CI P
Sex -0.62 -0.94; -0.29 2.0e-04 -1e-02 -0.04; 0.06 0.72
Alcohol 0.00 -0.001; 0.009 8.5e-01 0e+00 -0.000; 0.000 0.15
Former vs never smokers -3.07 -3.54; -2.61 2.0e-38 4e-03 -0.07; 0.08 0.91
Current vs never smokers -10.76 -11.30; -10.22 1.0e-50 1e-02 -0.08; 0.10 0.82
Exposure to dust -0.65 -1.04; -0.26 1.0e-03 -5e-02 -0.12; 0.01 0.11
Exposure to passive smoking -0.46 -0.78; -0.15 4.0e-03 -3e-02 -0.08; 0.03 0.34
Current use of tobacco to per cigarette equivalent -0.06 -0.08; -0.03 9.0e-05 -1e-03 -0.005; 0.004 0.72
Cumulative use of tobacco to per pack-year -0.05 -0.06; -0.04 4.0e-28 -5e-04 -0.002; 0.001 0.54
For the allele score, genotypic effects were scaled to equate to the same magnitude of effect as a per 1% increase in
methylation. Regressions were adjusted for the other factors in the table
Table 7.9: One-sample MR analysis of the effect of AHRR methylation (%) on lung cancer risk
in the CCHS
Smoking status Total N N events Age and sex adjusted HR (95% CI) P
All 8,758 357 0.88 (0.78; 1.00) 0.05
Current 4,262 305 0.90 (0.79; 1.03) 0.12
Former 2,548 43 0.86 (0.61; 1.22) 0.41
Never 1,948 9 0.83 (0.38; 1.85) 0.66
HR = hazard ratio, P = P value
Given contrasting findings with the main MR analysis, where cg05575921-AHRR methylation
was not causally implicated in lung cancer, and the lower power in the one-sample analysis to de-
tect an effect of equivalent size to the observational results (power = 19% at alpha = 0.05), a fur-
ther two-sample MR was performed based on the four mQTLs using data from both CCHS (sam-
ple one) and the TRICL-ILCCO consortium (sample two). Results showed no strong evidence
for a causal effect of DNA methylation on total lung cancer risk (OR=1.00 [95% CI=0.83,1.10]
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per SD increase) (Figure 7.8). There was also limited evidence for an effect of cg05575921-
AHRR methylation when stratified by cancer subtype and smoking status (Figure 7.8) and no
strong evidence for heterogeneity of the mQTL effects (Table 7.10). Conclusions were con-
sistent when MR-Egger (242) was applied (Figure 7.8) and when accounting for correlation
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Figure 7.8: Two-sample Mendelian randomization analysis of DNA methylation at AHRR
on lung cancer. Analysis are divided into these categories: a) All lung cancer b) Squamous cell
carcinoma c) Adenocarcinoma d) Small cell carcinoma e) All lung cancer in never smokers only
f) All lung cancer in ever smokers only
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Table 7.10: Two sample MR analysis for AHRR
FE meta-analysis Correction for correlation
Lung cancer N SNP Beta SE Beta SE Het-Q Het-DF Het-P
All 4 -0.005 0.010 -0.004 0.009 2.73 3 0.43
Squamous cell 4 0.003 0.024 0.004 0.014 6.65 3 0.08
Adenocarcinoma 4 -0.022 0.011 -0.022 0.012 1.06 3 0.79
Small cell carcinoma 4 0.002 0.021 0.001 0.022 0.14 3 0.99
All in never smokers 4 -0.003 0.025 -0.003 0.026 1.37 3 0.71
All in ever smokers 4 -0.017 0.010 -0.016 0.011 1.63 3 0.65
N SNP = number of SNPs used in the analysis as instrumental variables
FE = fixed effects
Q = Cochrane’s Q statistic
DF = degrees of freedom
P = P value
7.4.3 Tumour and adjacent normal lung tissue methylation patterns
For cg05575921-AHRR, there was no strong evidence for differential methylation between ade-
nocarcinoma tissue and adjacent healthy tissue (P=0.963), and weak evidence for hypermethy-
lation in squamous cell carcinoma tissue (P=0.035) (Figure 7.9, Table 7.11). For the other
CpG sites there was evidence for a difference in DNA methylation between tumour and healthy
adjacent tissue at several sites in both adenocarcinoma and squamous cell carcinoma, with
consistent differences for CpG sites in ALPPL2 (cg2156642, cg05951221 and cg01940273),
as well as cg23771366-PRSS23, cg26963277-KCNQ1, cg09935388-GFI1, cg0101332-ARRB1,
cg08709672-AVPR1B and cg25305703-CASC21. However, hypermethylation in tumour tissue
was found for the majority of these sites, which is the opposite to what was observed in the
EWAS analysis.
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Figure 7.9: Differential DNA methylation in lung cancer tissue. A comparison of methylation
at each of the 16 CpG sites identified in the meta-analysis was made between lung cancer tissue
and adjacent healthy lung tissue for patients with lung adenocarcinoma (A) and squamous cell
lung cancer (B). Data from The Cancer Genome Atlas was used for this analysis.
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Table 7.11: Comparison of MR results with tumour-healthy tissue differential methylation
Adeno-MR Adeno-T/H SCC-MR SCC-T/H
CpG Gene Direction P Direction P Direction P Direction P
cg23387569 AGAP2 hypo 0.006 hyper 8.8e-01 hyper 0.364 hypo 5.0e-01
cg05575921 AHRR hypo 0.089 hypo 9.6e-01 hypo 0.052 hyper 3.5e-02
cg05951221 ALPPL2 hyper 0.916 hyper 8.0e-03 hyper 0.273 hyper 1.0e-09
cg21566642 ALPPL2 hypo 0.673 hyper 1.0e-04 hypo 0.016 hyper 8.0e-07
cg27241845 ALPPL2 hyper 0.532 hypo 7.6e-02 hypo 0.101 hyper 2.8e-01
cg01901332 ARRB1 hypo 0.045 hyper 3.0e-16 hypo 0.778 hyper 8.0e-12
cg08709672 AVPR1B hyper 0.129 hyper 3.0e-02 hypo 0.862 hyper 2.0e-02
cg25305703 CASC21 hyper 0.170 hypo 3.0e-05 hypo 0.792 hypo 8.0e-04
cg03636183 F2RL3 hypo 0.151 hyper 8.0e-04 hyper 0.758 hypo 7.6e-01
cg09935388 GFI1 hypo 0.831 hyper 2.0e-04 hyper 0.567 hyper 2.0e-20
cg26963277 KCNQ1 hypo 0.299 hyper 3.6e-02 hypo 0.314 hyper 3.0e-03
cg23771366 PRSS23 hyper 0.819 hypo 4.0e-09 hypo 0.047 hypo 3.3e-02
cg11660018 PRSS23 equal 0.999 hypo 3.0e-08 hypo 0.062 hypo 1.3e-01
T/H = comparison of tumour and healthy tissue
Adeno = Lung adenocarcinoma
SCC = squamous cell carcinoma
P = P value
hyper = hypermethylation is associated with lung cancer
hypo = hypomethylation is associated with lung cancer
For tumour/healthy tissue comparison, pos = hypermethylation of the CpG within the tumour tissue (neg is
the opposite)
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7.4.4 Gene expression associated with mQTLs in blood and lung tissue
Of the 10 genes annotated to the 14 CpG sites, eight genes were expressed sufficiently to be
detected in lung (AVPR1B and CASC21 were not) and seven in blood (AVPR1B, CASC21 and
ALPPL2 were not). Of these, gene expression of ARRB1 could not be investigated as the
mQTLs in that region were not present in the GTEx data. rs3748971 and rs878481, mQTLs
for cg21566642 and cg05951221 respectively, were associated with increased expression of
ALPPL2 in lung tissue (P=0.002 and P=0.0001). No other mQTLs were associated with ex-
pression of the annotated gene at a Bonferroni corrected P value threshold (P<0.05/19=0.0026)
(Table 7.12).
Table 7.12: mQTL-gene expression analysis in lung and whole blood using data from GTEx
Lung Whole blood
Gene SNP CpG Trans SNP chr:pos A1 A2 MAF Beta SE P Beta SE P
AGAP2 rs1048691 cg16823042 N 12:58152948 T C 0.207 0.011 0.046 0.81500 0.053 0.037 0.153
AGAP2 rs1048691 cg23387569 N 12:58152948 T C 0.208 0.011 0.046 0.81500 0.053 0.037 0.153
AHRR rs11746538 cg05575921 N 5:26366 A C 0.121 -0.009 0.075 0.90100 -0.050 0.072 0.491
AHRR rs11744553 cg05575921 N 5:427466 C G 0.311 -0.259 0.103 0.01230 -0.032 0.110 0.773
ALPPL2 rs56080708 cg27241845 N 2:233250683 A C 0.078 0.020 0.131 0.87800 NA NA NA
ALPPL2 rs878481 cg05951221 N 2:233274475 G C 0.408 0.396 0.123 0.00148 NA NA NA
ALPPL2 rs3748971 cg21566642 N 2:233285872 T C 0.074 0.257 0.065 0.00011 NA NA NA
F2RL3 rs734568 cg03636183 N 19:17015685 T C 0.361 0.071 0.048 0.14500 -0.093 0.039 0.017
GFI1 rs17518433 cg09935388 N 1:92599172 A T 0.236 0.114 0.052 0.03130 -0.001 0.036 0.986
KCNQ1 rs463924 cg26963277 N 11:2717680 T C 0.304 0.008 0.038 0.83000 0.003 0.028 0.919
PRSS23 rs1939110 cg11660018 N 11:86505120 T C 0.286 -0.151 0.092 0.10100 0.026 0.042 0.534
PRSS23 rs72967500 cg23771366 N 11:86515072 T C 0.132 -0.061 0.067 0.36300 0.014 0.027 0.614
Trans = trans mQTL (Yes/No)
chr:pos = chromosome:position
MAF = minor allele frequency
A1 = effect allele
P = P value
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7.5 Discussion
In this study, 16 CpG sites associated, at P<1x10-7, with lung cancer in a meta-analysis of EWAS,
of which 14 have been previously identified in relation to smoke exposure (1) and six were high-
lighted in a previous study as being associated with lung cancer (137). This previous study used
the same data from the four cohorts investigated here, but in a discovery and replication, rather
than meta-analysis framework. Overall, under the MR framework there was limited evidence
supporting a potential causal effect of methylation at the CpG sites identified in peripheral blood
on lung cancer. This aligns with the results presented in Chapter 6, where evidence was found
that EWAS results were unlikely to be aetiologically relevant. These findings are in contrast
to previous analyses suggesting that methylation at two CpG sites investigated (in AHRR and
F2RL3) mediated > 30% of the effect of smoking on lung cancer risk (217). This previous study
used methods which are sensitive to residual confounding and measurement error that may have
biased results (53,120). These limitations are largely overcome using MR (120). While there was
some evidence for an effect of methylation at some of the other CpG sites on risk of subtypes of
lung cancer, these effects were not robust to multiple testing correction and were not validated
in the analysis of tumour and adjacent normal lung tissue methylation nor in gene expression
analysis.
A major strength of the study was the use of two-sample MR to integrate an extensive epigenetic
resource and summary data from a large lung cancer GWAS to appraise causality of observational
associations with >99% power. Evidence against the observational findings were also acquired
through tissue-specific DNA methylation and gene expression analyses.
Limitations include potential “winner’s curse” which may bias causal estimates in a two-sample
MR analysis towards the null if the discovery sample for identifying genetic instruments is used
as the first sample, as was done for the main MR analysis using data from ARIES (247). How-
ever, findings were similar when using replicated mQTLs in NSHDS, indicating the potential
impact of this bias was minimal (Figure 7.4). Another limitation relates to the potential issue
of consistency and validity of the instruments across the two samples. For a minority of the
mQTL-CpG associations (4 out of 16), there was limited replication across time points and in
particular, 6 mQTLs were not strongly associated with DNA methylation in adults. Further, the
primary data used for the first sample in the two-sample MR was ARIES, which contained no
male adults at the time of the study. If the mQTLs identified vary by sex and time, then this could
bias the results. However, the replication cohort NSHDS contains adult males. Therefore, the
10 mQTLs that replicated in NSHDS are unlikely to be biased by the sex discordance. Also, the
findings for cg05575921 AHRR in CCHS, which contains both adult males and females, were
replicated in a two-sample MR analysis, suggesting these results are also not influenced by sex
discordance. Caution is therefore warranted when interpreting the null results for the two-sample
MR estimates for the CpG sites for which mQTLs were not replicated, which could be the result
of weak-instrument bias.
The lack of independent mQTLs for each CpG site did not allow us to properly appraise horizon-
tal pleiotropy in the MR analyses. Where possible I only included cis-acting mQTLs to minimise
pleiotropy and investigated heterogeneity where there were multiple independent mQTLs. Three
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mQTLs were nominally associated with smoking phenotypes, but not to the extent that this
would bias the MR results substantially. Since this study was conducted, the Genetics of DNA
Methylation Consortium (GoDMC) has released a large set of SNP-DNA methylation associa-
tions from a sample size that is over ten times that of ARIES (170). The genetic architecture
of DNA methylation, as revealed by that paper and others, has shown that few independent cis-
acting mQTLs can be identified for the vast majority of DNA methylation sites, with Min et
al. detecting a median of two independent cis-acting mQTLs across all DNA methylation sites
measured (170). Therefore repeating this analysis using instruments identified from GoDMC
is unlikely to alter the results or conclusions, especially as there was over 99% power to detect
effects as large as the observational associations using data presented in this chapter.
Some of the mQTLs used influence multiple CpGs in the same region, suggesting genomic
control of methylation at a regional rather than single CpG level. This was untested, but methods
to detect differentially methylated regions (DMRs) and identify genetic variants which proxy for
them may be fruitful in probing the effect of methylation across gene regions.
A further limitation relates to the inconsistency in effect estimates between the one- and
two-sample MR analysis to appraise the causal role of AHRR methylation. While findings in
CCHS were supportive of a causal effect of AHRR methylation on lung cancer (HR=0.30 [95%
CI=0.10,1.00] per SD), in two-sample MR this site was not causally implicated (OR=1.00 [95%
CI=0.83,1.10] per SD increase). It was verified that this was not due to differences in the genetic
instruments used, nor due to issues of weak instrument bias. Given the CCHS one-sample MR
had little power (19% at alpha = 0.05) to detect a causal effect with a size equivalent to that of
the observational analysis, there should be more confidence in the results from the two-sample
approach.
Peripheral blood may not be the ideal tissue to assess the association between DNA methylation
and lung cancer. While a high degree of concordance in mQTLs has been observed across lung
tissue, skin and peripheral blood DNA (248), this was not directly evaluated here. A possible
explanation for a lack of causal effect at AHRR is due to the limitation of tissue specificity as
it was found that the mQTLs used to instrument cg05575921 were not strongly related to ex-
pression of AHRR in lung tissue. However, findings from MR analysis were corroborated by
the lack of evidence for differential methylation at AHRR between lung adenocarcinoma tissue
and adjacent healthy tissue, and weak evidence for hypermethylation (opposite to the expected
direction) in squamous cell lung cancer tissue. This result may be interesting in itself as smoking
is hypothesized to influence squamous cell carcinoma more than adenocarcinoma. However, the
result conflicts with that found in the MR analysis. Furthermore, another study investigating tu-
morous lung tissue (N=511) found only weak evidence for an association between smoking and
cg05575921 AHRR methylation, that did not survive multiple testing correction (P=0.02) (249).
These results do not fully exclude AHRR from involvement in the disease process. AHRR and
AHR form a regulatory feedback loop, which means that the actual effect of differential methyla-
tion or differential expression of AHR/AHRR on pathway activity is complex (156). In addition,
some of the CpG sites identified in the EWAS were found to be differentially methylated in the
tumour and adjacent normal lung tissue comparison. While this could represent a false negative
result of the MR analysis, it is of interest that differential methylation in the tissue compari-
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son analysis was typically in the opposite direction to that observed in the EWAS. Furthermore,
while this method can be used to minimize confounding, it does not fully eliminate the possi-
bility of bias due to reverse causation (whereby cancer induces changes in DNA methylation) or
intra-individual confounding e.g. by gene expression. Therefore, it doesn’t give conclusive evi-
dence that DNA methylation changes at these sites are not relevant to the development of lung
cancer.
While DNA methylation in peripheral blood may be predictive of lung cancer risk, according
to the present analysis it is unlikely to play a causal role in lung carcinogenesis at the CpG
sites investigated. Findings from this study issue caution over the use of traditional mediation
analyses to implicate intermediate biomarkers (such as DNA methylation) in pathways linking
an exposure with disease, given the potential for residual confounding in this context (120).
However, the findings of this study do not preclude the possibility that other DNA methylation
changes (i.e. changes at different sites in the genome or in different tissues) are causally related






Phenotypic variation cannot occur without molecular change. Identifying the changes that cause
phenotypic variation adds to the aetiological understanding of traits and thus has the potential
to uncover novel therapeutic targets. Further, studying the association between molecular marks
and complex traits may yield new, valid predictors, that could augment current prediction capac-
ity within clinical practice (57). This is true regardless of whether the molecular marks identified
are causal.
Given the strong links made by experimental researchers between DNA methylation and the
regulatory processes in cells (20–23,41–44), there has been precedence for studying the covaria-
tion between DNA methylation and complex traits with the hope of discovering new regulatory
features underlying trait biology.
Over the past 15 years, hundreds of EWAS have been conducted, but the number of associations
identified have varied dramatically by trait. EWAS have identified numerous associations be-
tween DNA methylation and complex traits such as smoking (1,112,113) and body mass index
(3,69,175,176). However, there are also many examples where EWAS have identified few sites
that reliably associate with a complex trait; in The EWAS Catalog (Chapter 3), roughly 25% of
the EWAS report fewer than 10 associations. Given the phenotypic nature of DNA methylation,
one might expect to see covariation of complex traits and DNA methylation to be identified in
abundance across the majority of EWAS. This has not been the case thus far. Understanding the
aspects of EWAS that can explain associations across complex traits is imperative to progressing
study designs and was the focus of this thesis.
In this body of work hundreds of published EWAS along with hundreds more EWAS I conducted
were catalogued in an open access database. Using these results, I showed that unaccounted for
technical effects may explain over 10% of reported associations. When accounting for these
technical effects, the total predictive capacity of DNA methylation measured using the HM450
array in whole blood was low across 400 complex traits (median was near zero). This did vary
substantially between traits, yet having smoked cigarettes was the only trait for which there was
evidence that the total predictive capacity was greater than zero (FDR < 0.1). This suggests
that the lack of association between DNA methylation (as measured in blood by the HM450
array) and some complex traits is unlikely due to power, and we should not expect to see similar
levels of wide-spread perturbations of DNA methylation in relation to traits like with smoking,
when similar sample sizes for analysis are obtained. This apparent lack of covariation between
DNA methylation and complex traits may be surprising given the phenotypic nature of DNA
methylation, but as this study (as with most EWAS) only measured methylation at less than 2%
of the total number of CpG sites across the genome and in only one tissue, it is plausible that
much of the covariation between DNA methylation and complex traits was missed. Despite
evidence of little predictive capacity, there are still EWAS that have identified numerous DMPs.
However, it was found that EWAS for eight traits identified no more genes and genesets in
common with corresponding GWAS than expected by chance, suggesting that the majority of
DMPs identified were either acting through pathways independent of genetics or were not of
aetiological relevance for the traits examined. Confounding and reverse causation may explain
the marked differences in EWAS and GWAS results of corresponding traits. In the specific
scenario of an EWAS of lung cancer, whether DNA methylation changes may be on the causal
pathway to disease was examined. Observational EWAS of lung cancer identified associations
with large effect sizes between DNA methylation, measured long before disease onset, and lung
cancer risk. However, in a well powered Mendelian randomization (MR) analysis, none of these
associations could be replicated.
This work also revealed some promising aspects of the current EWAS study design. Firstly,
the regions targeted by probes on the HM450 array were designed to be enriched for promoters
of protein-coding genes and work presented in Chapter 4 suggests DMPs are also enriched
for these regions. Therefore, this decision may have increased likelihood in identifying sites
associated with complex traits. Secondly, the evidence that EWAS are identifying separate genes
and genesets to GWAS does not preclude the possibility that these EWAS associations are useful.
In fact, if overlap was very high then it would suggest a large amount of redundancy in the
studies, but instead it is likely the study types are capturing very different information.
Overall though, these findings suggest that substantial changes may be required in the design of
EWAS to improve predictive capacity and enhance aetiological insight.
8.2 Extensions to this work
Indeed the issues pertaining to some design flaws and potential improvements that can aid in-
terpretation of EWAS has already been reviewed (6,56,214,251). Lappalainen & Greally also
suggested moving to conducting “second generation EWAS,” which focused on improving in-
terpretability of EWAS, especially when conducting them as a means to understand trait biology
(251). They argue that there are four key aspects which should be the focus for future EWAS.
Firstly, the hypothesised method for which cellular changes will result in phenotypic variation
should be clear. Secondly, participants and cell samples collected should be obtained to answer
necessary questions regarding causality. Thirdly, cell types present in samples should be mea-
sured as precisely as possible. Finally, as many complementary genome-wide assays as possible
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should be conducted in the same samples and these assays should survey the maximum amount
of loci possible. Reflecting on the work presented in this thesis, and following on from these
points, here I discuss ideas that could be applied to improve both yield and interpretation of
EWAS.
8.2.1 Beyond the HM450 array in blood
The work in this thesis focuses on DNA methylation measures taken for the majority of published
EWAS, namely the use of the HM450 array to measure DNA methylation in blood samples. The
HMEPIC array is now regularly used, but as will be explained, many of the limitations of EWAS
identified in this thesis apply to studies using the contemporary array technology. However, given
the correlation structure across all DNA methylation sites in the genome is not known, this work
can not be generalised to DNA methylation studies as a whole. Further, although certain aspects
of observational EWAS, such as propensity for confounding, will always hinder interpretation of
results, other aspects of this thesis may not apply to data from other tissues.
There is overwhelming evidence that complex traits are polygenic (influenced by multiple genes)
(199,252) and some hypothesise that they may even be omnigenic (influenced by potentially
all genes, even if the influence of some genes is almost immeasurably small) (253). As DNA
methylation is highly correlated with factors of gene expression regulation, it seems likely that
either DNA methylation or something coupled to it has a substantial impact on the aetiology
of many complex traits. Thus, the issues uncovered with EWAS in this thesis, such as the lack
of covariation between DNA methylation and complex traits, may be because too few sites are
being measured in the wrong tissues. Finucane et al. devised a method that used LD-score
regression and publicly available gene expression data to identify the most relevant tissue and
cell types for 34 traits (254). Without access to large datasets with DNA methylation available
in a plethora of tissues, molecular epidemiologists could rely on inferences made from studies
such as this to help design future EWAS. Importantly, before such work is used to inform future
studies, the definition of the relevant cell type should be clear. This will undoubtedly depend on
the phenotype of interest, but will also differ based on the hypotheses being tested.
The impact of different methylation states of the genome, such as hydroxymethylation, is also
beginning to be explored (255–257). The current methods employed by EWAS, which revolve
around bisulphite conversion, capture all methylation states as one measurement. If these states
have differing effects, separating these out will increase power and impart greater biological
understanding.
In a similar vein to other omics, sequencing technology will likely continue to improve and will
become cheap enough to use across population samples (258,259). Therefore, identifying the
differential methylation states using techniques such as single-molecule real-time (SMRT) se-
quencing will hopefully become more frequent (260). Also, despite the vast majority of EWAS
being conducted using blood (Table 4.1), there are 42 tissue types recorded in The EWAS Cata-
log. The Cancer Genome Atlas (TCGA) has recorded DNA methylation data in a large number
of tissues also (261), and the trend to measure other tissues is likely to continue, especially as the
number of reliable sites identified in EWAS tends to be low. As discussed in Section 1.3.2, DNA
methylation is a relatively stable molecular trait and this is consistent across tissues. Therefore,
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if tissues can be sampled, measurement of DNA methylation is simpler than other molecular
traits such as RNA levels and histone modifications across any tissue. In addition, manuscripts
using techniques to measure gene expression and DNA methylation in single cells are becoming
more common (262–266). Simple experiments have also shown that single cell RNA sequencing
can give much greater resolution of cell types in a sample compared to other techniques (251).
Given the issues of cell specificity, these studies may prove pivotal in advancement of the field
of epigenetic epidemiology.
As discussed in Chapter 4, DNA methylation is a binary feature, yet by pooling groups of cells
and measuring methylation at each site as a proportion of the DNA molecules that are methylated,
a continuous measure is derived. If cells of the same type are identical then one might expect they
would be methylated at the same sites as one another (6). However, a mosaicism of methylation
across cells may exist. If so, then pooling groups of cells for analysis, and taking account of
differences between higher order cell types, will remain a valid approach for EWAS. However, if
strong evidence is provided that this cellular mosaicism is improbable between cells of the same
type, rapid movement towards single-cell techniques is likely.
8.2.2 New methods and data
There is still substantial interest in assessing the association between DNA methylation and
complex traits. In 2020, there have been over 100 EWAS conducted that have been or will
be added to The EWAS Catalog. These EWAS are excluding studies that did not meet the
criteria for inclusion into the database and studies that did not report findings relevant to the
database. Further, new methods are being developed to measure the association between DNA
methylation and complex traits. Two recent examples include Zhang F et al., who created a
command line tool to conduct EWAS using different models, OSCA, (267) and a study that
developed a Bayesian approach to conduct EWAS, using various confounders including genotype
in their model (197).
This interest will hopefully lead to a continuation in developments across the field of molecular
epidemiology, but the complex nature of molecular pathways to disease may limit the speed
at which robust aetiological inferences are made. Causal inference methods such as MR aid
aetiological studies, but the lack of independent instruments coupled with the complexity of
gene regulation make it difficult to be confident the key assumptions of MR (Figure 1.3) are
met (57,85,128,170). Colocalization is now being readily used in the context of molecular MR
(128,170), but this only provides evidence that the complex trait and the molecular phenotype
have the same putatively causal genetic variant(s) (128), and do not provide evidence against
these variants being pleiotropic.
Lack of large-scale studies was a problem in identifying valid instruments for individual CpG
sites, including within my study in Chapter 7, but this has been partially alleviated by the forma-
tion of Genetics of DNA Methylation Consortium (GoDMC) (170). This consortium has already
yielded interesting results. Min et al. performed MR to establish whether there was likely an
effect of DNA methylation changes, measured by the HM450 array, on 116 complex traits (170).
Similarly to the results presented in this thesis, they found that evidence for the aetiological
relevance of DNA methylation measured across those sites was lacking. In the future, estab-
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lishing tissue-specific mQTLs will be important in understanding whether tissue-specific DNA
methylation changes are likely to have an effect on complex trait variation.
For prediction, the complexity of establishing causality and understanding cellular function need
not apply. Whether the goal is to identify DNA methylation differences that co-exist with dis-
ease states and could therefore help diagnose these states, or truly predict diseases before they
arrive is important to consider. For the former, cross-sectional studies suffice, but for the latter
cohort studies that have DNA methylation data collected prior to disease onset such as ALSPAC
(141,142) are required. Larger studies, such as Generation Scotland (268), provide the opportu-
nity for developing more precise predictors and further, the power gained from the extra samples
would enable one to estimate the total predictive capacity of DNA methylation for individual
traits with relatively high precision using the methods laid out in Chapter 5.
8.2.3 Beyond DNA methylation
As the premise of aetiological EWAS is that DNA methylation changes may impact upon some
cellular function, which leads to phenotypic changes, reliable associations between DNA methy-
lation and complex traits is not enough to impart translatable opportunities. How DNA methy-
lation is changing these cellular functions is key for two reasons, 1. It might not be possible
to target DNA methylation directly to treat/prevent disease and 2. DNA methylation may just
be tagging some other epigenetic mark and in fact may be inconsequential to phenotypic state.
Therefore, once a link between DNA methylation and complex traits is established, it is required
that experimental work is undertaken to fill in the gap of how DNA methylation changes relate
to cellular function differences that influence the trait.
With initiatives such as ENCODE and the Roadmap Epigenomics Project (174,269), along with
gene expression datasets such as GTEx (245), the functional implications of DNA methylation
changes may be predicted. However, experimental work should be used to confirm these predic-
tions.
As discussed in Section 1.2, DNA methylation is not the only epigenetic mark in human cells.
Technology has been a hindrance to population based studies of histone modifications genome-
wide. At least one such study has been conducted (270), and the frequency is likely to increase
as the cost of high throughput chromatin immunoprecipitation procedures, such as ChIP-seq,
decreases.
Recently large-scale datasets have been developed to analyse the relationship between protein ex-
pression and gene expression with complex traits (245,271,272). Proteins are often the ultimate
target for many pharmaceuticals. As understanding of function and quantification of proteins
and their variants increases, protein-based epidemiological studies may supersede EWAS with
regards to their frequency. Indeed pharmaceutical companies may start interrogating potential
drugs by identifying targetable proteins. DNA methylation, and other molecular traits, may also
add to the evidence that regulation of a particular protein target is important for disease devel-
opment or progression. However, as discussed, the interpretability of EWAS makes discerning
whether or not observed differences in DNA methylation between individuals are important for
disease aetiology.
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Similarly to DNA methylation studies, problems with confounding and cell specificity will be
present in protein and gene based studies. Modifications to RNA transcripts and proteins pro-
vide an additional level of complication. RNA transcripts can be spliced and altered by post-
transcriptional modifications and proteins can be modified post-translation of gene transcript (9–
12). In extreme cases, proteins have been known to have their function reversed after their state is
modified. The protein p53 naturally acts as a tumour suppressor, but during cancer development
there is evidence that the protein can be modified and become oncogenic (9).
Studying each molecular measure will come with its own difficulties, and each can add to our
understanding of human phenotypic variation. Therefore, instead of any one study superseding
others, it seems likely that using a combination to untangle biological complexity will become
more common. In fact, one thing Lapallainen and Greally stress is how, in their opinion, invest-
ment in deep molecular phenotyping of the same samples, although expensive, will likely pay
high dividends with regards to interpretability of molecular epidemiological studies (251).
8.3 Final conclusions
The human body is unfathomably complex. Understanding it requires a huge concerted effort
from the entire, global research community. Returning to the example of p53, by 2010 there
had been nearly 50,000 studies on this single family of genes (273). The decades of research
conducted to elucidate the function, importance and interactions of this single family of genes
illustrates the patience required to understand the molecular underpinnings of disease. Given the
brevity of existence molecular epidemiology has had, I’d argue that judging whether it has been
a success or failure is a frivolous task. However, to speed up development of the field, there is a
need to understand the limits of the current methodologies.
This thesis provides evidence that the study design of current EWAS is unlikely to provide sub-
stantial improvements in the ability to predict or understand the aetiological aspects of complex
traits.
Key next steps will be diversifying the tissue and cell types collected as well as the DNA methy-
lation sites measured in the genome. Further, more experimental studies, that will inevitably
come with time, will aid in epidemiological inferences.
It is important to note that this thesis, and many other molecular epidemiology studies, primarily
focuses on samples of European origin. Datasets exist that contain individuals from different
ethnic backgrounds and there have been EWAS conducted in non-Europeans (Table 4.1), but
there is certainly a bias towards European samples. To realise the full potential of molecular
epidemiology and to help benefit all in our society, efforts should be made to reduce the bias in
sample collection and expand analyses, where possible, to those of all ethnic backgrounds.
Despite the apparent shortcomings, there is still great potential for EWAS to uncover important
facets of complex trait biology. Imperative to the development of the studies will be the constant
re-assessment of the predictive capacity and aetiological insights that can be gleaned from DNA
methylation as more data is collected in different samples.
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Appendix A
Further assessment of the overlap
between genes and genesets identified










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































E.  The proportion of causal EWAS genes =  1
Figure A.1: Full results from simulations assessing power to detect overlap between genes
and genesets identified by corresponding EWAS and GWAS. Simulations were set up as
illustrated in Figure 6.3. The ability to distinguish between results generated when EWAS and
GWAS were sampling, in part, from the same set of causal genes and results generated when
EWAS was sampling random genes from the genome. The header of each set indicates the
proportion of genes identified by the simulated EWAS that were set to be causal. or_g = assessing
overlap of genes, or_p = assessing overlap of genesets, rho_p = assessing correlation between
geneset enrichment scores. go = gene ontology, ppi = protein-protein interaction database from
EpiGraphDB.
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Figure A.2: Simulations to understand the likely number of genes still to identify in EWAS
and GWAS of six traits under different trait architectures. Simulations were set up as illus-
trated in Figure 6.5. Correlation of geneset enrichment scores from empirical data (Table 6.3),
is shown as a red dashed line. Box plots show the range of enrichment score correlations from
1000 simulations using the parameters indicated. The number of causal and associated genes, as
well as the overlap between these genes were varied. NKEG = number of known EWAS genes,
NKEG = number of known GWAS genes, NKTG = number of known total genes (NKEG + NKGG).
By way of an example, when NKTG = 491 and the ratio of causal and associated genes relative
to NKTG is 1:1, the number of causal genes in the simulations will be 557 and the number of
associated genes in the simulations will be 491. Scenarios which lie close to the empirical result
(red dashed line) are more likely to reflect the true underlying number of genes related to a trait















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































E.  The proportion of causal EWAS genes =  1
Figure A.3: Power to detect overlap between genes and genesets identified by corresponding
EWAS and GWAS when mapping signal to all genes and protein coding genes. Simulations
were set up as illustrated in Figure 6.3. The ability to distinguish between results generated
when EWAS and GWAS were sampling, in part, from the same set of causal genes and results
generated when EWAS was sampling random genes from the genome. The header of each set
indicates the proportion of genes identified by the simulated EWAS that were set to be causal.
or_g = assessing overlap of genes, or_p = assessing overlap of genesets, rho_p = assessing corre-
lation between geneset enrichment scores. go = gene ontology, suffix of ‘-genes’ denotes using
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